A Study of Strategic Alliances Between Indian and Foreign Companies With Reference to The Indian Pharmaceutical industry by Priyadharshini, Veena
A STUDY OF STRATEGIC ALLIANCES BETWEEN 
INDIAN AND FOREIGN COMPANIES WITH 
REFERENCE TO THE INDIAN 
PHARMACEUTICAL INDUSTRY 
ABSTRACT 
OF THE 
THESIS 
SUBMITTED FOR THE AWARD OF THE DEGREE OF 
^ . S . {Jtttsiimtt lainntnuttratton) 
BY 
VEENA PRIYADHARSHINI 
Under the Supervision of 
DR. MOHD. AFAQ KHAN DR. SANDHYA ANVEKAR 
Assistant Professor Professor & Head Researcit 
Department of iSusiness Administration M.S. Ramiah Institute of Management 
Faculty of Management Studies & Research Bangalore 
Aligarh Muslim University, Allgarh Kamataloi 
DEPARTMENT OF BUSINESS ADMINISTRATION 
FACULTY OF MANAGEMENT STUDIES AND RESEARCH 
ALIGARH MUSLIM UNIVERSITY 
ALIGARH-202 002 (INDIA) 
2013 
INTRODUCTION 
Strategic Alliances 
Sustained inflation; heavy costs of developing and commercializing new technologies, 
processes and products; increased complexity of regulatory compliance; the need to compete on 
a world-wide basis and the increased marketing costs associated with competing in a mature 
market have led to increase in business expenses (Barrie, 1985). Firms are looking at alliance 
strategies, which can offset, to some extent, some of the high cost/high risk syndrome. 
An alliance is defined as any inter-firm co-operation that falls between extremes of discrete, 
short-term contracts and the complete merger of two or more organizations, {Contractor & 
Lorange, 2002). 
Growing regulatory pressures and introduction of risk evaluation and mitigations strategies, 
makes it increasingly difficuh for the approval of new drugs, which would eventually lead to 
greater cooperation between pharmaceutical companies. An understanding of the 
pharmaceutical environment in India and the alliances that have happened between Indian and 
foreign pharmaceutical companies over the last four decades can help companies in the future 
to realize their business objectives effectively through alliances and collaborations. Some of 
the reasons that substantiate the necessity of a research on this subject are enumerated below: 
• The alliances between Indian and foreign pharmaceutical companies have increased 
over the years. 
• Alliances today involves multimillion dollars, with clear business objectives, hence 
understanding them can mitigate failures. 
• Alliances have an impact on many aspects of the business including people, studying 
the factors that have influenced the alliances between Indian and foreign 
phanmaceutical firms can help develop a clear picture of alliance success factors. 
• An in depth research highlighting the areas of improvement may prompt increased 
regulations, which will enhance the scope for investments. 
LITERATURE REVIEW 
Porter (1980), indicated that a firm's membership in an industry governs its strategic 
orientation. Porter develops three potentially successful generic strategies for creating 
defensible position and outperforming competitors in a given industry. 
• Overall cost leadership in consideration with quality and service. 
• Differentiation either in product or service that is recognized industry wide as being 
unique. 
• Focus strategy, in which the firm concentrates on a particular group of customers, 
geographic markets or product line segments. 
Global Trends in Strategic Alliances in the Pharmaceutical Industry 
The pharmaceutical industry is a knowledge driven industry and is heavily dependent on 
Research and Development for new products and growth. Since 1930 many large firms have 
specialized in chemical modifications of basic compounds in the quest to produce new 
drugs. The resources required to invest in the search for new molecules, conduct clinical 
trials and market the drug was huge and only large pharmaceutical firms could invest in 
these activities extensively. Thus the main reasons for the strategic consolidation of the 
pharmaceutical industry are: lack of new products, globalization of the world economy, 
high R&D costs, large investments on global sales and marketing activities, increased 
competitiveness, reforms in the world healthcare, increased importance of regulation in the 
global context. 
Strategies for Growth 
Strategic actions that have been discussed in pharmaceutical literature can be categorized 
as corporate, global, network, marketing, research & development and investment strategies 
{Langley, 2005). Companies can adopt different strategies based on their strategic orientation 
and business plans. The growth strategy concentrates on growth of the organization and the 
various types of growth strategies can be categorized under six heads based on their 
strategic action points and implications. 
Grand Strategies Implemented by Pharmaceutical firms 2001- 2002 
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Strategic Alliance between Indian and Foreign Pharmaceutical Companies 
Over the years the Indian pharmaceutical companies have used multiple strategies to 
build the pharmaceutical industry in India. According to Sampath (2005), the major strength 
of the Indian pharmaceutical company was the cost competitive manufacturing base and the 
extensive skill in chemistry. He has identified the strategies adopted by Indian firms as: 
• R&D Strategies 
• Competitive strategies 
• Collaborative strategies 
The R&D strategies of Group 1 firms are driven by the need for entry and establishment 
in the regulated markets. Hence the strategy would be greater investment into R&D to 
generate innovative generic products, process and bulk drugs. Group 2 firms are driven by 
the need to strengthen competitive advantages, make use of CRAM opportunities, to take 
advantage of the business. Their strategic orientation would be towards generating active 
supply of off- patent generics to the unregulated and semi regulated markets and establish 
themselves as niche players in contract research, by choosing specific areas like - clinical 
research, domestic marketing etc. Group 3 firms are driven by the need to survive in the 
scenario of complete TRIPS compliance, thus leading towards the up gradation of 
facilities to continue being outsource centers for Group 1 and 2 firms. The competitive 
strategies adopted by Indian companies are centered around R&D involving research on 
new chemical entities, non infringing processes, novel drug delivery systems generics and 
specialty generics for regulated market and biopharmaceutical research. 
Factors that Impact Strategic Alliances 
Parvartiyar and Gupta (1994), discusses the benefits sought by Indian companies as: 
Reasons for Alliances 
1. Governmental Policy related factors 
i. Intellectual properties 
ii. Deregulation and Economic liberalization 
2. Gaining competitive advantage 
i. Growth strategy 
ii. Mimic competition 
iii.Gain access to key attributes 
3. Globalization 
i. New market access 
ii. International harmonization of standards 
4.Cost related aspects 
i. Cost of production 
ii. Cost of R&D 
iii. Cost of marketing and distribution 
5. Innovations 
i. Achieve high profits 
ii. Achieve vertical integration 
6. Technology and knowledge management related 
i. 
ii. 
iii 
Rapid advances in technology - related to 
Increasing role of information technology 
. Strate gic importance of speed 
lifescience 
Impact of Strategic Alliances 
Alliances, which are a consequence of growth strategy and which are clearly envisioned 
and implemented, can prove to be beneficial to both the alliance partners. 
Impact of Alliances on Business Aspects of Pharmaceutical Companies 
1. Product 
i. New product development 
ii. New product launches - domestic and international markets 
iii. Enhanced product portfolio 
2. Marketing 
Access to new markets 
ii. Enhanced sales promotional activities and spend 
iii. New distribution channels 
3 Technology 
i. Access to new technology 
ii. R&D capability 
iii. GMP manufacturing facilities knowhow 
4 Manufacturing 
i. Cost optimization 
ii. Quality management techniques 
iii. Common asset and operational synergy 
5 Competitive advantage 
i. Increased market share 
ii. Increased profitability 
iii. Intellectual and managerial skills 
Success Factors for Alliances 
Two types of uncertainties in alliances: uncertainty regarding future events and uncertainty 
regarding partner's responses to those future events. Alliances involve considerable investment 
of resources and need to be nurtured and managed well, if they are to be successful. 
Strategic fit involves six drivers, siiaring a common vision, having a compatibility of 
strategies, mutual dependency, market acceptability of the alliances, should add value for the 
partners and their customers, and finally the alliance should be of strategic importance to 
both the partners. The drivers for organizational fit includes: addressing organizational 
similarities and differences in the alliance, providing for strategic and organizational 
fiexibility, reducing the design complexity, enabling effective management control by both 
partners, overcoming potential strategic conflicts and enabling partners achieve their 
strategic objectives. 
Factors Affecting the Success of Alliances 
1. External factors 
i. Legal and regulatory policies 
ii. Currency related aspects 
2. Strategic fit 
i. Strategic fit 
ii. Organisational fit 
iii. Cultural fit 
3. Governance 
i. Day to day operations 
ii. Communication 
4. Trust 
i. Formal and informal relationships 
ii. Collaborative activities 
Conclusion and Research Gaps: 
Strategic alliance between Indian and foreign pharmaceuticals is a phenomenon that is here to 
stay for many more years in the future. Literature has discussed extensively the driving factors 
for the alliances and the trend of alliances in the 5 decades starting from 1960 till 
2010.Research gaps can be summarized as follows: ' 
Literature Gaps 
1. Trends Strategic alliances 
i. No decade wise analysis 
between Indian and foreign pha rmaceutical companies 
ii. Data is available till 2006 only 
iii. No study on the objectives of the alliances is available 
2. Factors that have led to formation of alliances between Indian and foreign pharmaceutical firms 
i. Role of technological factors in alliance formation 
ii. Role of economic factors in alliance formation 
iii. Role of competitive advantage related aspects in alliance formation 
3. Business implications of strategic alliances between Indian and foreign pharmaceutical firms 
i. The major business area impacted during an alliance 
ii. Impact of alliance on marketing elements 
iii. Impact of alliances on the People of the firms who have formed an alliance 
4. Factors that are critical for a successful alliance between Indian and foreign pharmaceutical firms 
i. Critical success factors with respect to Indian context 
ii. Beneficial aspects of alliances to Indian firms 
iii. Negative fallouts of alliances with regards to Indian pharmaceutical industry 
RESEARCH METHODOLOGY 
Research Objectives 
i 
The research objectives are derived from the gaps in literature review. The research questions 
are some of the icey aspects to which the answers need to be sought. Both the aspects of the 
research are illustrated in the table below. [ 
1. To study the factors that influence Indian pharmaceutical companies to form 
strategic alliances with foreign pharmaceutical firms. 
2. To study the impact of the strategic alliances between Indian and foreign 
pharmaceutical companies on various business aspects of the Indian pharmaceutical 
firm. 
3. To formulate strategies for Indian pharmaceutical companies to avail maximum 
benefit, from the alliances undertaken with foreign pharmaceutical companies. 
I 
Scope of the Research 
The research study analyses the alliances that have happened between Indian and foreign 
pharmaceutical companies. The period under consideration is the last 5 decades that is, 
from 1950-2009. It traces the evolution of the Indian pharmaceutical industry over the 
years and also draws a comparison with the global pharmaceutical firms. The study tracks 
the alliances of 5 major Indian pharmaceutical companies, along with the reason for the 
alliance. Empirical study is conducted to understand the impact of alliances on various 
aspects of the business: Product, Marketing, Technology, Manufacturing and Competitive 
Advantage. Personal interviews of CEOs/ MDs of Indian pharmaceutical companies 
gives an idea on the various critical parameters that impact alliance formation and the 
areas that are impacted during an alliance. 
The study does not discuss the alliances happening in other countries, especially between 
firms in developed countries. The study does not study each of the alliance in detail and 
analyze the success or failure of the alliance. It does not discuss the alliance outcomes in 
relation to business goal achievements, impact on turnover etc. 
I 
Research Questions 
1* Efesearci'ljuestions' Data ' :'f 
( What are the factors that influence the formation of strategic 
alliance between Indian and foreign pharmaceutical firms ? 
What are the major business implications of strategic alliances 
between Indian and foreign pharmaceutical alliances? 
What are the hindrances for strategic alliances between Indian 
and foreign pharmaceutical companies? 
Primary data 
Primary data 
Primary data 
Variables and Literature References 
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Strengthen product portfolio 
Acquire marketing knowhow 
Access to highly regulated markets 
Collaborative R&D 
Overall cost minimization 
Improve market positions 
Exploit common assets 
Develop financial strength 
Establish a brand name abroad 
Access to worldwide information on 
latest technology and products 
Managerial knowhow - access to 
superior managerial skills 
Access to superior Quality management 
systems 
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Launch new patented molecules 
Launch new generic molecules in the 
foreign markets 
Gain access to highly regulated market 
Achieved R&D capability 
Gain access to new technology 
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Gain capability to invest in marketing 
and sales promotional activities 
Gain GMP compliant manufacturing 
capabilities 
Achieve cost minimization 
Achieve increased market share 
Achieve increased profitability 
Exploit common assets 
Gain enhanced product portfolio 
Establish a brand name abroad 
Access to worldwide information - latest 
advancements in technology and products 
Enabled Managerial knowhow - access to 
superior management systems 
Access to superior Quality systems 
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Hypotheses 
1 : RELATED TO IMPACT ON PRODUCTS 
Impact of Strategic alliances between Indian and foreign pharmaceutical companies on the 
launch of new patented molecules. 
HOI: There is no significant difference in the mean value of launch of new patented molecules 
as an area if impact of strategic alliances between Indian and foreign pharmaceutical companies 
across the types of Indian pharmaceutical companies. 
H02: There is no significant difference in the mean value of launch of patented molecules 
as an area of impact of strategic alliances between Indian an foreign pharmaceutical 
companies, across the types of activity undertaken by Indian pharmaceutical companies. 
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H03: There is no significant difference in the mean value of launch of patented molecules as 
an area of impact of strategic alliances between foreign pharmaceutical companies, across 
Indian pharmaceutical companies of differing turnover. 
Impact of Strategic alliances between Indian and foreign pharmaceutical companies on the 
launch of generic pharmaceutical products in India. 
H04: There is no significant difference in the mean value of launch of generic pharmaceutical 
products abroad as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across all types of Indian pharmaceutical companies. 
H05: There is no significant difference in the mean value of launch of generic pharmaceutical 
products abroad as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across the types of activity undertaken by Indian pharmaceutical 
companies. 
H06: There is no significant difference in the mean value of launch of generic pharmaceutical 
products abroad as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies of varying turnover. 
Impact of Strategic Alliances between Indian and foreign pharmaceutical companies on the 
launch of generic pharmaceutical products abroad. 
H07: There is no significant difference in the mean value of launch of new generic 
pharmaceutical products in the domestic market as an area of impact of strategic alliances 
between Indian and foreign pharmaceutical companies on the, across the types of Indian 
pharmaceutical companies. 
H08: There is no significant difference in the mean value of launch of new generic 
pharmaceutical products in the domestic market as an area of impact of strategic alliances 
between Indian and foreign pharmaceutical companies across the types of activity undertaken 
by Indian pharmaceutical companies. 
H09: There is no significant difference in the mean value of launch of new generic 
pharmaceutical products in the domestic market as an area of impact of strategic alliances 
between foreign pharmaceutical companies, across Indian pharmaceutical companies with 
different turnovers. 
Impact of Strategic alliances with foreign pharmaceutical companies on gaining a wider 
product portfolio 
HOlO: There is no significant difference in the mean value of expansion of product portfolio 
as an area impact of strategic alliances between Indian and foreign pharmaceutical 
companies, across all types of Indian pharmaceutical companies. 
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HOll: There is no significant difference in the mean value of expansion of product portfolio as 
an area of impact of strategic aUiances between Indian and foreign pharmaceutical 
companies, across Indian pharmaceutical companies indulging in various activities. 
H012: There is no significant difference in the mean value of expansion of product portfolio as 
an area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across Indian pharmaceutical companies of varying turnover. 
2: RELATED TO IMPACT ON MARKETING ASPECTS 
Impact of Strategic Alliances between Indian and foreign pharmaceutical companies on 
gaining access to highly regulated markets abroad 
H013: There is no significant difference in the mean value of gaining access to highly 
regulated markets abroad as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across all types of Indian pharmaceutical companies. 
H014: There is no significant difference in the mean value of gaining access to highly 
regulated markets abroad as an area of impact of strategic alliances between Indian and 
foreign pharmaceutical companies, across Indian pharmaceutical companies undertaking 
different activities 
H015: There is no significant difference in the mean value of gaining access to highly 
regulated markets abroad as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies across Indian pharmaceutical companies of different turnover 
Impact of Strategic Alliances between Indian and foreign pharmaceutical companies on 
gaining capability to invest in sales and marketing. 
H016: There is no significant difference in the mean value of gaining investment capability 
into sales and marketing as an area of impact of strategic alliances between Indian and 
foreign pharmaceutical companies, across all types of Indian pharmaceutical companies. 
H017: There is no significant difference in the mean value of gaining investment capability 
into sales and marketing , as an area of impact of strategic alliances between Indian and 
foreign pharmaceutical companies, across Indian pharmaceutical with varying business 
activities. 
H018: There is no significant difference in the mean value of gaining investment capability 
into sales and marketing, as an area of impact of strategic alliances between Indian and 
foreign pharmaceutical companies, across Indian pharmaceutical companies with varying 
turnover 
Impact of Strategic Alliances between Indian pharmaceutical companies on gaining 
access into foreign distribution networks abroad. 
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H019: There is no significant difference in the mean value of gaining access to foreign 
distribution networks abroad as an area of impact of strategic alliances between Indian and 
foreign pharmaceutical companies, across all types of Indian pharmaceutical companies. 
H020: There is no significant difference in the mean value of gaining access to foreign 
distribution networks abroad as an area of impact of strategic alliances between Indian and 
foreign pharmaceutical companies, across Indian pharmaceutical companies with differing 
turnover 
H021: There is no significant difference in the mean value of gaining access to foreign 
distribution networks abroad as an area of impact of strategic alliances between Indian and 
foreign pharmaceutical companies, Indian pharmaceutical companies undertaking different 
activities 
3: RELATED TO IMPACT ON TECHNOLOGY 
Impact of Strategic Alliances between Indian and foreign pharmaceutical companies on 
gaining access to new technology, 
H022: There is no significant difference in the mean value of gaining technological 
competency as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across all types of Indian pharmaceutical companies. 
H023: There is no significant difference in the mean value of gaining technological 
competency as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies indulging in various 
activities. 
H024: There is no significant difference in the mean value of gaining technological 
competency as an area impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies of varying turnover. 
Impact of Strategic Alliances between Indian and foreign pharmaceutical companies on 
achieving R&D capability. 
H025: There is no significant difference in the mean value of achieving R&D capability, as an 
area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across all types of Indian pharmaceutical companies 
H026: There is no significant difference in the mean value of achieving R&D capability, as an 
area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across Indian pharmaceutical companies indulging in various activities. 
H027: There is no significant difference in the mean value of achieving R&D capability, as an 
area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across Indian pharmaceutical companies of varying turnover. 
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Impact of Strategic alliances between Indian and foreign pharmaceutical companies on 
gaining access to the latest information on technological and product related upgrades. 
H028: There is no significant difference in the mean value of accessibility of Indian 
companies to latest technological and product related upgrades as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies on, across all types 
of Indian pharmaceutical companies. 
H029: There is no significant difference in the mean value of accessibility of Indian 
companies to latest technological and product related upgrades as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies, across Indian 
pharmaceutical companies of different turnover. 
H030: There is no significant difference in the mean value of accessibility of Indian 
companies to latest technological and product related upgrades as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies, across Indian 
pharmaceutical companies with different activities. 
Impact of Strategic alliances between Indian and foreign pharmaceutical companies on 
gaining GMP compliant manufacturing sites. 
H031: There is no significant difference in the mean value of development of GMP 
compliant production capacities by Indian pharmaceutical companies as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies, across all types of 
Indian pharmaceutical companies. 
H032: There is no significant difference in the mean value of development of GMP 
compliant production capacities by Indian pharmaceutical companies as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies, across Indian 
pharmaceutical companies performing different activities. 
H033: There is no significant difference in the mean value of development of GMP 
compliant production capacities by Indian pharmaceutical companies as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies, across Indian 
pharmaceutical companies of different turnover. 
4: RELATED TO IMPACT ON MANLFACTURING 
Impact of Strategic Alliances between Indian pharmaceutical companies on cost 
optimization. 
H034: There is no significant difference in the mean value of cost optimization as an area of 
impact of strategic alliances between Indian and foreign pharmaceutical companies across the 
types of Indian pharmaceutical companies. 
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H035: There is no significant difference in the mean value of cost optimization as an area of 
impact of strategic alliances between Indian and foreign pharmaceutical companies across the 
types of activity undertaken by Indian pharmaceutical companies. 
H036: There is no significant difference in the mean value of cost optimization as an area of 
impact of strategic alliances between Indian and foreign pharmaceutical companies across 
Indian pharmaceutical companies of varying turnover. 
Impact of Strategic Alliances between Indian pharmaceutical companies on exploiting 
common assets. 
H037: There is no significant difference in the mean value of achieving operational synergy as 
an area of impact of strategic alliances between Indian and foreign pharmaceutical companies 
across the types of Indian pharmaceutical companies. 
H038: There is no significant difference in the mean value of achieving operational synergy as 
an area of impact of strategic alliances between Indian and foreign pharmaceutical companies 
across the types of activity undertaken by Indian pharmaceutical companies.. 
H039: There is no significant difference in the mean value of achieving operational synergy as 
an area of impact of strategic alliances between Indian and foreign pharmaceutical companies 
across Indian pharmaceutical companies of varying turnover. 
Impact of Strategic Alliances between Indian and foreign pharmaceutical companies on 
gaining superior quality management skills. 
H040: There is no significant difference in the mean value of quality related skills acquired 
by Indian pharmaceutical companies, as an area of impact of strategic alliances between 
Indian and foreign pharmaceutical companies, across all types of Indian pharmaceutical 
companies. 
HO^l: There is no significant difference in the mean value of quality related skills acquired 
by Indian pharmaceutical companies, as an area of impact of strategic alliances between 
Indian and foreign pharmaceutical companies, across Indian pharmaceutical companies of 
different turnover. 
H042: There is no significant difference in the mean value of quality related skills acquired 
by Indian pharmaceutical companies, as an area of impact of strategic alliances between 
Indian and foreign pharmaceutical companies, across Indian pharmaceutical companies with 
different activities. 
5: RELATED TO IMPACT ON COMPETITIVE ADVANTAGE 
Impact of Strategic Alliance between Indian and foreign pharmaceutical companies on 
increased market shares, 
H043: There is no significant difference in the mean values of increased market share as an 
area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across all types of Indian pharmaceutical companies. 
H044: There is no significant difference in the mean values of increased market share as an 
area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across Indian pharmaceutical companies indulging in various activities. 
H045: There is no significant difference in the mean value of increased market share as an 
area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across Indian pharmaceutical companies of differing turnovers. 
Impact of Strategic Alliances between Indian and foreign pharmaceutical companies on 
increase in overall profitability. 
H046: There is no significant difference in the mean value of on enhanced profitability as an 
area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across Indian pharmaceutical companies of differing company types. 
H047: There is no significant difference in the mean value of on enhanced profitability as an 
area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across Indian pharmaceutical companies indulging in various activities. 
H048: There is no significant difference in the mean value of on enhanced profitability as an 
area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across Indian pharmaceutical companies of differing turnovers. 
Impact of Strategic Alliances between Indian and foreign pharmaceutical companies on 
establishing new brands in the global market, 
H049:There is no significant difference in the mean value of establishment of Indian 
pharmaceutical brand names in the global market as an area o/impact of strategic alliances 
between Indian and foreign pharmaceutical companies, across the types of activities 
undertaken by Indian pharmaceutical companies. 
H050: There is no significant difference in the mean value of establishment of Indian 
pharmaceutical brand names in the global market as an area of impact of strategic alliances 
between Indian and foreign pharmaceutical companies, across the types of Indian 
pharmaceutical companies. 
H051:There is no significant difference in the mean value of establishment of Indian 
pharmaceutical brand names in the global market as an area of impact of strategic alliances 
between Indian and foreign pharmaceutical companies, across Indian pharmaceutical 
companies of varying turnover. 
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Impact of Strategic alliances between Indian and foreign pharmaceutical companies on 
acquiring superior managerial skills. 
H052: There is no significant difference in the mean values of acquisition of management 
skills by hidian pharmaceutical companies as an area of impact of strategic alliances between 
Indian and foreign pharmaceutical companies on the, across all types of Indian 
pharmaceutical companies. 
H053: There is no significant difference in the mean value of acquisition of management 
skills by Indian pharmaceutical companies as an area of impact of strategic alliances between 
Indian and foreign pharmaceutical companies, across Indian pharmaceutical companies of 
different turnover. 
H054: There is no significant difference in the mean value of acquisition of management 
skills by Indian pharmaceutical companies as an area of impact of strategic alliances between 
Indian and foreign pharmaceutical companies, across pharmaceutical companies indulging in 
various activities. 
Research Design 
The exploratory study was conducted with the following objectives in mind, 
• Establish the research questions 
• Establish the hypotheses 
Method of exploratory study: 
Here the exploratory research is qualitative in nature and was executed by: 
• Secondary data analysis 
• Experience survey 
Secondary data analysis involved extensive literature review which includes articles and 
publication which were related to the study topic. Additionally annual reports of Indian 
companies, news paper articles, reports from business consultants like KPMG and McKinsey 
became sources of information which helped to crystallize the research questions. 
Experience surveys which were designed to seek out important ideas and concepts on the 
strategic alliances between Indian and foreign pharmaceutical companies was undertaken. The 
participants in the exploratory surveys were the top executives of Indian pharmaceutical 
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companies who had undertaken alliances with foreign pharmaceutical companies. The sample 
size was limited to 4 participants only. 
. Sampling 
The sample population for this study is derived from the list of Indian pharmaceutical 
companies registered in recognized databases namely IDMA and OPPI. The IDMA has 300 
registered members and includes companies dealing with pharmaceutical manufacturing. The 
sample would consist of firms which have undergone strategic alliances with another foreign 
firm. The respondents will be: 
• Top executives of pharmaceutical companies in India 
Top executives here refers to the senior managers in Marketing , CEO, MD, Heads of R&D , 
Heads of Production, Executives from Strategy and Development and other functions who 
are privy to high level activities like alliances and acquisitions. The inputs from the top 
executives of pharmaceutical companies in India, gives a complete perspective of the strategic 
alliances between Indian and foreign pharmaceutical companies. 
Sample frame: 
The sample frame for the top executives in pharmaceutical companies of Indian origin extends 
to across India irrespective of the turnover, type and activity of the company. The database was 
acquired ft-om the Indian Drug Manufacturer's Association (IDMA), which is a registry for 
Indian pharmaceutical companies. 
Sampling method: 
The database of firms that have undertaken strategic alliance was created. This included a 
number of 250 Indian companies. From this overall number companies were selected randomly 
to administer the questionnaire. 
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Questionnaire 
The primary data is collected witii tlie help of a specific questionnaire. The questionnaire is 
designed to gather the reasons for alliances between Indian and foreign pharmaceutical 
companies and understand the outcome of the alliances. The questionnaire is divided into 4 
sections. 
The 1st section has 15 variables. Each variable corresponds to each factor that has 
influenced the formation of strategic alliances between Indian and foreign pharmaceutical 
companies. The variables are derived from literature references. 
The 2"'' section has 18 variables. This is aimed at gathering data from the responding 
pharmaceutical firms on their experience with strategic alliances that they have undertaken with 
foreign pharmaceutical companies. 
The 3'^ '' section, has 6 factors which are identified as the possible hindrances in the formation of 
strategic alliances in the Indian context. 
The 4* section aims at gathering firm specific data. The descriptive analyses of the 
responding firm, will contain data relating to the Type of company, type of activity of the 
responding company and turnover of the responding company. 
Scale and Design: 
Convergent and discriminant validity of the scales were Weak and bad items from the original 
construct were redefined. The resulting construct was subjected to preliminary test 
followed by a pilot scale field test. The Questionnaire is designed as per Likert scale, thus 
the level of variables are ordinal. The data scale has order but no magnitude and is a 
categorical data. The Non parametric tests will be used for hypotheses testing. 
Method of Analysis and Justification 
The scale of measurement for the data collected is nominal in nature, and hence non-
parametric. Random sampling method was used for data collection. Hypotheses were tested 
using single and multiple variables. 
The variables chosen were: 
• Type of pharmaceutical companies (API, Formulations, R&D, Clinical Research) 
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• Type of activities of the pharmaceutical companies (Manufacturing, R&D , Contract 
Research, Distribution) 
• Turnover of the pharmaceutical companies (<100 cr, IOO-300Cr, 300-500 cr, >500cr 
annually) 
The groups are independent, that is presence of the members in one group is not dependent 
upon membership in another. The statistical techniques that were used are: 
• Non parametric tests which assesses the population distribution 
• One sample tests to understand the aspects which drive strategic alliances 
between Indian and foreign pharmaceutical companies 
• K- sample tests to evaluate the variables for the three groups from the population 
o One way Analysis of Variance (ANOVA) 
• Correlation to assess the correlation between scale variables 
• Regression to predict a model fit 
Limitations of the Research 
The study does have certain limitations which are enumerated as follows: 
• Time span: The research considers the strategic alliance between Indian and foreign 
pharmaceutical companies in the last 4 decades till 2010. 
• Sampling limitations: Inadequate representations under the various categories of the 
pharmaceutical companies. 
• Gaps in data: In India there is no single database which records all the alliances 
that have happened in the Indian pharmaceutical industry in the last few decades. The 
compilation was done through secondary data from journals, newspapers and articles. 
There are possibilities that all the alliances between companies may not have been 
recorded. 
Analysis and Interpretation of Results 
Reasons for the Formation of Alliances between Indian and Foreign Pharmaceutical 
Companies 
.i 4 J 
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1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
Strengthen product portfolio 
Establishing brands abroad 
Launching new product lines 
Entering global emerging markets 
Entering regulated markets 
Establishing distribution channels abroad 
Accessing new technology 
Undertaking collaborative R&D 
Obtaining USFDA approved 
Cost minimization 
Achieving operational synergy 
Achieving quality management 
Achieving market position 
Achieving financial power 
Enhancing company image 
3.83 
3.94 
3.76 
3.83 
3.94 
3.76 
3.32 
3.30 
3.17 
2.91 
2.86 
3.28 
3.91 
3.98 
4.04 
.62 
.76 
.71 
.62 
.76 
.71 
.64 
.90 
.93 
.90 
.91 
.67 
.72 
.69 
.71 
6 
4 
8 
7 
3 
9 
10 
11 
13 
14 
15 
12 
5 
2 
1 
Impact of Strategic Alliances between Indian and Foreign Pharmaceutical Companies on 
Indian Pharmaceutical Companies 
' Nwi WpoiWeses Level of Oiitcoitie 
„. Si&,„.,„, «,„„„.„„ ^  «»„. 
HOI There is no significant difference in the mean value of launch of new patented 
molecules as an area if impact of strategic alHances between Indian and foreign 
pharmaceutical companies across the types of Indian pharmaceutical companies 
0.061 Supported 
H02 There is no significant difference in the mean value of launch of patented 
molecules as an area of impact of strategic alliances between Indian an 
foreign pharmaceutical companies, across the types of activity undertaken by 
Indian pharmaceutical companies 
0.002 Not 
supported 
H03 There is no significant difference in the mean value of launch of patented 
molecules as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies of differing 
turnover 
0.005 Not 
supported 
H04 There is no significant difference in the mean value of launch of generic 0.102 
pharmaceutical products abroad as an area of impact of strategic alliances 
between Indian and foreign pharmaceutical companies, across all types of 
Indian pharmaceutical companies 
Supported 
H05 There is no significant difference in the mean value of launch of generic 
pharmaceutical products abroad as an area of impact of strategic alliances 
between Indian and foreign pharmaceutical companies, across Indian 
pharmaceutical companies indulging in various activities 
O.OIO Not 
supported 
H06 There is no significant difference in the mean value of launch of generic 0.001 Not 
pharmaceutical products abroad as an area of impact of strategic alliances supported 
between Indian and foreign pharmaceutical companies, across Indian 
pharmaceutical companies of varying turnover 
H07 There is no significant difference in the mean value of launch of new generic 0.201 Supported 
pharmaceutical products in the domestic market as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies, 
across the types of Indian pharmaceutical companies 
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H08 There is no significant difference in the mean value of launch of new generic 
pharmaceutical products in the domestic market as an area of impact of strategic 
alliances between Indian and foreign pharmaceutical companies across the types 
of activity undertaken by Indian pharmaceutical companies 
H09 There is no significant difference in the mean value of launch of new generic 
pharmaceutical products in the domestic market as an area of impact of strategic 
alliances between Indian and foreign pharmaceutical companies, across Indian 
pharmaceutical companies with different turnovers 
HO 10 There is no significant difference in the mean value of expansion of product 
portfolio as an area impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across all types of Indian pharmaceutical companies 
HOI 1 There is no significant difference in the mean value of expansion of product 
portfolio as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies indulging 
in various activities 
HO 12 There is no significant difference in the mean value of expansion of product 
portfolio as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies of varying 
turnover 
HO 13 There is no significant difference in the mean value of access to highly 
regulated markets abroad as an area of impact of strategic alliances between 
Indian and foreign pharmaceutical companies, across all types of Indian 
pharmaceutical companies 
H014 There is no significant difference in the mean value of access to highly regulated 
markets abroad as an area of impact of strategic alliances between Indian and 
foreign pharmaceutical companies, across Indian pharmaceutical companies 
undertaking different activities 
HO 15 There is no significant difference in the mean value of access to highly regulated 
markets abroad as an area of impact of strategic alliances between Indian and 
foreign pharmaceutical companies across Indian pharmaceutical companies of 
different turnover 
HOI6 There is no significant difference in the mean value gaining investment capability 
into sales and marketing as an area of impact of strategic alliances between 
Indian and foreign pharmaceutical companies, across all types of Indian 
pharmaceutical companies 
HO 17 There is no significant difference in the mean value of gaining investment 
capability into sales and marketing, as an area of impact of strategic alliances 
between Indian and foreign pharmaceutical companies, across Indian 
pharmaceutical with varying business activities 
HOI8 There is no significant difference in the mean value of gaining investment 
capability into sales and marketing, as an area of impact of strategic alliances 
between Indian and foreign pharmaceutical companies, across Indian 
pharmaceutical companies with varying turnover 
HOI9 There is no significant difference in the mean value of gaining access to 
foreign distribution networks abroad as an area of impact of strategic alliances 
between Indian and foreign pharmaceutical companies, across all types of 
Indian pharmaceutical companies 
H020 There is no significant difference in the mean value of gaining access to foreign 
distribution networks abroad as an area of impact of strategic alliances between 
Indian and foreign pharmaceutical companies, across Indian pharmaceutical 
companies with differing turnover 
H021 There is no significant difference in the mean value of gaining access to foreign 
distribution networks abroad as an area of impact of strategic alliances between 
Indian and foreign pharmaceutical companies, Indian pharmaceutical 
0.056 Supported 
0.048 Not 
supported 
0.165 Supported 
0.005 Not 
supported 
O.I 10 Supported 
0.697 Supported 
0.096 Supported 
0.191 Supported 
0.000 Not 
supported 
0.000 Not 
supported 
0.001 Not 
supported 
0.001 Not 
supported 
0.015 Not 
supported 
0.000 Not 
supported 
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companies undertaking diflFerent activities 
H022 There is no significant difference in the mean value of gaining technological 
competency as an area of impact of strategic alliances between Indian and 
foreign pharmaceutical companies, across all types of Indian pharmaceutical 
companies 
H023 There is no significant difference in the mean value of gaining technological 
competency as an area of impact of strategic alliances between Indian and 
foreign pharmaceutical companies, across Indian pharmaceutical companies 
indulging in various activities 
H024 There is no significant difference in the mean value of gaining technological 
competency as an area impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies of varying 
turnover 
H025 There is no significant difference in the mean value of achieving R&D 
capability, as an area of impact of strategic alliances between Indian and 
foreign pharmaceutical companies, across all types of Indian pharmaceutical 
companies 
H026 There is no significant difference in the mean value of achieving R&D capability, 
as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies indulging 
in various activities 
H027 There is no significant difference in the mean value of achieving R&D capability, 
as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies of varying 
turnover 
H028 There is no significant difference in the mean value of development ofGMP 
compliant production capacities by Indian pharmaceutical companies as an area 
of impact of strategic alliances between Indian and foreign pharmaceutical 
companies, across all types of Indian pharmaceutical companies 
H029 There is no significant difference in the mean value of development of GMP 
compliant production capacities by Indian pharmaceutical companies as an area 
of impact of strategic alliances between Indian and foreign pharmaceutical 
companies, across Indian pharmaceutical companies performing different 
activities 
H030 There is no significant difference in the mean value of development of GMP 
compliant production capacities by Indian pharmaceutical companies as an area 
of impact of strategic alliances between Indian and foreign pharmaceutical 
companies, across Indian pharmaceutical companies of different turnover 
H03I There is no significant difference in the mean value of accessibility of Indian 
companies to latest technological and product related upgrades as an area of 
impact of strategic alliances between Indian and foreign pharmaceutical 
companies on, across all types of Indian pharmaceutical companies 
H032 There is no significant difference in the mean value of accessibility of Indian 
companies to latest technological and product related upgrades impact of 
strategic alliances between Indian and foreign pharmaceutical companies, across 
Indian pharmaceutical companies of different turnover 
H033 There is no significant difference in the mean value of accessibility of Indian 
companies to latest technological and product related upgrades as an area of 
impact of strategic alliances between Indian and foreign pharmaceutical 
companies , across Indian pharmaceutical companies with different activities 
H034 There is no significant difference in the mean value of cost opfimizafion as an 
area of impact on Strategic alliances between Indian and foreign 
pharmaceutical companies, across the types of Indian pharmaceutical 
companies 
0.691 Supported 
0.139 Supported 
0.301 Supported 
0.039 Not 
supported 
0.001 Not 
supported 
0.024 Not 
supported 
0.014 Not 
supported 
0.023 Not 
supported 
0.035 Not 
supported 
0.001 Not 
supported 
0.064 Supported 
0.000 Not 
supported 
0.304 Supported 
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H035 There is no significant difference in the mean value of cost optimization as an 
area of impact on strategic alliances between Indian and foreign pharmaceutical 
companies, across the types of activity undertaken by Indian pharmaceutical 
companies 
0.184 Supported 
H036 There is no significant difference in the mean value of cost optimization as an 
area of impact on strategic alliances between Indian and foreign pharmaceutical 
companies across Indian pharmaceutical companies of varying turnover. 
0.232 Supported 
H037 There is no significant difference in the mean value of achieving operational 
synergy as an area of impact on strategic alliances between Indian and foreign 
pharmaceutical companies across the types of Indian pharmaceutical companies. 
0.763 Supported 
H038 There is no significant difference in the mean value of achieving operational 
synergy as an area of impact on strategic alliances between Indian and foreign 
pharmaceutical companies across the types of activity undertaken by Indian 
pharmaceutical companies. 
0.800 Supported 
H039 There is no significant difference in the mean value of achieving operational 
synergy as an area of impact on strategic alliances between Indian and foreign 
pharmaceutical companies across Indian pharmaceutical companies of varying 
turnover 
0.528 Supported 
H040 There is no significant difference in the mean value of quality related skills 
acquired by Indian pharmaceutical companies, as an area of impact of strategic 
alliances between Indian and foreign pharmaceutical companies, across all types 
of Indian pharmaceutical companies 
0.406 Supported 
H041 There is no significant difference in the mean value of quality related skills 
acquired by Indian pharmaceutical companies, as an area of impact of strategic 
alliances between Indian and foreign pharmaceutical companies, across Indian 
pharmaceutical companies of different turnover 
0.237 Supported 
H042 There is no significant difference in the mean value of quality related skills 
acquired by Indian pharmaceutical companies, as an area of impact of strategic 
alliances between Indian and foreign pharmaceufical companies, across Indian 
pharmaceutical companies with different activities 
H043 There is no significant difference in the mean values of increased market share as 
an area of impact of strategic alliances between Indian and foreign 
pharmaceufical companies, across all types of Indian pharmaceutical companies 
H044 There is no significant difference in the mean values of increased market share as 
an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies indulging in 
various activities 
H045 There is no significant difference in the mean value of increased market share as 
an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies of differing 
turnovers 
H046 There is no significant difference in the mean value of on enhanced profitability 
as an area of impact of strategic alliances between Indian and foreign 
pharmaceufical companies, across Indian pharmaceufical companies of differing 
company types 
H047 There is no significant difference in the mean value of on enhanced profitability 
as an area of impact of strategic alliances between Indian and foreign 
pharmaceufical companies, across Indian pharmaceutical companies indulging in 
various activifies 
H048 There is no significant difference in the mean value of on enhanced profitability 
as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies of differing 
turnovers ^ 
H049 There is no significant difference in the mean value of establishment of Indian 0.050 Supported 
0.800 Supported 
0.136 Supported 
0.223 Supported 
0.185 Supported 
0.008 Not 
supported 
0.013 Not 
supported 
0.004 Not 
supported 
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pharmaceutical brand names in the global market as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies, 
across the types of activities undertaken by Indian pharmaceutical companies 
H050 There is no significant difference in the mean value of establishment of Indian 0.107 
pharmaceutical brand names in the global market as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies, across 
the types of Indian pharmaceutical companies 
Supported 
H051 There is no significant difference in the mean value of establishment of Indian 0.027 
pharmaceutical brand names in the global market as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies, 
across Indian pharmaceutical companies of varying turnover 
Not 
supported 
H052 There is no significant difference in the mean values of acquisition of 
management skills by Indian pharmaceutical companies as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies on the, 
across all types of Indian pharmaceutical companies 
0.166 Supported 
H053 There is no significant difference in the mean value of acquisition of 
management skills by Indian pharmaceutical companies as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies, across 
Indian pharmaceutical companies of different turnover 
0.194 Supported 
H054 There is no significant difference in the mean value of acquisition of 
management skills by Indian pharmaceutical companies as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies, across 
pharmaceutical companies indulging in various activities 
O.OIO Not 
supported 
for Formation of Strategic Alliances between Indian and Foreign Pharmaceutical 
Companies on Indian Pharmaceutical Companies 
1 
2 
3 
4 
5 
6 
li^ * 
Lack of data related to organizations and their Interests 
Lack of governmental policies and 
Unclear alliance objectives of Indian pharmaceutical 
companies regarding alliance formation 
Lack of communication among between alliancing 
Indian and foreign pharmaceutical companies 
Lack of alliance progress monitoring between Indian 
and foreign pharmaceutical companies 
Lack of Trust among alliancing companies 
^ l l « i p i 
3.38 
3.52 
3.34 
3.71 
3.68 
3.79 
"'"Sl5*""lf 
.98 
.80 
.73 
.73 
.66 
.79 
5 
4 
6 
2 
2 
1 
Correlation 
Factors \ \ 
Product 
Variables 
Strengthen product portfolio 
Establish brands abroad 
Launch new products 
Correlation 
.343 
.280 
.066 
Influence 
Moderate 
Moderate 
Low 
K square 
.126 
26 
Marketing 
Technology 
Manufacturing 
Competitive Advantage 
Global emerging markets 
Regulated markets 
Distribution channels abroad 
Access new technology 
Collaborative R&D 
USFDA approvals 
Cost minimization 
Common assets 
Quality management 
Market position 
Financial power 
Image 
.328 
.345 
.259 
.025 
.300 
.134 
-.138 
.162 
-.162 
.063 
.315 
.296 
Moderate 
Moderate 
Moderate 
Low 
Moderate 
Low 
Low 
Low 
Low 
Low 
Moderate 
Moderate 
.159 
.095 
.108 
.145 
a. Factors that influence Indian pharmaceutical companies to form strategic alliances with foreign 
pharmaceutical firms. 
b. Impact of the strategic alliances between Indian and foreign pharmaceutical companies on various 
business aspects of the Indian pharmaceutical firm. \ 
c. 
' ? ' J ^ T ^ S ' " ' • - '••••••• • ' 
j iactors 
Product 
Marketing 
Techngy 
Manufacturing 
Competitive Advantage 
New patents 
New generics abroad 
New generics domestic 
Wide portfolio 
Regulated market 
Investment capability 
Foreign distribution 
New technology 
R&D capability 
GMP compliance 
Access to information 
Cost optimization 
Common assets 
Quality management 
Increased market share 
Increased profits 
Established new brands 
Managerial capabilities 
.403 
.452 
.324 
.187 
.305 
.423 
.466 
.132 
.295 
.250 
.463 
.261 
.120 
-.164 
.154 
.229 
.300 
.255 
impact 
High 
High 
Moderate 
Low 
Moderate 
High 
High 
Low 
Moderate 
Moderate 
High 
Moderate 
Low 
Low 
Low 
Moderate 
Moderate 
Moderate 
*^^BmSmm 
.277 
.278 
.226 
.139 
.108 
d. External and Internal hindrances for the formation of strategic alliances between Indian and foreign 
pharmaceutical companies. 
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py Rsq||L 
1 \ternal 
Internal 
Information 
Govt, policies 
Unclear objectives 
Lack of communication 
Non monitoring of alliance 
Lack of trust 
-.126 
-.063 
.193 
.102 
-.243 
-.012 
Negative .198 
Negative 
Low 
Low 
Negative 
Negative 
CONCLUSIONS, RECOMMENDATIONS AND DIRECTIONS FOR FUTURE 
RESEARCH 
Conclusions for the Main Research Problem 
After analyzing the primary data, the following conclusions can be drawn with reference 
to reasons for strategic alliances, impact of strategic alliances and the hindrances for 
strategic alliance between Indian and foreign pharmaceutical companies. However the 
expected outcome of these factors differs from company to company. 
Conclusions Relating to Reasons for Strategic Alliance between Indian and Foreign 
Pharmaceutical Companies: 
• Strengthen product portfolio 
This research work has indicated that for Indian pharmaceutical companies a driving factor 
for the formation of Strategic alliances between Indian and foreign pharmaceutical companies 
is the need to strengthen the existing product portfolio of Indian companies. 
Establish new brand abroad 
Primary research indicates that Indian pharmaceutical companies look at strategic alliances 
with foreign pharmaceutical companies, to establish their products and brands in the foreign 
market. This is also substantiated by Pradhan (2007). 
Launch new product lines 
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Research indicates that Indian companies seek alHances with foreign pharmaceutical firms to 
enable them launch new products in the market. 
Enter global emerging markets 
Expanding the market by entering new emerging markets is a strong driver for Indian 
pharmaceutical companies to form strategic alliances with foreign pharmaceutical 
companies. 
• Enter regulated markets 
Indian pharmaceutical companies consider entry into regulated market like US, UK, 
European Union as the third most important reason which drives strategic alliances between 
Indian and foreign pharmaceutical companies. 
• Establish distribution channels abroad 
The need to establish new distribution channels in foreign market which will eventually 
help in marketing the products, drives strategic alliances between Indian and foreign 
pharmaceutical companies.. 
• Access new technology 
Research indicates that Indian pharmaceutical companies consider gaining access to new 
technology as a reason that can drive strategic alliances between Indian and foreign 
pharmaceutical companies. 
Undertake collaborative R&D 
Indian companies consider collaborative R&D as a driver for strategic alliances between Indian 
and foreign pharmaceutical companies. 
Obtain USFDA approved manufacturing facilities 
Pharmaceutical companies in India look at strategic alliances with foreign pharmaceutical 
companies to gain access to USFDA approved manufacturing facilities. 
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Cost minimization 
Research indicates that cost minimization is a factor that can influence the formation of 
strategic alliances between Indian and foreign pharmaceutical companies. 
Achieve operational synergy 
Achieving operational synergy may be a reason for strategic alliances between two firms, 
however with respect to Indian and foreign pharmaceutical companies, this is not a strong 
driving factor for Indian pharmaceutical companies to look, at strategic alliances with 
foreign pharmaceutical companies. 
• Achieve quality management 
Gaining knowledge on quality related aspects and managing overall quality is a driver for 
strategic alliances. However with respect to Indian pharmaceutical companies, this is not a very 
critical driver for strategic alliances with foreign pharmaceutical companies. 
• Achieve market position 
This research has indicated that achieving high market position is a key factor which 
drives Indian pharmaceutical companies to form strategic alliances with foreign 
pharmaceutical companies. 
• Achieve financial power 
The need to have adequate financial power through high profits is a strong driver for 
Indian pharmaceutical; companies to form strategic alliances with foreign pharmaceutical 
companies. 
Enhance company image 
This research indicates that Indian pharmaceutical companies feel that the primary reason for 
strategic alliances between Indian and foreign pharmaceutical companies is the need to 
enhance the company image and score on competitive advantage. 
Conclusions Relating to Impact of Strategic Alliance 
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Analysis of the primary data from Indian pharmaceutical companies indicate that strategic 
alliances between Indian and foreign companies has a direct impact on new patent filing and 
new product launches from Indian pharmaceutical companies. 
• Strategic alliances and introduction of new patents from Indian pharmaceutical 
companies 
The response from the Indian companies indicates that there is a strong impact of strategic 
alliances with foreign pharmaceutical companies on the introduction of new patents by the 
Indian pharmaceutical companies. 
Strategic alliances and launch of generic products abroad 
This research indicates that there is a strong impact of strategic alliances with foreign 
pharmaceutical companies on the launch of generic products abroad in foreign markets. 
Strategic alliances and launch of generic products in domestic market 
This study indicates that the Indian pharmaceutical companies of varying sizes find that 
strategic alliances between Indian and foreign pharmaceuticals impact the launch of generic 
products in the domestic market. 
Strategic alliances and enhanced product portfolio 
This research indicates that Indian pharmaceutical companies across various phannaceutical 
activities like manufacturing R&D, contract manufacturing and distribution, feel the impact 
of strategic alliances with foreign pharmaceutical companies on their portfolios positively. 
Strategic alliances and access to regulated markets 
Primary research indicates that strategic alliances between Indian and foreign pharmaceutical 
companies have a positive influence in helping Indian pharmaceutical companies gain access 
into regulated markets like US and Europe. 
31 
Strategic alliances and investment in sales and marketing 
Primary research indicates that strategic alliances between Indian and foreign pharmaceutical 
companies have a considerable impact in enhancing marketing capability, across all sizes, 
types and activities of the Indian pharmaceutical company. Chitoor, Ray and Sarkar 
( 2008)\x\d\caiQd that alliances enhance investment capabilities among organizations. 
. Strategic alliances and access to foreign distribution network. 
Primary research indicates that strategic alliances between Indian and foreign pharmaceutical 
companies have considerably influenced Indian companies, of different sizes, activities and 
types, to gain access into distribution channels in foreign market. 
Strategic alliances and access to new technology 
Primary research indicates that strategic alliances between Indian and foreign pharmaceutical 
companies have no impact on the acquisition of new technology by Indian pharmaceutical 
companies. 
Strategic alliances and achieving R&D capability 
Primary research indicates that strategic alliances between Indian and foreign pharmaceutical 
companies have helped Indian companies achieve R&D capability.Indian pharmaceutical 
companies are moving from traditional manufacturing related activities towards R&D and 
research and strategic alliances are proving to be one of the routes that companies are resorting 
to. 
Strategic alliances and GMP compliant production capacities 
Primary research indicates that strategic alliances between Indian and foreign pharmaceutical 
companies have an impact on Indian companies gain GMP compliant capacities 
Strategic alliances and access to information 
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Primary research indicates that strategic alliances between Indian and foreign pharmaceutical 
companies have helped Indian companies gain access to information. 
Strategic alliances and cost optimization 
Primary research indicates that strategic alliances between Indian and foreign pharmaceutical 
companies have no impact on the cost optimisation in the manufacturing activities of Indian 
phannaceutical companies. 
Strategic alliances and achieving operational synergy 
Primary research indicates that Indian pharmaceutical companies have no implication on 
operational synergy sue to strategic alliances between Indian and foreign pharmaceutical 
companies . 
Strategic alliances and quality management 
Primary research indicates that strategic alliances between Indian and foreign pharmaceutical 
companies have no impact on cost optimisation in their manufacturing activities for Indian 
companies. 
Strategic alliances and increased market share 
Many pharmaceutical companies have increased their market shares over the years due to 
enhanced economic activities, which has increased their turnover and in turn increased their 
market share. 
Strategic alliances and increased overall profitability 
Primary research indicates that strategic alliances between Indian and foreign pharmaceutical 
companies have helped Indian companies achieve overall profitability. 
. Strategic alliances and brand building 
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Primary research indicates that strategic alhances between Indian and foreign pharmaceutical 
companies have helped Indian companies enhance their brand value. 
Strategic alliances and acquiring superior managerial skills 
Primary research indicates that strategic alliances between Indian and foreign pharmaceutical 
companies have helped Indian companies acquire superior managerial skills. 
Conclusions Relating to Hindrances for Strategic Alliance 
There are many factors which hinder the formation and successful progress of an alliance with 
a foreign pharmaceutical company. For a successful progress these aspects need to be identified 
and monitored. 
External: Lack of information 
In this study the respondent consider the lack of information as a strong factor which impedes 
the formation of strategic alliance between Indian and foreign pharmaceutical companies. 
External: Governmental policies 
In this study the respondents consider lack of policies, guidelines and governmental support 
as a key deterrent for the formation of strategic alliances between Indian and foreign 
pharmaceutical companies. 
Internal: Unclear objectives 
In the study the respondents indicate that clear objective goes a long way in determining the 
success of a partnership. 
Internal :Lack of communication 
. In the current study, the respondents indicate that lack of communication does cause fractures 
in the alliance which can ultimately lead to failure to achieve the objectives 
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Internal: Non monitoring of alliances 
In this study the respondents indicate that it is critical to monitor the alliance progress and the 
success of the alliance is dependent how close the top management is involved in the alliance 
and its progress. 
Internal: Lack of trust 
The respondents in the study have indicated strongly that lack of trust is a serious threat to the 
success of any alliance. Trust can be built by communication, interactions, transparency and 
clarity on the objectives of both the alliancing companies 
Recommendations for Indian Pharmaceutical Companies Undertaking Strategic Alliances 
Based on the study and analyses of strategic alliance between Indian and foreign 
pharmaceutical companies, the following strategic orientation can be adopted for Indian 
pharmaceutical companies. 
Indian Pharmaceutical Companies of Different Turnover: 
Small pharmaceutical companies 
• Concentrate on meeting stringent regulatory norm specified by USFDA, GMP etc. This 
will help generate new avenue for growth by entering into contract manufacturing for 
MNCs. 
• Develop and upgrade the manufacturing facilities both for capacity enhancement and 
quality related aspects, this will open up opportunities 
Middle tier pharmaceutical companies 
• Generic sales particularly to foreign market is a large business segment with scope to 
grov ,^ Indian pharmaceutical companies should make use of this growth phase. Getting 
into alliances with MNCs whose drugs are expected to go off patent, can be an approach. 
This will help in enhancing the capacity of middle tier companies and help them to 
reach new market and increase their turnover. 
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• Concentrate on enhancing their production capacities to be able to take advantage of the 
growing demand for cheaper drugs. This can be achieved by undertaking collaborations 
with firms both in India and abroad. 
• Gain expertise in regulatory requirement across the world, to develop the necessary 
competency to cater to all the market across the world. This can be achieved by 
alliance with a partner with adequate market specific experience and knowledge in 
regulatory requirement and is in compliance. 
Large pharmaceutical companies 
• Current Indian skill set is in synthetic chemistry. There is scope for growth in area like 
new lead molecule new target in new area like medicinal biology and protein chemistry. 
High level of research and new drug development can be achieved with collaboration 
with MNC. 
• Concentrate effort in BioPharma for both regulated and non regulated markets. 
Indian pharmaceutical companies can enter into collaboration with BioPharma 
companies to develop new products. This will take top pharmaceutical companies 
towards innovation. 
Indian Pharmaceutical Companies of Different Types of Activities 
Manufacturing : 
• Develop international grade of manufacturing facilities which can meet stringent 
regulatory requirements . 
• Undertake alliances with Indian and foreign pharmaceutical firms to utilize the 
capacity to the fullest and undertake contract manufacturing 
Ri&D: 
• Develop strategic alliances with research oriented pharmaceutical companies to access 
latest advancements in science and technology. 
• Provide contract research facilities to other pharmaceutical firms 
Contract manufacturing: 
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• Develop manufacturing capacities to high standards to enable international companies 
get into alliances 
• Focus on meeting stringent regulatory norms both domestic and international 
• Enhance production capacities to meet the requirement of the off patent drugs 
Indian Pharmaceutical Companies of Different Types of Companies: 
API : 
• Develop capabilities to move upwards the value chain towards the manufacturing of 
formulations and specialty drugs. Can be achieved by alliances and self 
development. 
• Concentrate on alliances with different pharmaceutical companies to supply and 
develop new API molecules with the growing demand in the market 
Formulations : 
• Adopt competencies to move towards specialty drugs and R&D . This can be 
achieved through alliances with suitable partner 
• Invest in R&D 
• Invest in development of facilities to meet stringent regulations thereby enhancing 
prospects in domestic and international market 
Clinical Research : 
• Develop competencies to meet regulatory requirements across the world to enable 
more scope of clinical research in India . 
Strategies for long term success of alliance 
• Alliance should be well thought out and directly should be linked to growth 
objective. 
• Alliances should have a clear monitoring at every stage with roles and 
responsibilities defined 
• Communication should be focused on both e internally and with the alliancing 
partner 
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• Trust is developed slowly, and can be enhanced with successful alliances for various 
aspects 
Suggestions 
• Government needs to initiate a database of each company about the current alliances 
and the core competency of each company to help prospective alliances select right 
allaincing partners. 
Future Research Directions 
Future Research Direction s are as follows: 
• Identify some specific product related factors which are influential. Future research can 
throw some more light in this direction. 
• There is scope for future research to identify more factors that influence strategic 
alliances between Indian and foreign pharmaceutical companies. 
• Future research can throw light on other technological reasons for strategic alliance. 
This research study indicates a collaborative R&D to be a significant driver for alliances. 
• Identify other manufacturing related factors that can influence strategic alliances 
between Indian and foreign pharmaceutical companies. 
• Future research can be directed towards identifying more competitive factors which 
influence alliance formation between Indian and foreign pharmaceutical companies. 
• Strategic alliances has impact on many more aspects of the organization like 
employees, customers, other alliances etc which are not covered in their research. This 
can be a future scope of study as this will give the entire picture of the strategic 
alliance and its impact. 
• There are other factors which can be influenced by alliances and this is a scope for 
future research. 
• Future research can analyse the other hindrances for the alliance like employee related 
aspects, training and learning related aspects and market related aspects. 
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PREFACE 
Increasing levels of competition has increased the costs of doing business substantially. 
Sustained inflation; heavy costs of developing and commercializing products; regulatory 
compliance; and globalization have increased marketing costs leading to increase in 
business expenses across all industries. Pharmaceutical industry in India has grown from 
virtual non existence in the 1940s to a fast growing, third largest industry in India, which 
is all set to grow three fold to US $20 billion by 2015. Patent expiry and rising cost 
pressures encourages the alliance formation of multinational companies with local players 
in the emerging markets, India being the foremost among them. 
Sustainability of a pharmaceutical company is dependent upon the continuity of its new 
drug pipelines, which is often achieved through acquisition of smaller research driven 
firms. Small research driven companies lack the capital for product launches and 
marketing, thus alliances are the directions taken by most companies. India is not far 
behind in alliance formation. Over the last decade the number of alliances has increased. 
Most alliances are successful as the objectives are met, many are not. 
This empirical study attempts to understand the strategic alliances between Indian and 
foreign pharmaceutical with a reference to the Indian pharmaceutical industry. It tries to 
understand the reasons that have led Indian pharmaceutical companies to form strategic 
alliances with foreign companies over the years. It also tries to estimate the actual 
implications of the alliances on business related aspects. The study makes an attempt to 
identify the hindrances for the successful formation of strategic alliances between Indian 
and foreign pharmaceutical companies. 
The study involves development of a research questionnaire with the insights derived 
from industry experts whose firms have undertaken strategic alliances with foreign 
pharmaceutical companies. The factors that have influenced the formation was 
alliances were derived from existing literature and expert opinions. The questioimaire 
was then administered to top executives of Indian pharmaceutical companies, who have 
been involved in strategic alliances with foreign companies. The samples were 
categorized based on the type of pharmaceutical company, the activities undertaken by 
the pharmaceutical company and the annual sales turnover of the company. The 
responses were analyzed using statistical tools on the SPSS software. 
Increasing costs and competition has ensured that strategic alliances are a norm of today. 
Three critical aspects regarding the strategic alliances between Indian and foreign 
pharmaceutical companies were tested: the factors influencing the formation of 
alliances between Indian and foreign pharmaceutical companies, the impact of strategic 
alliances on business aspects of the Indian pharmaceutical company and the hindrances 
for the formation of strategic alliances between Indian and foreign pharmaceutical 
companies. 
The outcome of this work can help in drawing out some concrete strategies that will enable 
the Indian pharmaceutical companies gain the maximum out of strategic alliances with 
foreign pharmaceutical companies. This work will be beneficial to both Indian and 
foreign pharmaceutical companies, seeking out alliances as it will throw light on the 
motivating factors for the alliances, expected areas of impact and the hindrances for 
the alliances. By adopting better objectivity and understanding the roadblocks the 
success rated of the alliances can be maximized for mutual benefits by the alliancing 
companies. 
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Monopolies and Restrictive Trade Practices Act 
Organization of Pharmaceuticals Producers of India 
Exclusive Marketing Rights 
Drugs and Cosmetic Act 
Drugs and Cosmetics Rules 
Hindustan Antibiotics Ltd 
Indian Drugs and Pharmaceuticals Ltd 
Trade Related Intellectual Property Rights 
Central Drugs Standard Control Organization 
Drugs Controller General of India 
Food and Drug Administration 
Advertising Standards Council of India 
Trade and Merchandise Marks Act 
Clearing and Forwarding 
Drugs Price Control Order 
National Pharmaceutical Pricing Authority 
All India Organization of Chemists and Druggists 
New Chemical Entity 
New Drug Delivery Systems 
World Health Organization 
United Nations Children's Emergency Fund 
Foreign Direct Investment 
Joint Venture 
Abbreviated New Drug application 
Drug Master File 
Intellectual property 
Cumulative Annual growth rate 
CHAPTER 1: INTRODUCTION 
/. 1 Strategic Alliances 
A company can outperform rivals only if it can establish a difference that it can preserve. 
/•or/erfiPPd,) indicated that the company must deliver greater value to customers or create 
comparable value at a lower cost in order to create a differentiation. Competitive strategic 
focus is deliberately choosing a set of activities to deliver unique value to the customer, 
thereby creating a differentiation in the eyes of the customer, which will prove to be 
advantageous to the firm. 
Increasing levels of competition has increased the costs of doing business substantially. 
Sustained inflation; heavy costs of developing and commercializing new technologies, 
processes and products; increased complexity of regulatory compliance; the need to compete on 
a world-wide basis and the increased marketing costs associated with competing in a mature 
market have led to increase in business expenses (Barrie, 1985). While new technologies have 
aided large scale international communication and transportation, companies themselves have 
moved internationally to seek new markets both to obtain new sources of growth outside 
mature home markets. 
Firms are looking at alliance strategies, which can offset, to some extent, some of the high 
cost/high risk syndrome. Significant change in the business environment due to economic 
conditions, high costs, the globalization of business and increasing political control has 
changed the focus of alliance strategies to the point where they are now becoming the rule 
rather than the exception (Barrie, 1985). 
1.1.1 Theories of Strategic Alliances 
An alliance is defined as any inter-firm co-operation that falls between extremes of discrete, 
short-term contracts and the complete merger of two or more organizations, {Contractor & 
Lorange, 2002). Alliances can be temporary like licensing agreements which are revoked after 
a particular period or permanent as evident by the formation of conglomerates with the mergers 
of multiple companies. 
Alliances can be: 
• Horizontal - marketing alliances between companies 
• Vertical - R&D efforts of one firm being commercialized by another 
There are a number of theories which explain strategic alliances; five approaches which are 
discussed in the literatures are as follows. 
(1) Resource based theory 
(2) Strategic behavior theory 
(3) Theory of synergy 
(4) Transactions costs theory 
(5) The theory of mimetic organizations 
Tsang (1997), attempted to explain strategic alliance formation from the resource-based 
approach while he identified five major motives for strategic alliance, namely creation of rents, 
expansion of resource usage, diversification of resource usage, imitation of resources and 
disposal of resources. While explaining them he indicated that a firm's resources consist of all 
its assets, knowledge, organizational structure, procedures, and so forth that are controlled by 
the firm. These resources are classified into three categories, physical resource, human resource 
and organizational resource. Physical resources include tangible assets such as land, plant, 
equipment, finished and semi-finished goods, as well as intangible assets such as brand name, 
copyright and patent. Human resources include the education, training, experience, 
relationships, skills, and intelligence of individual staff in a firm. Organizational resources 
include corporate culture, organizational structure, rules, procedures, management information 
sy.stems, as well as a firm's relationships with external institutions. He defined strategic alliance 
as a long-term co-operative arrangement between two or more independent firms that engage in 
business activifies for mutual economic gain. Ricardian rent which is the result of possessing 
valuable resources such as trade secrets, cutting edge technologies, copyrights and patents are 
of importance in alliances. 
The strategic behavior theory approaches long term profitability by improving the competitive 
positions against competing firms. Cooperative arrangements through alliances speed up the 
commercialization process especially in a technology intensive industry. These firms believe in 
the first mover approach, wherein the first mover can gain access and block the entry of 
competition. This is critical in the pharmaceutical industry as many companies produce 
innovative drugs which are patented to allow the company to reap maximum benefits. 
Additionally, the brand names play a key role as physicians remember the name for a 
very long time, especially so if the molecule is a new blockbuster or first mover in the 
market. Strategic behavior posits that firms transact by the mode which maximizes profits 
through improving a firm's competitive position vis-a-vis rivals (Kogut, 1998). 
The theory of synergy builds on the symbiotic relationships between two firms. This is a 
mutually beneficial association which can be linked to complementarity of assets. 
Shan and Visudtibhan (1990), have endorsed that inter-firm cooperative arrangements span 
a wide spectrum of organizational forms between spot market relationship and complete 
merger. According to them, the most intuitive explanation for cooperative arrangements is their 
obvious synergistic effects: risk reduction, economies of scale and scope, production 
rationalization, and convergence of technology. When the synergies created by pooling the 
resources of cooperating partners outweigh the hitches in the relationships of the two firms, 
then cooperative relationships can be created. 
Transaction costs theory which was developed Williamson (1975), proposes that firms choose 
how to transact according to the criterion of minimizing the sum of production and transaction 
costs. Transaction cost theory posits that firms transact by the mode which minimizes the sum 
of production and transaction costs. Kogut (1988), indicates that Transaction costs refer to the 
expenses incurred for writing and enforcing contracts, for haggling over terms and contingent 
claims, for deviating from optimal kinds of investments in order to increase dependence on a 
party or to stabilize a relationship, and for administering a transaction. 
Theory of mimetic organizations indicates that some organizations enter into alliances only 
because it has become a fashionable or a common thing to mimic (McCutchen, 2004). Mimetic 
organizations are followers of key strategies in the industry. 
1.1.2 Types of Strategic Alliances 
Contractor and Lorange (2002), have graphically represented the various alliance possibilities 
on a relationship based continuum. One time contracts involves those situations wherein the 
alliancing partners come together for a particular activity or project and do not repeat the 
Illustration 1 : Alliances 
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partnership. Relational contracts are those situations where the alliancing partners come 
together for a turnkey project and may repeat this for future projects. Medium term contractual 
relationship involves specific long duration activities like licensing, distribution etc. Another 
long term relationship is equity joint venture. The final piece in the continuum is the complete 
merger of one company with another. 
1.J.3 Alliance Process 
Strategic alliances between firms involve interactions between two or more firms which lead to 
co-evolution driven by a process of co-operation and understanding. The basis for any alliance 
is in the strategic growth plan of the organization. A typical alliance formation involves the 
following steps: 
• Development of growth strategy for the organization: which is a roadmap of the plans, 
wherein the need for an alliance will emerge as a key action point. 
• Alliance Strategy development: involves studying the feasibility of an alliance focusing 
on issues and challenges, including aspects of technology, production and people. 
• Assessing the partners for the alHance: involves analyzing the alliancing partner's 
stren j^ths and weakness, understanding the synergies, capability gaps. 
• Negotiating the contract: wherein the objectives, responsibilities and expectations are 
worded in a document format. Aspects of arbitration need to be articulated for clear 
understanding. 
• Alliance operation: is the actual day to day functioning of the alliance. It involves a 
feedback process which monitors the progress of the alliance and takes up corrective 
actions wherever required. 
• Alliance termination: involves the closure of the alliance after the objectives are met. 
Sometimes alliance may be terminated due to lack of trust and working relationship 
between the two organizations. 
Hoffmann and Schlosser (2001) have suggested a conceptual framework for the alliance 
evolution. They are: 1. Strategic analysis and the decision to co-operate, 2. Search for a 
partner, 3. Designing the partnership, 4. Implementation and management of the partnership, 
5. Termination of the partnership. 
1.2 Major Types of Strategic Alliances among Pharmaceutical Companies 
In the pharmaceutical sector, McCutchen (2004) has identified and studied the following 
categories of strategic alliances. 
1. R&D/marketing and licensing wherein one partner receives or shares marketing rights 
to a product and provides development funding and/or research. 
2. Marketing/licensing: In this deal, marketing rights are granted, but no significant 
funding for research of the product is involved. 
3. Acquisitions: An acquisition means that one firm takes over part or all of the assets of 
another firm. 
4. Alliances with equity investment: The terms of the deal include an acquisition of shares. 
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5. Joint venture wherein the partners form a new entity together, of which each partner 
owns a certain percentage. 
6. Co-promotion: Two or more partners agree to market a product in the same territory 
using the same brand name. 
7. Manufacturing/supply: One partner performs manufacturing for another, or agrees to 
supply a product to the other. Agreements with companies whose primary business is 
contract manufacturing are not included. 
8. Product acquisition: One company acquires exclusive worldwide rights (or rights for a 
certain geographic territory) to a product. This differs from a license agreement in that it 
does not imply an ongoing relationship. 
9. Comarketing: Two or more partners will market a product in the same territory under 
their own distinct brand names. 
In the pharmaceutical industry the firms can access new technology either by developing its 
internal R&D functions or through acquiring technologies from smaller firms. Smaller biotech 
companies which are developed as the result of innovations are a good source of technology 
upgradation. 
1.3 Strategic Alliances in the Indian Pharmaceutical Industry 
Costs of doing business, sustained inflation, heavy expenses involved in product research & 
development, complexity of regulatory compliance, marketing costs, worldwide business 
expansion are driving companies towards alliances {Barrie, 1985). 
Tracing the pharmaceutical alliances over the last 4 decades, indicate that there has been a 
dramatic surge in the strategic alliances in the last couple of decades. Indian 
pharmaceutical companies have sought the option of entering into joint ventures or 
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acquiring a firm in the maricet of their choice. Thus, over the years they have established 
manufacturing faciHties in various countries across the globe. In the period between 1976-
^^{anmxure 2) due to prevailing norms, foreign collaborations into India were limited. The 
trend shows an outward orientation of the then Indian giants. They were very keen to set up 
manufacturing facilities across various third world countries to take advantage of the local 
needs. These markets were non-regulated and gaining access to these markets was relatively 
easy. The nature of the alliances ranged from manufacturing facility acquisition and 
development to market development, establishing their production facilities either as a joint 
ventures or wholly owned subsidiaries. 
The period 1990-1999 (annexure 2), witnessed sweeping reforms in the pharmaceutical 
industry. India implemented transitory measures for intellectual property protection to meet the 
WTO obligations. Additionally, the licensing requirements for entry and expansion of the firms 
were abolished, thus allowing 100 percent inward foreign investment. With the onslaught of 
competition, domestic companies opened up to new business opportunities abroad and locally. 
Another interesting aspect in alliances during this period was the surge in the involvement of 
developed countries. Regulated markets like US and UK became the favorite alliancing 
partners to top Indian firms. 
The pioneers in international strategic alliances during this time were: Ranbaxy 
Laboratories, Sun Pharmaceuticals and Wockhardt. Ranbaxy acquired Ohm Laboratories in 
1995, to develop its presence in the US OTC market and it also supported the 
manufacturing of its approved abbreviated new drug application products. Sun 
Pharmaceuticals entered the US generic market by acquiring a 30 percent equity stake in 
Caraco pharmaceuticals in 1997. Wockhardt ventured into the European market by acquiring 
the UK based Wallis Laboratory in 1998, thus opening the doors to supply its own 
healthcare products into the UK. During this period, another interesting avenue that surfaced 
was contract manufacturing. Companies like Ranbaxy, Lupin and Shasun signed contract 
manufacturing agreements with US based firms. 
The period between 2000 and 2005 (amexure 2), witnessed large number of trans- border 
alliances and acquisitions totaling to 49 with an aggregate consideration of $1.3 billion. The 
7 
outward alliances involved acquisition of various companies across the globe, by many top 
Indian firms. The objective behind the alliances ranged from acquiring manufacturing 
capabilities in regulated market especially for generic products to gaining entry into 
international markets, through already established local firms. The period also witnessed 
large number of inward alliances. Many multinational companies from USA, Europe and 
Japan were involved in collaborative activities with the Indian pharmaceutical companies. An 
analysis of the alliance objectives indicate new drug development, acquiring manufacturing 
capabilities of generics, developing new formulations to be the main reasons for the 
collaboration. 
Table No: I Alliances between Indian Companies and MNCs post 2006 
WL Quarters 
Description 
Advinus Therapeutics 
Suven Life sciences 
Indus Biosciences 
GVK Biosciences 
Niciioias Piramal 
Ranbaxy 
Shantha Biotech 
Dabur 
Strides Aroclab 
Aurobindo 
Claris Life science 
Dr Reddy's 
Strides Arcolab 
Torrent 
Cadiia Healthcare 
Wockhardt 
Wockhardt 
Shantha Biotech 
OrchidChemicals 
Vendant Drugs and 
Pharmaceuticals 
Famycare 
Piramal Healthcare 
2U06 
2006 
2006 
2006 
2007 
2008 
2008 
2008 
2008 
2009 
2009 
2009 
2009 
2009 
2009 
2009 
2009 
2009 
2009 
2009 
2009 
2010 
Merck 
Eli Lily & Co 
Galapagos NV 
Wyeth 
Pharmaceuticals 
Eli Lilly & Co 
Daiichi Sankyo Co 
Ltd 
Sanofi Aventis 
Fresenius Kabi 
GSK 
Pfizer 
Pfizer 
GSK 
Pfizer 
AstraZeneca 
Abbott 
Vetoquinol SA 
Abbott Laboratories 
Sanofi Aventis 
Hospira 
Perrigo 
Mylan Labs 
Abbott Laboratories 
US 
US 
Belgium 
US 
US 
Japan 
France 
Singapore 
UK 
US 
US 
UK 
US 
UK 
US 
France 
U.S. 
France 
US 
USA 
Drug development 
Drug development 
Integrated chemistry services-
DD 
Synthetic chemistry 
Development and 
commercialization 
Emerging markets 
Generic 
Generic in US 
Generic to western mkts 
Animal Care Subsidiary 
Nutrition Business 
Injectable business 
Company acquisition 
15% stake 
Formulation business with one 
manufacturing unit 
Source : collated from KPMG report - The Indian Pharmaceutical Indiistrv. krc eaiiilv research- krc.research&.krchoksev.com 
Post 2000, the pharmaceutical companies started to enter into alliances both in foreign and 
domestic markets in an unprecedented scale. The quantum of inward alliances almost doubled 
between 2000 and 2005, from $48 million to $114million. Trans-border acquisitions totaled at 
49 with an aggregate of $1.3 billion. 
Table No. 2: Recent Alliances in Indian Pha-'macculical Span-
•iv'..-.* .»...: U^ . • • - • • • • • ••-•'• 
May 2009 Pfizer - Aurobindo Pharnia 39 generic finishpd-dose products in the US and 20 in Europe, plus 
an additional 11 in France. The supply pact later extended for 
another 60 products for selling in several countries through Asia, 
Latin America Africa and West Asia 
May 2009 Pfizer- Claris Lifesciences Pfizer entered into a partnership with Claris Lifesciences, an 
injectable drug maker, to commercialize off-patent drugs in the US, 
Canada, Australia, New Zealand and Europe 
Jan 2010 Pfizer-Strides Arcolab Strides Arcolab signs a major licensing and supply deal with Pfizer 
to source 40-patent free medicines mostly injectable cancer 
therapies for sale in US 
Source - IDFC - SSKl Research, Changing Landscapes - a special report on the World's Top 50 Pharma Companies, 
wwM.pharniexec.com,may 2006 
1.4 Strategic Alliances of Top 5 Indian Pharmaceutical Companies 
There are several national and international pharmaceutical companies that operate in India. 
Ranbaxy Laboratories Limited is the biggest pharmaceutical manufacturing company in 
India. The company is ranked at the 8th position among the global generic pharmaceutical 
companies and has presence in 48 countries including world class manufacturing facilities in 10 
countries and serves to customers from over 125 countries. In 1960 Ranbaxy started 
manufacturing antibiotics and became a public limited company in 1973. Ranbaxy was 
instrumental in developing new processes for patented drugs which were cost effective and 
served the domestic Indian markets, thus developing the technological competencies of the 
firm. 
In 1977 and 1983, Ranbaxy entered into joint ventures with Nigeria and Malaysia respectively 
with the objective of supplying cheap drugs. Additionally these countries had slack patent 
policies. It further expanded its geographical presence through joint ventures in countries 
like Thailand, Canada and China wholly owned subsidiaries in Netherlands and Hong Kong 
during 1980s-90s. 
Table No. 3: Ranbaxy Alliances 
». ! -i. f - • .. •• • 
Outbound 
Ohm Laboratories 
Guangzhou China 
RPG (Aventis) 
Bayer 
Bayer 
Nippon Chemiphar 
Be Tabs pharma 
Glaxo smithkline 
Terapia 
Inward 
Eli Lilly 
Zenotech 
Domestic 
Orchid Chemicals 
Glaxo smithkline 
IPCA 
Cipla 
Zydus Cadila 
MAJORITY PARTNER 
Daiichi Sankyo (2009) 
Source: www.ranbaxv.com 
USA (1995) 
Lagos (Nigeria) 1977 
JV(1993) 
France(2004) 
Germany (1999) 
Germany (2000) 
Vietnam (2001) 
Japan (2005) 
South Africa (2006) 
Spain and Italy (2006) 
Romania (2006) 
USA(2001) 
USA(2006) 
Marketing (2008) 
R&D (2003 and 2007) 
Manufacturing (2007) 
Marketing (2001) 
Marketing (2001) 
1 •' Objective 
Manufacturing 
Manufacturing 
Marketing of ciprofloxacin 
Acquires generics business 
Manufacturing 
Marketing ofVogseal for diabetes 
Generic company 
Acquires generics business 
Generic company 
Clinical trials and market products in India 
Market oncology products globally 
API and dosage forms 
Chemistry »leads » clinical proof 
Anti diabetic medications 
NDDS - Cifran and Zanocin 
NDDS - Cifran and Zanocin 
combine innovation and generic competency 
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In 1995, Ranbaxy acquired Ohm Laboratories (North Brunswick, New Jersey, USA) which 
provided it with an entry into the US OTC market. It also gave Ranbaxy the access to USA-
FDA approved manufacturing. This acquisition also helped Ranbaxy file and receive approvals 
for a number of ANDAs, by reducing timelines, which has helped Ranbaxy develop, file 
and manufacture more than 99 product filings. Access to the European market was through the 
acquisition of Basics in Germany, Bayer's generics business. This acquisition allowed Ranbaxy 
access to Europe's generic market as well as provided a channel for the introduction of new 
products in its portfolio. 
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In 2005, Ranbaxy entered into a JV with Nippon Chemiphar, a midsized drug company 
and gained access into tlie Japanese generics market. Tlie objective was to launch the anti-
diabetic drug Voglibose in the Japanese market. This JV was dissolved in 2009 when Ranbaxy 
was acquired by Daiichi Sankyo. 
In 2001, Eli Lilly a US based company with focus on oncology, entered into alliance with 
Ranbaxy with the long term objective of undertaking clinical trials for their products in 
oncology, diabetes, cardiovascular and internal medicine. In 2006 Ranbaxy entered into an 
alliance with Zenotech Laboratories Ltd, a Specialty Generic Injectables company with strong 
expertise in the area of Bio-technology. This enables Ranbaxy to enter into the niche therapy 
areas like Oncology and Anesthesiology. Zenotech has Research and Development facilities in 
India and in the U.S. 
In 2008 , Ranbaxy entered into a strategic alliance with Chennai based Orchids chemicals 
and pharmaceuticals for the dosage formulations and API business. Collaboration for New 
Drug Discovery Research between Ranbaxy and GSK was initiated in 2003, which was 
again expanded in 2007. The agreement between the two companies was to collaborate on two 
research programs: chronic obstructive pulmonary disease and anti- infectives. 
Cipla : An Indian pharmaceutical company, renowned for the manufacture of low cost anti 
AIDS drugs, was founded by Dr. K. A. Hamied in 1935. Before 1984 the company was known 
as The Chemical Industrial and Pharmaceutical Laboratories Ltd. Cipla's product range 
cover anti retroviral, antibiotics, anti-bacterial, anti-asthmatics, anthelminthetics, anti-ulcerates, 
oncology, corticosteroids, nutritional supplements, face wash, contraceptive pills, weight loss, 
and cardiovascular drugs. Cipla exports raw materials, intermediates, prescription drugs, OTC 
products and veterinary products to the tune of INR 17,800 million. The company offers 
technology for products and processes, and services like quality control, engineering, project 
appraisal, plant supply, consulting, commissioning and know-how transfer, support. 
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Table No. 4 : Cipla Alliances 
Ctfinpaiiy CTountrv 
Outward 
Neolab 
Medpro 
Genopharma 
Novopharm 
Channel 
Zenith & Goldman 
Pentech Pharma 
Ivax 
Eon 
Morton grove 
Chanelle 
Teva 
Akom 
Heiiopharm 
Aotuokang 
Pharmaceutical 
Inward 
Watson pharma 
Pfizer 
Avestha Gengraine 
Domestic 
Ranbaxy 
Stempeutics 
Source: www.cipla.com 
U.K.(1999) 
South Africa( 1992) 
Australia(2001) 
Canada 
Ireland 
US 
US(2004) 
US(2004) 
US(2004) 
US(2004) 
Ireland (1998) 
Israel (2005) 
US 
Egypt 
China 
US (2002) 
US (2009) 
France 
Co-marketing 
Research & marketing (2010) 
Generic products manufacturing 
Manufacturing 
OTC range manufacturing 
Anti asthmatic products manufacturing 
All products 
Anticancer 
Generic products 
Generic products 
Generic products 
Generic products 
green field manufacturing facility 
Generic products 
Generic products 
Generic products 
Generic products 
develop 26 generic products 
Generic products 
collaborative biopharmaceutical development 
Carvedol (cardiovascular), Atorvastafin (cholesterol 
reducer), Cefpodoxime (antibiotic) and Venlafaxine 
(anti-depressant) 
Stem cell therapy 
Cipla has entered into alliances with reputed international companies for marketing its products. 
The company as a strategy has not established overseas offices but has entered into marketing 
alliances. In 2001, Cipla tied up with US based Zenith Goldline and United Research Labs for 
marketing Flutamide an oncology drug in the US and European markets. It's alliance with 
Neolab, UK and Chanelle Pharma, Ireland enabled it to market generic products in the 
European markets. In 2004, Cipla allied with Pentech, Ivax, Eon and Morton grove, generic 
pharmaceutical companies in the US for a range of products. The alliance partners have 
enabled Cipla to file more than 66 ANDAs in two years. Cipla has entered into alliances with 
global generic giants like Teva (Israel), Watson Pharma ( US ) for the supply of bulk drugs 
12 
to these global firms. In 1999, Cipla and Ranbaxy entered into a strategic partnership to 
jointly market a select basket of drugs in the cardiovascular and perennial anti- infective 
market. In 2010 Bangalore based Stempeutics has entered into strategic alliance with Cipla for 
marketing its products. Under this alliance, Cipla is sponsoring upto Rs. 50 crores in 
Stempeutics in the initial phase for research and development of stem cell based products. 
Dr. Reddy's Laboratories: 
Table No. 5: Dr. Reddy 's Laboratories - Alliances 
Outward 
NovoNordisk 
NovoNordisk 
Novartis 
BMS laboratories 
Meridian Healthcare 
Trigeneis 
Roche 
Rheoscience 
Merck 
Betapharm 
BASF 
Dow Phartna 
Inward 
GSK 
Domestic 
Benzex Labs pvt 
American Remedies 
Cheminor Drugs 
Aurigene (Indian 
Subsidiary ) 
Source :www. drreddys. com 
Russia (1995) 
1997 
1998 
2001 
UK (2002) 
UK (2002) 
Mexico (2005 ) 
2005 
US (2006) 
Germany (2006) 
US (2008) 
UK (2008) 
Marketing in emerging 
markets (2009) 
Bulk actives business 
Merger 
Merger 
Joint venture 
Licensed antidiabetic molecule 
Licensed DRF2725(Ragaglitazar) 
DRF4158 out licensed 
Manufacturing 
Manufacturing 
Access to drug delivery technology platforms 
API business 
Co development and commercialization (DRF 
2593) 
Generic partner for Proscar and Zocor brands 
Generic facility 
Manufacturing 
Small molecule business 
Manufacturing & marketing of branded drugs 
Acquired to consolidate manufacturing 
Reorganise Drug discovery 
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Dr. Reddy's Laboratories manufactures and markets a wide range of pharmaceuticals both in 
India and abroad. The company has 60 active pharmaceutical ingredients to manufacture drugs, 
critical care products, diagnostic kits and biotechnology products. The company has 6 FDA 
plants that produce active pharma ingredients and 7 FDA inspected and ISO 9001 and ISO 
14001 certified plants. Dr. Reddy's Ql FY 10 result shows the revenues of the company at Rs. 
18,189 million which is up by 21%. During this quarter the company introduced 24 new 
generic products, applied for 22 new generic product registrations and filed 4 DMFs. 
DRL entered the global market by first exporting drugs to Europe and Far East in 1990, 
set up a JV in Russia. In 1998, it licenses the anti diabetic molecule Ragaglitazar(DRF-2725) 
to NovoNordisk. In 2002, it acquires BMS laboratories and Meridian Healthcare in the UK. In 
2005 it acquired Roche's API business and state of art, manufacturing site in Mexico. In 2006, 
it acquires Betapharm the fourth largest generics company in Germany. In 2008, it acquired 
BASF's Pharmaceutical manufacturing facility at Louisiana. 
In 2009, GSK had announced an agreement with DRL to develop and market as select group of 
products in the emerging markets excluding India. It merged the Drug Discovery Operations 
into Aurigene, a wholly owned subsidiary of Dr. Reddy's. 
Lupin : 
Table No. 6: Lupin - Alliances 
Outward 
Company 
Kyowa Pharmaceuticals 
Hormosan 
Pharma Dynamics 
Generic Health 
Forest Labs 
Multicare Pharmaceuticals 
Domestic 
Rubamin Laboratories 
Source: www.lupinworld.com 
Country 
Japan(2007) 
Germany(2008) 
South Africa(2008) 
Australia (2008) 
USA(2008) 
Philippines (2009) 
manufacturing 
..^ PHHtaMHl^ ^ t^aMB,/ 
Products 
Generics 
Generics - CNS(Acquisition ) 
Generics- CVS (Acquisition) 
Marketing branded products 
Branded Generics (Acquisition) 
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Lupin Ltd. has a strong research base in Generics, New Chemical Entity, Novel Drug Delivery 
Systems and research. It's global footprint include USA, Japan, Australia, UK, Germany. In 
2008, Lupin entered a multiyear promotion and marketing agreement for the AeroChamberPlus 
line of products with Forest Laboratories. 
Sun Pharmaceuticals: Sun Pharmaceuticals was started in 1983, with 5 products and today 
has emerged as one of the leading pharmaceutical companies in India. They are involved in 
making specialty API and pharmaceuticals for India, US and the world markets. Through a 
series of acquisitions, Sun Pharma has achieved the organic growth it desired. The acquisition 
of Caraco, a US based generic manufacturer in 1997, gave access to a US FDA approved 
manufacturing facility thereby aiding the process of bringing new drugs into the US market. 
Table No 7: Sun Pharma - Alliances 
i- '' Outward 
Company 
Caraco Pharma (1997- 2004) 
ICN- Alkaloida 
Bryan, ohio 
Able Labs 
Taro Pharmaceuticals 
Chattem Chemicals 
Domestic 
Phlox Pharma 
Pradeep Drug Company 
Miimet labs 
MJ Pharmaceuticals 
Gujarat Lyka Organics 
TDPL 
Source: \vww.sunpharma. com 
Country 
US 
Hungary (2005) 
US 
US 
US, Israel, Cananda 
(2007) 
Tennesse, 
USA(2008) 
Merged 2004 
Acquisition 2000 
Acquisition 1999 
Equity 1996 
Equity 1996 
extensive products 
(1997) 
m^^^m^^tlBtKB^^^ • 
Products 
generic and branded 
bulk activities 
Manufacturing Plant 
intellectual property 
Multinational generic manufacturer 
Narcotic raw material importer and manufacturer 
of controlled substances 
API manufacturing - cephalosporins 
API manufacturing site 
Opthalmology brands 
Manufacturing capability 
Cephalexin 
Oncology, fertility, pain management 
The acquisition of Taro Pharma allowed access to countries like US, Israel and Canada. Taro 
has more than 100 ANDA approvals in US and has a strong franchise in dermatology, 
cardiovascular, neuropsychiatry and anti-inflammatory therapeutic categories. In 2008 Sun 
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acquired Chattem Ltd. a narcotic raw material Importer and manufacturer of controlled 
substances. 
1.5 Need for Research 
McKinsey report indicates that with the current economic growth pattern, the Indian 
pharmaceutical market will triple to US$ 20billion by 2015 which is attributed to six trends: 
Doubling of disposable incomes of middle class; Expansion of medical infrastructure; 
Popularity of health insurance; Chronic diseases; Adoption of product patents; and Aggressive 
market penetration by smaller companies. According to IMAP healthcare report (2011), 
although there has been a reduction in the number of mergers in the pharmaceutical sector in 
2011 in comparison to 2009, global pharmaceuticals continue to look at emerging markets to 
secure future growth by acquiring and alliancing with various companies including generic 
ones. 
Patent expiry and rising cost pressures will encourage the alliance formation of multinational 
companies with local players in the 17 emerging markets, India being the foremost among them. 
Growing regulatory pressures and introduction of risk evaluation and mitigations strategies, 
makes it increasingly difficult for the approval of new drugs, which would eventually lead to 
greater cooperation between pharmaceutical companies. Sustainability of a pharmaceutical 
company is dependent upon the continuity of its new drug pipelines, which is often achieved 
through acquisition of smaller research driven firms. Small research driven companies lack the 
capital for product launches and marketing, thus alliances are the directions taken by most 
companies. India is not far behind in alliance formation. Over the last decade the number of 
alliances has increased. Most alliances are successful as the objectives are met, many are not. 
Recently the alliance between Biocon and Pfizer was called off. There are many reasons why 
an alliance can fail. Since the alliance is an outcome of a business objective and involves 
considerable investment, it is critical that companies need to focus on making it successful. An 
understanding of the pharmaceutical environment in India and the alliances that have happened 
between Indian and foreign pharmaceutical companies over the last four decades can help 
companies in the future to realize their business objectives effectively through alliances and 
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collaborations. Some of the reasons that substantiate the necessity of a research on this subject 
are enumerated below: 
• The alliances between Indian and foreign pharmaceutical companies have increased 
over the years. 
• Alliances today involves multimillion dollars, with clear business objectives, hence 
understanding them can mitigate failures. 
• Alliances have an impact on many aspects of the business including people, studying 
the factors that have influenced the alliances between Indian and foreign 
pharmaceutical firms can help develop a clear picture of alliance success factors. 
• Very little research has been done on the subject of strategic alliances in the Indian 
pharmaceutical industry, its impact on business aspects considering the fact that it is 
the most important science based industry in India. 
• An in depth research highlighting the areas of improvement may prompt increased 
regulations, which will enhance the scope for investments. 
1.6 Objectives of the Research 
A study on the strategic alliances between Indian and foreign pharmaceutical firms, tracks the 
Indian Pharmaceutial industry over the last 5 decades. It is aimed at understanding the various 
politico-legal, economic and technological aspects that have laid the foundation for the 
alliances in India. Studying the evolution of the pharmaceutical industry in India would throw 
light on the key players in the Indian pharmaceutical industry. 
The specific objectives of this study are: 
• To analyze the business related factors responsible for the strategic alliances between 
Indian and foreign pharmaceutical companies in the period starting from 1970-2009. 
The strategic alliances have been on the rise in the last two decades. Understanding the 
reasons for the same would throw light on the influencing factors of alliances. 
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• To understand and analyze the implications of strategic alliances that benefit the 
pharmaceutical companies and the industry in general. 
The strategic alliances that have happened between Indian and foreign pharmaceutical 
companies have had positive and negative implications. Understanding the implications 
would help future alliances, to maximize the positive aspects and mitigate the negative. 
• To evolve a model on pharmaceutical alliances, which would help Indian 
pharmaceutical companies augment the beneficial aspects of the alliance. The outcome 
of the study will help realize the factors which can influence the future course of 
alliances in the country. Additionally factors which are critical for the success of 
alliances between Indian and foreign pharmaceutical companies can be correlated. 
1.7 Benefits of the Research 
The Indian pharmaceutical companies are entering into more and more alliances with 
foreign companies which will have an impact on various aspects of the organization like: 
people and their attitudes, processes being followed in the organizations and possibly the 
very existence of the organization. The research will help us identify the factors that 
encourage the formation of strategic alliances in the Indian pharmaceutical sector. By 
understanding the impact of the alliances on different business aspects, pharmaceutical 
companies can undertake alliances which are in line with their growth plans. 
Understanding the hindrances for alliances, the companies can mitigate the risks 
involved in the alliances and ensure the alliances success by meeting the objectives of 
the alliance. 
1.8 Research Framework 
The research is focused on the Indian pharmaceutical industry and its alliances and 
would cover aspects of the reasons for the alliances and the implication of the alliance. 
A focus group interview involving CEOs of Indian companies who were involved in 
strategic alliances with foreign pharmaceutical companies, was conducted to understand 
the alliances in the Indian pharmaceutical industries' context. This provided the necessary 
frame work for the study and helped to crystallize the objectives. 
An extensive literature review was undertaken to understand the alliances over the years. 
The literature review helped to identify the various factors that influence the formation of 
strategic alliances as well the factors which prove to be hindrances. The various aspects 
of business which are impacted by strategic alliances are identified by the literature review. 
These helped in crystallizing the research objectives and develop the research instrument 
to undertake the primary research. 
The primary research was conducted using a structured questionnaire and the respondents 
were selected from the Indian pharmaceutical industries who have undertaken strategic 
alliances with foreign pharmaceutical companies over the years, sourced from the OPPI 
database. The respondents were senior members of the organization who were able to 
respond to strategically relevant topic of alliances. 
The data was tested for consistency and analyzed with the SPSS software. The variables 
are analyzed using statistical tools. Regression analyses helped in assessing the correlation 
between the variables and develop a predictive model. 
CHAPTER 2: PHARMACEUTICAL INDUSTRY 
2.1 Overview of the Global Pharmaceutical Industry 
The pharmaceutical industry is the building block of the healthcare system. Research based 
pharmaceutical companies contribute to the global health through the development of 
innovative medicines. The IMS Institute for Healthcare Informatics predicts that the pharmaceutical 
market will reach nearly USD 1,200 billion by 2016, an increase of nearly USD 250 billion from the 
USD 956 billion recorded in 2011. This growth is due to the market expansion and generics(7F/^ M4, 
2012). 
2.1.1 Early Period in the World Pharmaceutical Industry 
The first known drug store was opened by Arabian Pharmacists in Baghdad in 754 CE, and was 
adopted into medieval Europe. The modern pharmaceutical industry has its origins in the coal 
tar industry that arose in German speaking lands in the mid-nineteenth century, and can be 
traced to tv/o sources: apothecaries that moved into wholesale production of drugs such as 
morphine, quinine, and strychnine in the middle of the 19th century and dye and chemical 
companies that established research labs and discovered medical applications for their products 
starting in the 1880s. Merck, for example, began as a small apothecary shop in Darmstadt, 
Germany, in 1668, only beginning wholesale production of drugs in the 1840s. Likewise, 
Schering in Germany; Hoffmann-LaRoche in Switzerland; Burroughs Wellcome in England; 
Etienne Poulenc in France; and Abbott, Smith Kline, Parke-Davis, Eli Lilly, Squibb, and 
Upjohn in the U.S. all started as apothecaries and drug suppliers between the early 1830s and 
late 1890s. William Perkins, in the nineteenth century manufactured the first artificial dye, 
aniline purple which instigated German and Swiss companies to take up the manufacture of 
dyes seriously, thereby leading to the discovery of a number of chemical compounds which 
were therapeutically useful. Bayer in Germany developed Aspirin in 1899. In 1880, Burroughs 
Wellcome & Co. was established by two American trained pharmacists who introduced 
American style marketing and manufacturing methods, and created a research laboratory within 
the company, the first of its kind in the country. The discovery of penicillin in the 1920s 
heralded the era of mass production of drugs and can be considered as the harbinger of the 
development of global pharmaceutical companies. 
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2.1.2 The Pharmaceutical Golden Era: 1930-60 
In 1942 Dr. Selman Waksman of Rutgers University discovered anti-tuberculosis agent 
streptomycin, thereby opening the flood gates for new products post World War II. The 
development of penicillin by 11 US Pharmaceutical companies, under the oversight of War 
Production Board, gave US firms a leading position after World War II. Antibiotics that were 
produced were streptomycin (Merck), chlortetracycline (Lederle), chloramphenicol (Parke-
Davis), erythromycin (Abbott and Lilly) and tetracycline (Pfizer). Success in these ventures, 
led the pharmaceutical companies to invest in synthetic chemistry. Rapid advance in analytical 
techniques and instrumentation aided in determining molecular structure and aided in the 
transition of wet chemistry to dry chemistry involving minute samples and molecular models. 
In 1938 Food Drugs and Cosmetic Act was enacted in the US. Approval of any new drug 
required preclinical and clinical trials failing which no new launch was approved by the Federal 
Authorities. The USFDA promoted the double-blind, clinically controlled trials as the gold 
standard for testing new medicines on patients. The decisions regarding the suitability of the 
drug was dependent upon, the characterization of safety and effectiveness of the drug in large 
populations, Thus the therapeutic revolution in drugs stimulated two fundamental changes in 
the manufacturing firms, major companies were transformed from a full line commodity 
house to a vertically integrated research and information intensive "specialty" manufacturer by 
the late 1950s, where the products were protected by patents, promoted by brand names and 
purchased only with a doctor's prescription. The second change was that nationally based 
companies became transnationally organized, thus sales, production, research and marketing 
were carried out in different countries. By 1950s, corticosteroids, oral contraceptives, 
antihistamines, antidepressants, diuretics, semi synthetic penicillin and many more drugs 
were discovered and patented, thereby transforming the pharmaceutical industry from a 
commodity business to a highly research intensive, marketing oriented , business (Taggart, 
1993). 
2.2 Characteristics of the World Pharmaceutical Industry 
The pharmaceutical industry is characterized by: High costs of drug discovery, patents and 
globalization in the recent times. The industry has large number of small companies and a small 
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number of large companies. The big pharmaceutical companies are concentrated in the highly 
industrialized, Organization for Economic Co-operation & Development (OECD) countries. 
2.2.1 Patents 
The patent protection for pharmaceutical industry is critical as the actual manufacturing process 
is easy to replicate and can be copied with very little investment. The TRIPS Agreement in 
1994, allowed the developing countries to be brought under the blanket of patent protection. 
Countries that have joined the WTO have obliged to accept the protection whereas the least 
developed countries are not required to meet this obligation until 2016. 
The World Trade Organization was established in 1994 in Marrakech after the Uruguay Round 
of Trade Negotiations. The predecessor to the WTO was the General Agreement on Tariffs and 
Trade (GATT). The Uruguay Round brought in the Agreement on Trade Related Aspects of 
Intellectual Property Rights, known as TRIPS. The objective of the TRIPS was to create an 
equitable system of international trade, wherein developed countries reduce import barriers and 
developing countries open the market for high value exports from developed nations. A 
unique aspect of the pharmaceutical industry is that the invention or the new molecule needs 
to be disclosed well before the product is brought to the market, to enable trials and share the 
information with the group. This leads to considerably short periods of patent exclusivity for 
the firm planning to launch the new product, thereby eroding its profits. According to UNCTC, 
the patent protection is of four types in the pharmaceutical industry: 
• Patents on the composition of matter 
• Patents granted for a specific product 
• Process patents relating to the production process rather than the finished products 
• Application or usage patents 
2.2.2 Globalization 
The International Monetary Fund (IMF), defines globalization as the growing economic 
interdependence of countries through increasing cross- border transactions in goods & services, 
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free flow of international capital, and rapid and widespread diffusion of technology. Narula & 
Dunning (1998) observed that globalization, alliance capitalism and R&D-intensive value 
adding activities are hallmarks of economic activity in advanced industrial countries. 
According to them globalization is an increasing interdependence and convergence in 
consumption patterns and technologies across countries, internationalization of production 
through networks, overlapping and merging of industrial sectors, increasing capital and 
knowledge intensity as well as a concurrent shortening of technology life cycles. They have 
observed an increase in alliances across all of the advanced industrialized economies and the 
nature of the alliances are strategic and alliances are no longer simply undertaken as a 
means of avoiding transaction and coordination costs of markets. One of the original motives 
for alliance formation was to acquire market access and/or overcome supply bottlenecks, i.e., to 
achieve vertical integration where such integration was not possible through hierarchies. They 
indicate that inter-firm alliances are increasingly being undertaken, through various modes, as a 
direct response to pressures brought about by contemporary technological developments and 
"lobalisation. & 
Kesic (2008), has identified some factors that are responsible for pharmaceutical globalization 
in the last decade. They include: Lack of new products in the pipeline, need for huge 
investment in R&D & marketing, increased competitiveness, world reforms in healthcare, and 
increased focus on regulations. The success of the molecule would depend on the marketing 
and sales activities. Therefore the success of a pharmaceutical company largely depends upon, 
strong research and development combined with a compelling marketing and sales related 
activities. The large pharmaceutical companies invest on an average, 16% of their sales turn 
over into R&D, and 26% into marketing and sales related activities (Kesic, 200(5/Originators 
invest heavily on R&D and produce new and inventive products which earn maximum profits 
during the patent period. The generics are engaged in producing cheap drugs by imitating the 
original one, thus their strategy is oriented towards producing products that are considerably 
less priced. 
2.2.3 Drug Development Process and Medical Research 
The actual drug manufacturing is the consequence of a complex and lengthy set of activities 
whose objective is new drug discovery. Every ethical drug manufacturing company is 
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constantly on the lookout for new molecules that would sustain the profitability when patented. 
A new molecular entity is discovered, developed and marketed through the process called as 
Drug Discovery. The new molecular entities discovered may be original or may be the 
outcome of minor molecular modifications of existing drugs. Drug Discovery process involves 
screening millions of chemical compounds with therapeutic properties. The objective is to find 
potential molecules which can alleviate or prevent disease conditions (Ratti and Trist, 2001). 
The process of developing a molecule for therapeutic applications involves a number of 
complex steps including clearance from regulatory authorities. The phases are : 
(i) Target selection, wherein a promising compound with therapeutic efficacy is 
selected from a myriad of chemical entities 
(ii) Preclinical phase involves the necessary testing on animals before it is tried on 
humans. The toxicity of the drug is evaluated in this phase 
(iii) Clinical phase: 
• Phase I - the compound is studied for the first time in healthy human volunteers 
• Phase II - proof of concept and evidence of efficacy and safety in patients 
• Phase III - the studies are conducted on a large population to generate data on safety 
and efficacy of the drug. The therapeutic product is then filed for license for 
marketing purpose 
• Phase IV- post marketing studies 
DiMasi and Grabowski (2003), have estimated the research and development costs of 68 
randomly selected new drugs of 10 pharmaceutical companies and arrived at a figure of USD 
$403million. They indicate that the expenditures on pharmaceuticals have grown since the late 
hi 990s, which was attributed to the lengthy and costly process of new drug development. They 
have described that an overall clinical approval success rate is the probability that a compound 
that enters the clinical testing pipeline will eventually be approved for marketing and attrition 
rates describe the rate at which investigational drugs fall out of testing in the various clinical 
phases. R&D costs for new drugs (including the costs of failures and time costs) have been 
estimated to average in excess of $800 million (in year 2000 dollars) for development that led 
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to approvals in the 1990s, with a marked upward trend relative to earlier decades (DiMasi et al, 
2003). 
2.3 Leading Pharmaceutical Companies of the World 
According to Kesic (2006), the leading ten world pharmaceutical companies command more 
than 42% of the market share of the global pharmaceutical market. The global pharmaceutical 
companies can be categorized as Originators and Generic firms. Originators include those 
companies who invest substantial amounts on R&D and bring out new block buster molecules. 
The generics include those firms that produce equivalents of the original block buster 
molecules. These manufacturing giant are able to achieve cost actualization with massive scale 
ups. 
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Increased competitiveness is pushing the pharmaceutical companies towards consolidation 
which leads to the formation of bigger pharmaceutical concerns across the globe. It is 
also evident that innovator companies invest substantial amounts of their profits into R&D. 
2.4 Indian Pharmaceutical Scenario 
Traditionally two systems of medicine were in vogue in India, the Ayurvedic and the Arabian 
medicine systems. The ayurvedic medicine uses a combination of herbs and minerals and has 
references in the ancient texts like Vedas. The Arabian medicinal systems are the outcome of 
innumerable invasions from the Arabic world. With the advent of the British rule, the western 
medicinal system, namely the Allopathic medicinal system was introduced into India. With the 
educational system, including the medical education being modeled on the British system, 
allopathic and modern medicine started taking roots in India and has evolved to be widely 
accepted over the last 250 years. 
The exact date on which the Allopathic medicine entered India is not really documented, 
however it is assumed to be during the early part of the 19* century. Medicines imported by the 
British for their personal use marked the beginning of the usage of allopathic medicines in 
India. In 1901, the Bengal Chemical and Pharmaceutical Works was started with the objective 
of starting indigenous production of medicines in India. The company started with the 
production of Tetanus antitoxin, in 1930.Two MNCs namely ParkeDavis(1907)and Burroughs 
Welcome(1912), commenced trading operations for formulations. Indigenous production was 
sufficient to meet only 13 percent of the demand, thus a large portion of the domestic demand 
was still being supported through imports mainly from Germany and United Kingdom. 
Between 1904 and 1907 four research institutes were commissioned: Haffkine Institute, King 
Institute, Pasteur Institute and Central Research Institute. The domestic production of medicine 
received an impetus due to the steep demand during the First World War. Production of 
caffeine and quinine salts registered substantial growth, till the end of the war {Bhojwani, 2005). 
By 194], the Indian pharmaceutical industry took up the manufacture of new drugs like 
iodochloro-hydroxyl-quinolone as well as a number of alkaloids like ephedrine and codeine. 
Chemotherapeutic drugs, anti-leprotics, glandular extracts - liver extracts, colloidal solutions of 
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- Calcium, Manganese, Silver and Iodine were being produced by the Indian Pharmaceutical 
industry during this period. By the end of the First World War, four global pharmaceutical 
majors- Glaxo, Boots, May&Baker, CibaGeigy had established their presence in India 
moJM'uni, 2005). 
Post the war a large number of pharmaceutical products entered obsolescence, thereby older 
antibiotics and chemotherapeutic agents were replaced by newer ones. This was indeed a set 
back to the Indian industry. They started the manufacture of formulations based on imported 
bulk drugs and the extraction of therapeutic agents from plant sources. 
2.4.1 Evolution of the Indian Pharmaceutical Industry 
Five decades ago, the pharmaceutical industry in India was at a rudimentary stage, with a high 
dependence on imported medicines from abroad. Manufacturing facilities in India were almost 
non existent due to the lack of manufacturing facilities as well as the archaic laws that were 
being followed post Indian independence. Medicines were priced very high and were beyond 
the reach of the common Indian. 
Post independence the Government embarked upon planned expansion of Indian industry 
including the pharmaceutical industry. In 1947, the estimated value of production of 
pharmaceuticals was Rs.lOcrores, which rose to a whopping Rs.26540crores in 2002-03. The 
evolution of this industry is the result of number reasons. The new Indian government in 1947, 
emphasized on industrialization invested in pharmaceuticals among other industries. The 
government did not discourage foreign firms from competing in India, as there were no local 
substitutes for MNCs technology. The first concrete step taken towards self reliance in 
pharmaceuticals was the establishment of Hindustan Antibiotics Ltd (HAL) in 1954 and Indian 
Drugs and Pharmaceuticals Ltd (IDPL) in 1961. The IDPL played an important role in 
developing technical know-how to develop antibiotics and move towards self reliance. It was a 
soviet sponsored program which showed that it was possible to produce drugs in India, it 
helped develop human and physical capital and spurred the mushrooming of support 
institutes like pharmacy colleges and other business elements upstream and downstream(S'efl« 
Eric Smith, 2000). 
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The colonial patent law of 1911 secured the Indian market to British industry. A large majority 
of drugs were imported from abroad until the Patents Act 1970 brought a turnaround. The 
major growth of the Indian pharmaceutical industry can be attributed to the enactment of the 
Indian patents Act 1970, which came into force in 1972 and was a part of a wider a set of 
policies of the government of India to develop 'self reliant' pharmaceutical industry. This Act 
provided for product patents for all inventions except for food, medicine, drugs and substances 
produced by chemical process. For the latter category only the process patent was accorded. 
The patent term was also reduced from 16years to 5 years from the date of patent approval or 7 
years from the date of application whichever is earlier. Consequently, Indian companies 
evolved to reverse engineer and copy the major drug and produce them at minimal costs. 
Although this act was ethically unacceptable to foreign MNCs, it provided the opportunity to 
develop India's pharmaceutical industry throughout the 70s and 80s. The provision of 
compulsory licensing which provided for the opening of the patented drug for the generic 
replication by others if the drug was found to be unnecessarily high priced was made after 
three years from the date of approval of the patent {Nauriyal D K, 2006). 
From 1970, local Indian firms reverse engineered bulk drugs, which they sold wholesale or 
processed into simple formulations, which further discouraged the MNCs to expose their IP. 
Thus by 1997, MNCs accounted for 30 percent of bulks and 20 percent of locally produced 
formulations. By 1970, the number of drug manufacturing units grew from 2257(in 1970), to 
5156(in 1980) to 16,000(in 1990) and to over 23000(in 2005) with 349 units in the formal 
sector. In the 1980s the industry had grown at a rapid rate of 11 percent per annum. The 
average growth of the industry in the last few years has been about 12% compared with the 
growth of the fast moving consumer goods sector, which has grown approximately at 4.7% 
(Greene William, 2007). 
The industry was producing only formulations in the pre-1970s, and started manufacturing 
more than 400 bulk drugs amounting to 6% of the international bulk drug market. More than 85%o 
of the formulations produced in the market are sold in the domestic market. The essential drugs 
comprising antibiotics, antibacterial antiparasitic and cardiovascular constitute a major portion 
of turnover of the industry. 
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The evolution of Indian pharmaceutical industry can be tracked over four stages: 
The first stage 1950s and 60s witnessed a huge dependency on foreign multinationals to 
provide essential medicine to the Indian population. The domestic manufacturers were engaged 
in repacking the formulations produced by multinationals {Lalitha, 2002).Since the Patents Act 
of 1911 was in vogue, the indigenous firms were legally prevented from manufacturing any 
drugs introduced in the country. The domestic firms, as per the laws prevailing at that time 
were also forbidden from processing a patented drug into formulations or importing it. 
The second stage of the industry took place in the 1970s with the enactment of the Indian 
Patent Act (IPA) 1970 and the New Drug Policy (NDP) 1978. This is a significant phase as 
this was the foundation for the development of the pharmaceutical industry in India. Critical 
aspect of this Act was reducing the scope of patenting to only process and not the product, for a 
short period of seven years, from the Initial period of 16 years. The 1970 Patent Act provides 
protection for the processes of manufacturing drugs for 7 years from the date of filing the 
application, or 5 years from the date of grant of the patent. Under this Act, onl> one process 
that was used to manufacture the drug could be patented. The NDP 1978 increased the pressure 
on the foreign firms to manufacture bulk drugs locally from the basic stage. This period led to 
the birth of "Reverse Engineering" in India. Pharmaceutical units started producing essential 
drugs and drugs that were imported till then. By 1972, over 100 essential drugs covering a 
wide spectrum of therapeutic groups like antibiotics, sulpha drugs, anti leprotic drugs, 
analgesics, antipyretics, vitamins, tranquillisers, photochemical and various other 
pharmaceutical chemicals were produced in India from basic stages {Narayana, 1983:42). 
This period also witnessed the introduction of two significant Acts: The Monopolies and 
Restrictive Trade Practices Act (MRTP) and the Foreign Exchange Regulation Act (FERA). 
These two Acts were aimed at reducing the concentration of economic power in the hands of a 
few units and controlling the flight of the foreign exchange from the country {Lalitha,, 2002). 
In the third stage of its evolution, domestic enterprises based on large scale reverse 
engineering and process innovation achieved near self sufficiency in the technology and 
production of bulk drugs belonging to several major therapeutic groups and have developed 
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modern manufacturing facilities for all dosage forms like tablets, capsules, liquids, orals and 
injectibles and so on. 
The fourth stage in the 1990s witnessed dramatic changes in the policy regime governing the 
pharmaceutical industry. The licensing requirement for drugs was abolished, 100 per cent 
foreign investment was permitted under automatic route, and the scope of price control had 
been significantly reduced. All those drugs which were limited to the public sector were de-
licensed, thus leading to an increase in drug production. This also enhanced the competition 
between domestic and foreign firms in the 1990s. The Government of India signed the TRIPS 
Agreement in 1994. Thus, started a new chapter in the history of Indian pharmaceutical sector 
where free imports, foreign investment and technological superiority would determine the trade 
patterns and industrial performance. 
The Indian pharmaceuticals industry has grown from a mere US$ 0.32 billion turnover in 1980 
to approximately US$ 21.26 billion in 2009-IO.The country now ranks 3rd in terms of volume 
of production (10% of global share) and 14th largest by value (Indian business.nic.in/industry). 
The Indian Pharmaceutical Industry currently represents US$ 6 billion of the $550 billion 
global pharmaceutical industry {KPMG 2007). It represents 8 percent of the global industry by 
volume and 13 percent by value, thereby taking the fourth place worldwide. 
The Indian pharmaceutical industry can be divided into two sectors, the organized sector 
consisting of 250-300 companies and the unorganized sector with an estimated 20,000 firms. 
An expert committee set up by the government of India has clarified the number of acfive units 
on the basis of drug manufacturing licenses issued to 5%ll{Sampath 2005). Primary 
associations which represents most of India's pharmaceutical companies: the Organization of 
Pharmaceutical Producers of India (OPPl), the Indian Pharmaceutical Alliance (IPA) and the 
Indian Drug Manufacturers' Association (IDMA). 
According to the OPPI, India has a strong well established manufacturing base and a large 
number of well educated, English speaking workforce which contributes to the positioning of 
India as a likely hub to meet the current worldwide demands for reduced manufacturing costs, 
trained personnel and reduced R&D costs. 700,000 scientists and engineers graduate every year, 
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including 122.000 chemists and chemical engineers with 1500 PhDs, thus providing a high 
intellectual capital per dollar worldwide. 
2.4.2 The TRIPS Agreement 
The Indian Government post independence was deliberating on the patent law, with the 
ultimate objective of reviving the domestic pharmaceutical industry. In 1972, after repeated 
expert reports and deliberations in Parliament, the India Patents Act of 1970 came into force 
{Mueller 2007, 22-2J).The 1970 Act with the intent to encourage indigenous technological 
skills and inventions imposed substantial limits on the patent rights of the western world 
{Katherine et al, 2003). Critical aspects were : 
a) Lack of patent protection for pharmaceutical products. 
b) Firms were permitted to patent only a single process for making a pharmaceutical product, a 
firm could not block competitors by patenting all possible processes for making a drug. 
c) The term for pharmaceutical process patents shortened to five years from the grant of the 
patent or seven years from application filing, whichever was less, compared to 14 years from 
application filing for all other inventions. 
d) The Act imposed very broad "compulsory licensing" provisions for pharmaceutical process 
patents. 
This legislation weakened the intellectual property protection in India thus making 
pharmaceutical products unpatentable, thereby allowing inventions patented elsewhere to be 
freely copied and marketed in India (Lanjouw, 1997). The reducing of the statutory term on 
pharmaceutical process patents opened the floodgates for the domestic players to reverse 
engineer and introduce cheaper generics into the Indian market. The number of patents 
granted per year fell by three-quarters over the following decade, from 3,923 in 1970-71 (of 
which 629 were to Indian applicants, 3,294 to foreign applicants) down to 1,019 in 1980-81 
(349 Indian, 670 foreign), (Lanjouw 1997). 
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In the Uruguay round of negotiations, India opposed the TRIPS mandate on pharmaceutical 
product patents. One of the implications of India joining the WTO is the requirement to comply 
with all the provisions of the Agreement on Trade Related Aspects of Intellectual Property 
Rights (TRIPs). The Government of India introduced the Patents (Amendment) Ordinance on 8 
January 1999 to meet part of the obligations under TRIPs. 
2.4.3 Major Players in the Indian Pharmaceutical Industry 
Many Indian companies have become global players, thanks to the convergent strategy 
adopted by them( Bower & Sulej,2007), which involves three steps: Develop generic drug 
manufacturing competency through reverse engineering, obtain approvals and market the 
generic products in regulated countries like USA and Europe and fmally develop in house drug 
discovery capabilities to produce new bio-molecules. Indian companies have already 
established their credibility in the first two aspects and now are concentrating their efforts 
towards R&D and Drug development. Dr Reddy's, Ranbaxy and Cipla have achieved 
considerable success in this regard. Some of the major players in the Indian pharmaceutical 
industry are in the table below. 
Table No. 10: Indian Pharmaceutical Industry ~ Major Players 
Iki 
•lillllfc 1 Cipla 
2 Ranbaxy 
3 Dr. Reddy's Lab 
4 Lupin 
5 Aurobindo Pharma 
mm%i 
1348.5 
1327.56 
1178 
929.8 
865.19 
1600U 
14000 
14900 
Source - IDFC - SSKl Research, Changing Landscapes - a spec 
www.pharmexec.com,may 2006 
1935 
1961 
1984 
1968 
1986 
Hal report on 
P^nfrastructiire 
Indore, Sikkim, Baddi, Goa, 
Mumbai, Bangalore, Patalganga, 
Kurkumbh 
Dewas, Mohali, Paonta Sahib, New 
Delhi, Goa 
6 FDA approved plants in India. 
FDA approved plants in Mexico, 
UK, USA 
Mandideep, Tarapur, Goa. 
Hyderabad 
the World's Top 50 Pharma Companies, 
2.4.4 Regulation in the Indian Pharmaceutical Industry 
In India, the import, manufacture, distribution and sale of drugs and cosmetics are regulated by 
the Drugs and Cosmetics Act, 1940 (DCA), the Drugs and Cosmetics Rules, 1945 (DCR). 
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Drug (Prices Control) Order, 1995, Drugs (Magic Remedies) Objectionable Advertisement Act, 
1954 and Pharmacy Act, 1948 are other regulations which have a bearing on the 
pharmaceutical business in India. The classification of the drugs in India is as: OTC drugs and 
Prescription drugs. ! 
i 
Over the Counter Medicines (OTC): 'OTC Drugs' means drugs legally allowed to be sold 
"Over The Counter' by pharmacists, i.e., without the prescription of a Registered Medical 
Practitioner. The current market for OTC medicines in India is about $940million and is 
growing at 20 percent a year, which is double the rate for prescription medicines. 
Prescription Drugs: Prescription drugs are those medicines that are listed in the Schedule H 
and X of the Drugs and Cosmetics Rule. Drugs listed in Schedule G do not need prescription 
to purchase but require a warning stating, "Caution: It is dangerous to take this preparation 
except under medical supervision". Drugs in the above three schedules are not advertised 
directly to the public under a voluntary commitment by the Pharmaceutical industry 
(OPPI,2009). 
Marketing of Drugs in India: [ 
The Ministry of Health and Family Welfare, Central Government is the responsible body for all 
legislations and regulating the pharmaceutical business in India. The state government through 
its Food and Drug Administration (FDA) enforces the Directives of the Ministry of Health. 
The office of the Drugs Controller General of India (DCGl ) has the primary responsibility 
of approving new drugs, molecules and standards, vaccines and sera, new usage and claims, 
new method of administration, clinical research and trials, introductions of new unique 
formulations and granting import and export licenses. 
The Drugs and Magic Remedies (Objectionable Advertisement) Act and Rule lists out the 
ailments for which advertising is not permitted in India A voluntary code on OTC Advertising 
is being followed by all OPPI member companies. Additionally based on the DCGl code the 
Advertising Standards Council of India (ASCI) has brought out a code of advertising for 
pharmaceutical products. 
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Distribution: 
Distribution in India is a cliallenge due to its iiuge geographical proportion. The drugs may be 
manufactured in any part of the country; however for it to reach the retail pharmacy a 
distribution system is essential. The manufacturer transports the drugs to depots for stocking 
before the sale is made. The depots can be company run depots or outsourced to Clearing and 
Forwarding (C&F) agents on behalf of the company. The C&F agent is supervised by the 
company directly. The C&F raises invoice to stockists or distributors who have stocking points 
in a particular area/ town. The stockist is responsible for the sale of goods to a retailer or 
wholesaler. i 
I 
Price Control in Indian Drug Market: J 
The Drugs Price Control Order (DPCO) exercises price control on certain drugs in India. It 
takes the base from the Essential commodities Act (ECA). It is the responsibility of The 
Ministry of Chemicals and Fertilizers, and is under the supervision of the National 
Pharmaceutical Pricing Authority (NPPA). As per the DPCO 1975, 347 drugs were under the 
price controlled category, which was brought down to 143 as per DPCO 1987. This number 
has been further brought down to 74 as per the DPCO-1995. In 1995, the DPCO introduces 
three criteria to assess whether a particular drug should fall in the price control market: 
turnover, monopoly and competition. The government will continue to fix prices of those drugs 
whose annual turnover exceeds' 44 million. A drug is said to enjoy monopoly when the retail 
sales fall in the lOmillion to 40 million bracket and a single manufacturer has a market share of 
90% and more. Ayurvedic medicines enjoy no price control. 
Pricing: \ 
The margins for the stockists and retailers are fixed by an agreement of Industry Associations 
and the All India Organization of Chemists and Druggists (AIOCD). The margin for the 
stockist/ wholesaler is fixed at 10% on the Maximum Retail Price and 20% for Retailers. For 
drugs which fall under the price controlled category the margins for the retailer is mandated at 
16% as per the DPCO. The stockists retain 5-6% margin and pass on 3-4% margin to the sub 
wholesaler or bulk retail buyer. | 
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2.4.5 Indian Pharmaceutical Industry Post 1995 - a Transition 
Rapid growth in the Indian pharmaceutical sector is attributable to three critical changes {Rai, 
2008), setting up of public sector enterprises to boost the pharmaceutical production of drugs 
and increase Indian competency in pharmaceutical production, second The Drug Price Control 
Order (DPCO) and third The Indian Patents Act of 1970, which opened the flood gates for 
generics in India. There was a spurt in activities around the drug production, including support 
areas like pharmacy colleges and downstream businesses. 
One of the important strategies adopted by the Indian pharmaceutical industry post 
liberalization was active internationalization (Chittoor et al. 2008). This includes external 
internationalization like overseas acquisitions and inward internationalization like import of 
technology, raw materials, capital goods and trained manpower. 
Sampath (2005) indicated that, the Indian pharmaceutical sector consisted of more than 20,000 
manufacturing units of which 5877 firms were actively involved in the production of bulk 
drugs and formulations. 300 companies account for over 95% of the total domestic market and 
the rest are small players. Based on the sales turnover the 300 firms can be categorized 
under 3 broad groups as indicated in the table below. 
Table 11 : Groupwise Representation of the Indian Pharmaceutical Industry 
Group 1 
Group 2 
Group 3 
Total 
Source: Sampath (2005). WHO-INTECH 
25 
275 j 
5700 
6000 
survey conducted in 2005 
bdiiction 
100 
200 
5700 
6000 
Group 1 comprises of large scale pharmaceutical firms that are subsidiaries of MNCs in India 
or wholly owned Indian firm. It includes firms like Ranbaxy, Cipla which spend considerable 
amount in R&D and are powered by the strategy to enter the global regulated market along 
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with semi regulated and domestic markets. Group 2 comprised of pure generic manufacturers 
who have h"mited competency on product development but are focused to cater to the needs of 
domestic and the semiregulated and unregulated markets. These firms are identified to have 
turnovers between Rupees 100-300crore. Group 3 includes companies which perform contract 
research and manufacturing (CRAM) for bigger Indian companies, both local and MNCs. 
These companies have an annual turnover of less than Rupees lOOcrore, whose strength is local 
network and connections. They do not have any R&D facilities and investments are made only 
towards upgradation of the manufacturing facilities. 
Rai (2008) demonstrated that the dominant strategy of Group 1 firms are positive patenting, 
research on new chemical entity (NCE), innovation, biopharmaceutical research and 
developing New Drug Delivery Systems (NDDS). The Group 2 firms focus on non-infringing 
processes, innovations, positive patenting and specialty generics. Group 3 firms do not have 
any dominant competitive strategy. 
Some of the criticisms that have been levied against the Indian pharmaceutical industry are: 
The focus on reverse engineering; Lack of expenditure on R&D; Inability to produce new 
drugs, which has resulted in an industry which is not invention based and aimed only at 
producing incremental modifications of existing drugs (Sampath, 2005). 
Today the Indian pharmaceutical industry is on the threshold of exploring new opportunities 
and scaling global heights. Although a large spectrum of the Indian pharmaceutical firms are 
active as generic manufacturers, many firms are focusing on R&D for innovations like novel 
drug delivery systems (NDDS), novel combinations, original R&D, thereby aiding the 
transition of the Indian Pharmaceutical Industry to modern times. 
Historically, Indian firms have begun their foray into the pharmaceutical industry by mastering 
the process of reverse engineering and developing low cost drugs to meet the domestic needs 
in India. Basic research, development of chemical entity was completely omitted. Large firms 
were in a position to move towards NDDS which is research based. 
Indian firms are building knowledge base and conducting incremental innovation through 
R&D and moving towards the generation of New Chemical Entities (NCEs), Indian 
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outsourcing industry for contract manufacturing and contract research (Chaturvedi and 
Chataway,2006). Additionally, many firms are outsourcing chemistry services to India 
primarily for organic synthesis and combinatorial chemistry to develop new chemical entities, 
which can be developed into new drugs. Indian contract manufacturing focuses on: contract 
manufacturing of patented drugs, specialized generics and old molecules {Nauriyal, 2006). 
The biopharmaceutical sector is a promising area for Indian manufacturers with the 
focus being on the development of vaccines like Hepatitis B vaccine. Another area of 
promise is the biogenerics sector like insulin, erythropoietin for the world market. 
Indian Phannaceutical Industry's capabilities include bioinformatics, organic chemistry 
syntheses, clinical research on bioavailability and bioequivalence. The areas of improvement 
are genomics, proteomics medicinal chemistry and animal trials (Lagnado, 2006). The new rule 
enacted by the government of India in Jan 2005, allows multinational companies to conduct 
trials of the same phase both in India and in other countries simultaneously. Thus with the 
genetically varied population, reduced costs of trials and companies have made India a clinical 
research hub (Nundy et al, 2005). 
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CHAPTER 3: LITERATURE REVIEW 
The thesis, "A Study of Strategic Alliances between Indian and Foreign Companies with 
Reference to the Indian Pharmaceutical Industry", traces the trends in the alliances in the Indian 
pharmaceutical industry over the decades spanning from 1960 to 2010. The last 20 years have 
transformed an inward looking industry to a globally recognized contributor today. 
Alliances in business have a long history, but over the last couple of decades they have become 
an important feature to such an extent that Dunning, a prominent researcher of multinational 
enterprises since the 1950's, has described this new trend which gives increased emphasis to 
cooperation as well as competition between firms as 'alliance' capitalism (Dunning 1995). 
Strategic alliances refer to alliances that enhance the long-term competitive advantage of an 
enterprise {Johnston et al, 7955).They are significantly different from the old style of 
collaborative agreement and can take many forms( Delvin & Biggs, 1989). The spectrum 
includes joint ventures, minority participation, co-manufacturing efforts, cross-marketing, cross 
distribution, cross-licensing arrangements, supply purchasing, franchising, R&D consortia, and 
partnerships in marketing and other areas. 
The literature review has been discussed under the following heads : 
• Global trends in strategic alliances 
• Global trends in strategic alliances in pharmaceutical companies 
• Strategic Alliances among Indian pharmaceutical companies 
• Factors that impact the formation of strategic alliances 
• Impact of strategic alliances on various aspects of the business 
• Success factors for strategic alliances 
3.1 Global Trends in Strategic Alliances 
According to Kesic (2008), the world pharmaceutical industry is characterized by increased 
globalization and increased competitiveness. Increased costs involved in the development of a 
new drug has led to firms adopting a strategic orientation, leading to fast consolidation and 
concentration of the world pharmaceutical industry. The investments involved in the 
development of a brand new drug is more than $1.2 billion and the time taken to bring 
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a molecule into the market is typically 12 years. The success of the molecule would depend 
on the marketing and sales activities. Thus, the success of a pharmaceutical company largely 
depends upon, strong research and development combined with a compelling marketing 
and sales related activities. 
Firms create competitive advantage by perceiving or discovering new and better ways to 
compete in an industry and bringing them to market, which is ultimately an act of innovation. 
Porter (1985), indicated that competitive advantage grows out of the value that a firm is 
able to create for its buyers that exceeds the cost of creating it. Competitive advantage 
is achieved by cost leadership and differentiation. In Built to Last, Collins and Porras (1994) 
outline habits of long-successful, visionary companies which is, an orientation towards 
evolutionary change: try a lot of stuff and keep what works. There is no one formula that 
would suit all the firms, but the core ideology of the company is the fundamental 
differentiator. 
Competitive strategy involves deciding how the company will compete within each line of 
business unit. Hamel (1991), indicated that core competencies and value creating 
disciplines are not distributed equally among firms, thereby indicating that international 
strategic alliance might play a crucial role in effecting partial redistribution of skills 
among partners. 
3.1.1 Competitive Advantage and Strategic Alliance: 
The pharmaceutical industry in the 1980s evolved to be a global oligopoly with 
unprecedented strategic activities which included 'mega mergers' and the disappearance of 
small p\ayers(Langley et al, 2005). Pharmaceutical industry researchers have tended to focus 
upon two types of strategy that create competitive advantage for pharmaceutical firms, namely 
research and development (R&D) and marketing on the basis that new technologies and new 
successful products improve the competitiveness of firms. The industry was plagued by high 
level of product failure, a widening gap in the product portfolio and an onslaught of cheaper 
generic products post patent expiry. There was a strong need among pharmaceutical firms 
to identify strategies that would reduce costs, strengthen the product pipeline and 
maximize revenue. Literature suggests two prominent views on competitive advantage: 
Industry structure view popularized by Porter and the Resource based view. 
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Porter (1980), indicated that a firm's membership in an industry governs its strategic 
orientation. Porter develops three potentially successful generic strategies for creating 
defensible position and outperforming competitors in a given industry. 
• Overall cost leadership in consideration with quality and service. 
• Differentiation either in product or service that is recognized industry wide as being 
unique. 
• Focus strategy, in which the firm concentrates on a particular group of customers, 
geographic markets or product line segments. 
A second view was creating unique resource combinations that, if valuable, rare, and 
difficult to imitate, can form the basis for a competitive advantage (Barney, 1991), which is 
why strategic resources are heterogeneously distributed across firms and that these 
differences are stable over time. Pe/era/f'i993), discusses the "Resource - Based" model of 
competitive advantage, where the cornerstones of competitive advantage are : Resource 
heterogeneity which creates Ricardian or monopoly rents. She explains that heterogeneity is 
the basic condition for sustainable competitive advantage, which is not sufficient as 
firms may have short lived readily imitable differences. So long as its assets are imperfectly 
mobile: inimitable and non substitutable, other firms will not be able to mimic its strategy. 
Heterogeneity is a short-lived phenomenon and sustained competifive advantage required the 
preservation of heterogeneity. Barney (1986) argued that the economic performance of firms 
depends not only on the returns from their strategies but also on the cost of implementing those 
strategies. This is very true to the pharmaceutical industry, which witnessed a sudden rise 
of alliances in the 80s. The last decade has witnessed more than 10,000 alliances in the 
pharmaceutical industry. For instance, Pfizer has been created from five big international 
players like Pfizer itself, Warner Lambert, Upjohn, Searle and Pharmacia, respectively. The 
world leading generic player, Teva from Israel, has acquired more than 10 generic companies, 
like Lemmon, Gry, Prosintex, Biogal, Human, Biocraft, Pharmasclence, Copley, Novofarm, 
Bayer Classics, Slcor and Ivax to form today's Teva (Kesic 2007). 
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3.2 Global Trends in Strategic Alliances in the Pharmaceutical Industry 
The pharmaceutical industry is a knowledge driven industry and is heavily dependent on 
Research and Development for new products and growth. Since 1930 many large firms have 
specialized in chemical modifications of basic compounds in the quest to produce new 
drugs. The resources required to invest in the search for new molecules, conduct clinical 
trials and market the drug was huge and only large pharmaceutical firms could invest in 
these activities extensively. Higgins (2005) indicated that productivity in the pharmaceutical 
industry declined in the late 1990s, because more drugs were coming off exclusivity 
protection than were being replaced by new Food and Drug Administration (FDA) approved 
products. New products take an average of ten to fifteen years to develop from initial 
discovery to final FDA approval and the cost of developing a new drug was estimated 
to be in excess of $800 million in the year 2000 {DiMasi, 2007). Pharmaceutical 
companies have responded to the decline in R&D productivity by: enhancing their internal 
R&D efforts through acquisition of smaller pharmaceutical and biotech companies, 
engaging in horizontal mergers to achieve greater economies of scale and scope in their 
research, acquiring existing mature products through licensing agreements, increasing 
alliance activity and changing their business models {Higgins (2006) , Kesic (2007)). 
Thus the main reasons for the strategic consolidation of the pharmaceutical industry are: 
lack of new products, globalization of the world economy, high R&D costs, large 
investments on global sales and marketing activities, increased competitiveness, reforms in 
the world healthcare, increased importance of regulation in the global context. 
Kesic (2007) argues that pharmaceutical companies make alliances to create common synergies 
and to better exploit their common assets, knowledge, product life cycle and, to improve their 
strategic market positions. Thus, the most important strategic activities of pharmaceutical 
firms include: R&D to create new products, development of products to gain market shares, 
acquire new markets through geographic expansion, organize and streamline marketing and 
sales activities to compete on the global markets, develop financial strength to create common 
cost reduction synergies and investment capabilities (Dyer, 1998). 
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In 1960s Discovery was by design. Today despite significant investments in pipeline 
management and novel technologies, there is still no recipe to ensure a block buster hit. 
R&D productivity, the ratio of input R&D versus its output, is suboptimal in the 
pharmaceutical industry. This is attributed to: 
1. Increased costs of R&D, driven by larger and more complex clinical studies 
2. Decline in per drug productivity 
3. Over supply of "me too" products or undifferentiated products which are also called 
as generic molecules I 
4. Lack of new promising molecules in the pipe- line, and long development times 
3.2.1 Strategies for Growth 
Strategic actions that have been discussed in pharmaceutical literature can be categorized 
as corporate, global, network, marketing, research & development and investment strategies 
{Langley, 2005). Companies can adopt different strategies based on their strategic orientation 
and business plans. The growth strategy concentrates on growth of the organization and the 
various types of growth strategies can be categorized under six heads based on their 
strategic action points and implications. 
Illustration 2: Mapping Pharmaceutical Strategic Actions with Related Strategies 
Mergers, acquisitions, vertical integration, retrenchment, divestment, 
diversification, creation of spin- off companies 
Related S i r a t ^ l 
Corporate strategy 
Niche marketing, advertising, "detailing" by sales representatives, marketing 
and distribution networks, co marketing agreements 
Marketing strategy 
Licensing agreements, R&D alliances, establishment of overseas R&D 
function, focus upon 'minor local products', 'me too' R&D Strategies 
Research & Development 
(R&D) strategy 
Raising additional funds, investing in other companies Investment strategy 
Licensing strategies, outsourcing, strategic alliances, joint ventures, co 
marketing agreements 
Network strategy 
Establishment of overseas subsidiaries and R&D facilities, cross border 
mergers and acquisitions, cross border co operative arrangements, co -
marketing agreements [ 
Globalization strategy 
Source : Compiled from Langley el al (2005) 
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3.2.2. Strategies Adopted by Pharmaceutical Companies 
The grand strategies adopted by the pharmaceutical companies can be a source of 
competitive advantage, Pearce and Robinson (2003), have proposed 14 grand strategies 
which were followed by the firms in the pharmaceutical industry during 2001 and 2002 
which were grouped as follows, 
Langley et al(2002), have developed upon Pearce and Robinson's identification of 14 
grand strategies in the pharmaceutical industry and have extended them. They are 
tabulated as follows: 
Illustration 3 : Grand Strategies Implemented by Pharmaceutical firms 2001- 2002 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
Source 
Organic concentration (market penetration) 
Co operative concentration (market penetration) 
Organic market development 
C'ooperative market development 
Organic product development (R&D) 
Cooperative market development (R&D) 
Acquisition based product development 
Organic innovation (R&D) 
Cooperative innovation (R&D) 
Organic innovation (Information Technology) 
Cooperative innovation (Information Technology) 
Horizontal integration 
Vertical integration 
Joint venture 
Organic concentric diversification 
M&A Concentric diversification 
Conglomerate diversification 
Turnaround / organic growth / retrenchment 
Divestment 
Liquidation 
External finance raising 
• Compiled from Langley et al (2005) 
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Higgins (2006), found evidence to suggest that firms experiencing declines in internal 
productivity engage in outsourcing of R.&D, in an effort to replenish their research 
pipeline. One of the method of outsourcing R&D is through mergers and acquisitions 
which was prevalent in the 1990s.Acquisition of latest external technologies ensures that 
pharmaceutical companies bridge their research gaps. Mc Cutchen (2004), studied the 
motivating factors for strategic alliances among small and large firms. He argued that the 
motivations of strategic alliances change with time, while in the 80s 90s the key factor 
was market access and risk mitigation. The motivational factors depend upon the size of the 
firms as well. Small firms need capital to deal with regulatory bodies, clinical testing, 
downstream processing and establishing marketing capabilities. The larger firms need the 
technological expertise and additional resource of new products hence are always on a 
lookout for new strategic partners. 
3.2.3 Strategic Alliance between Indian and Foreign Pharmaceutical Companies 
Over the years the Indian pharmaceutical companies have used multiple strategies to 
build the pharmaceutical industry in India. Before the signing of the TRIPS, the strategy 
was to make use of the product patent regime and produce new drugs through reverse 
engineering as the process patent was not applicable in India. Pharmaceutical companies 
produced drugs for the domestic consumption, which generated business and helped the 
companies to expand their facilities and look outwards by exporting essential medicines 
to third world countries. This was in line with observations from Hamel and Prahalad 
(1994), who indicated that firms should develop a portfolio of core competencies. 
According to Sampath (2005), the major strength of the Indian pharmaceutical company 
was the cost competitive manufacturing base and the extensive skill in chemistry. He has 
identified the strategies adopted by Indian firms as: 
• R&D Strategies 
• Competitive strategies 
• Collaborative strategies 
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The R&D strategies of Group 1 firms are driven by the need for entry and establishment 
in the regulated markets. Hence the strategy would be greater investment into R&D to 
generate innovative generic products, process and bulk drugs. Group 2 firms are driven by 
the need to strengthen competitive advantages, make use of CRAM opportunities, to take 
advantage of the business. Their strategic orientation would be towards generating active 
supply of off- patent generics to the unregulated and semi regulated markets and establish 
themselves as niche players in contract research, by choosing specific areas like - clinical 
research, domestic marketing etc. Group 3 firms are driven by the need to survive in the 
scenario of complete TRIPS compliance, thus leading towards the up gradation of 
facilities to continue being outsource centers for Group I and 2 firms. The competitive 
strategies adopted by Indian companies are centered around R&D involving research on 
new chemical entities, non infringing processes, novel drug delivery systems generics and 
specialty generics for regulated market and biopharmaceutical research. 
The main emerging collaborative strategies adopted by Indian firms are - In licensing 
arrangements, collaborative R&D and contract research. 
3.2.4 Need for Strategic Alliances in the Indian Pharmaceutical Industry 
The Indian pharmaceutical industry ranks very high among developing countries, in terms of 
technology and quality, and is today in the front rank of India's science based industries (DIPP, 
2005). The growth of the Indian pharmaceutical industry has been remarkable. From 1947 to 
1970; the Indian pharmaceutical industry was small in terms of number of firms and production 
capacities. In the 1950s the Indian pharmaceufical industry was mainly based on imported bulk, 
which was later processed into formulations in India {Bergman, 2006). India sensed a strong 
need to develop and strengthen the pharmaceutical industry to meet the demands of its 
millions. A crucial aspect of the Indian Pharmaceufical Industry is the role played by the 
Multinationals. They brought in foreign capital and technological knowhow into the sector. 
They also established collaborative relationship with the local Indian firms. 
The 1978 drug policy imposed conditions on foreign controlled firms and the Indian companies 
took advantage of the new policies and produced molecules that were still under patent 
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elsewhere, thus creating technological competence among the Indian firms and satisfying the 
demands of the domestic market. In the 1980s the government implemented a new drug policy. 
Technological obsolescence and the need to modernize the market were the critical 
factors that initiated the need for the new drug policy. The policy reduced the trade barriers 
and opened the doors for liberalization in 1991. In 1995, India joined the WTO TRIPS 
agreement and that was the turning point for the pharmaceutical industry in India, which 
has opened the door to innovation in this sector Bergman (2006). 
The study conducted by Beena (2008), indicated that, the Indian pharmaceutical industry 
experienced greater consolidation through mergers, acquisitions, alliances as well as sale of 
assets, which was very similar to the global trend. One of the major motives of the strategy is 
capacity expansion. Majority of the firms are using merger as a means to expand their product 
profile and thus to remain risk free. 
Thus the need for the alliances were two way: Indian firms needed the technological 
knowhow and foreign firms were on the lookout for a foothold in the huge domestic 
market in India. Additionally there was the attractiveness of available resources and plant 
capacities which could be utilized to produce drugs in large capacities to meet global 
demands. 
It is evident that many of the Indian pharmaceutical companies have undertaken alliances with 
companies in foreign country; inward alliances between multinationals or with other domesfic 
companies. These alliances have a definite clear objective. Many of the alliances have been 
successful for many years and have fulfilled their original purpose. The study of the alliances 
undertaken by the top 5 Indian Pharmaceutical companies indicates some interesting aspects. 
• Highly successful companies have entered into multiple alliances and have used 
alliance to time and again fulfil their business objectives - new market entry, develop 
generics production capability or develop new molecules. 
• The alliances are not restricted to foreign companies alone. Competing companies have 
undertaken alliance to achieve a particular business interest which is of mutual interest. 
• The objectives of the alliances can be grouped into the following categories: 
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o Acquiring manufacturing capabilities 
• Overseas in regulated (US, UK, France) and non-regulated markets 
(Nigeria, Malaysia etc) 
• Contract manufacturing for MNCs locally 
o Generic Business capability 
• Supply locally from India 
• Develop manufacturing capabilities at host country 
o Marketing 
• Specific therapeutic segment 
• Co- Marketing in a geography 
o Research and Development 
• Screen new chemical entities 
• Develop and commercialize promising molecules 
• Clinical Trials 
• New drug delivery systems 
o Access to emerging markets 
3.2.5 Inward and Outward Alliances 
Need for alliances emerge out of a company's basic mission and vision, and are used to fulfill 
long term objectives and achieve future competitive advantages. Foreign corporations are 
allowed to collaborate with Indian businesses in three basic ways: (1) licensing of technology 
where no equity capital is involved; (2) joint venture with foreign equity capital; and (3) 
outright purchase of technical know-how in the form of design and drawings. 
Data on alliances indicate that alliances between Indian pharmaceutical companies and 
foreign companies has evolved through different stages in the last four decades. The 
strategic alliances that took place in Indian pharmaceutical industry can be broadly classified as: 
• Outward FDl - Indian firms entering into alliances abroad 
• Inward FDI - Foreign firms entering into alliances in India 
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3.3 Factors (hat Impact Strategic Alliances 
Parvartiyar and Gupta (1994), discusses the payoffs in Indo -US strategic alliance that have 
happened in the 1990s. According to them, only those actions aimed at altering the strength of 
the company relative to that of its competitors can be considered as part of strategy. The 
spectrum includes joint ventures, minority participation, co-manufacturing efforts, cross-
marketing, cross distribution, cross-licensing arrangements, supply purchasing, franchising, 
R&D consortia, and partnerships in marketing and other areas. The Indian partners seek the 
benefit of technology available in the US, while their American counterparts like to achieve 
synergistic payoffs using the low labor cost in India. Both partners have defined roles. The 
Indian company concentrates on manufacturing quality products, and the necessary training is 
provided by the US partner. 
The benefits sought by Indian companies through alliances are listed as: 
• Availability of latest technology 
• Worldwide information on technology and products can be obtained through the 
alliance partner 
• Exposure to large global market 
• The ability to become part of a global supply network, thereby obtaining large volume 
production, less machine downtime due to economic production 
• Gain knowledge on systems and processes for planning, operations and control. 
• Higher credibility in the domestic market 
• Develop a culture with total quality consciousness and market orientation 
The benefits sought by foreign companies through Indian alliances are: 
• Entry into the Indian market, in some instances the Indian government has limited 
the entry mode, thus joint ventures being the route adopted 
• Setting up production base to serve Far East, USSR, Africa and South Asia 
• Low labor cost 
• Availability of cheap raw materials and skilled manpower 
• Obtain local market knowledge of Indian partners 
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• Capitalise on goodwill of local partners for further ventures and regular relationships 
• Avoid creating future competitor of an Indian partner 
With a lack of new blockbuster drugs in the pipeline, the global pharmaceutical industry is 
increasingly under financial pressure. According to a report released by the US Government 
Accountability Office, between 1993 and 2004 annual R&D spending by the pharmaceutical 
companies increased by 147%, to nearly $40 billion (Dragan, 2008). Yet during this period, 
new drug applications to the US Food and Drug Administration grew by only 38%, nearly two-
thirds of the new applications were for drugs that were modifications of existing medicines 
with only one-third for innovative new drugs. Such financial pressure explains in part why big 
pharmaceutical companies were rushing to set up collaborations with local companies in cost-
effective locations like India. In addition, a significant pool of trained biomedical and 
chemistry professionals, a strong bioinformatics tradition, and a large genetically diverse 
population from which to recruit patients for clinical trials, Bartlett & Ghosal (1989) makes 
India an attractive destination for alliances. 
The pharmaceutical companies have been compelled to move towards globalization for the 
following reasons: lack of new products to drive sales growth, huge investments needed for 
R&D, increased competitiveness, increased importance of regulatory issues, world reforms of 
healthcare system. According to Kesic(2009), there have been more than 10,000 alliancing 
processes in the last decade in the world pharmaceutical industry {Datamonitor, 2005). It has 
been found that the consolidation and alliancing processes have been carried out practically in 
all three segments of the world pharmaceutical industry (inventive - original pharmaceutical 
companies, generic producers and specialists). The alliancing process has churned the entire 
industry mitigating the identity of some firms and has led to the emergence of new firms. 
Pradhan and Alakshendra (2006), indicated that a variety of factors like liberalization of 
domestic policies, strong intellectual property right regime, increased competitive pressures 
and emerging new global market opportunities have instigated the Indian pharmaceutical 
industry towards rapid globalization. 
Some clear cut objectives of the alliances that emerged were as follows: 
49 
• Accessing firm specific Strategic assets like international USFDA approved 
manufacturing facilities 
• Acquiring new products and brands 
• Accessing advanced research capabilities 
• Gaining Access to new markets 
• Achieving operating synergies 
• Contract manufacturing 
• Outsourcing research and manufacturing of intermediaries 
Hagedoorn (1993), has studied the motives for strategic (technology ) alliances, he has 
identified broadly 3 groups of motives for inter-firm cooperation. 
The first group is related to the sharing and further advancement of research, increased 
complexity and inter-sectoral nature of new technologies, cross fertilization of scientific 
knowledge for instance the growing interrelationship between chemistry, physics, biology 
and computer science increases the need for close collaboration between these companies. 
The increase in the costs of R&D in a large number of fields has further encouraged this 
aspect. 
The second group of motives is related to the concrete innovative projects in a joint 
activity of two or more companies. Capturing the partner's tacit knowledge of technology, and 
innovative capability to enable technology transfer is the primary motive. Another motive that 
is considered here is the reduction of the total period of product-life-cycle and the 
contraction of the period between invenfion and market introduction. 
The third group of motives is linked to the market access and technology development through 
the combined effort of companies. Combining some activities of two geographically separated 
firms for particular markets favors internationalization and globalization of companies. 
Unlike most tangible physical resources which depreciate with use, a firm's skills of using 
technology and the technology itself actually improve with more practice, thus transferring 
technology through strategic alliances to other firm irons out the technical problems 
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encountered in application. The R&D cost incurred by a pharmaceutical company in 
developing a new drug is astronomical and mired with uncertainty. Thus there is a need to 
share the risks and project cost by collaborating and reducing risks. Although there is a 
possibility of pooling resources and reducing costs, the pressures of cultures and work 
procedures between collaborating companies can complicate decision making and thereby add 
onto the administrative costs. Strategic alliances dominated by the imitation motive are less 
stable than ones formed by other motives and are dependent on the absorptive capacity of the 
firm. While studying the strategic alliances among Indian pharmaceutical companies, they 
seem to be outcomes of clearly defined objectives. 
There is a lot of literature that have identified the various contributing factors for alliance 
formation. The focus of alliance have always been market access, technology acquisition, 
financial support, political insurance and competitive reality {Barrie, 1985). Varadarajan 
and Cunningham (1995), have indicated that the main motive for partnership between 
firms is the pooling of specific resources and skills. Alliances create value which is an 
ongoing process especially by fostering close interfirm ties which create more opportunity to 
exploit technology, marketing and other aspects. Wang and Zajac(2007), indicate that in 
today's business environment, firms constantly assess and reassess their own portfolios of 
resources and capabilities, and are typically open to the opportunities presented in the 
environment, including the opportunity to combine resources with other firms. They have 
focused on three types of paired - firm characteristics: (1) resource similarity and 
complementarity between two firms, (2) the combined relational capabilities of two firms 
and (3) the partner specific knowledge of two firms. 
Competitive advantage: Alliances gives access to new technology which can ultimately 
lead to better value addition to customers, thereby enhancing competitive advantage of a 
firm. Silverman & Baum (2002) have explored the competitive implications of alliances, and 
have indicated that rivals'alliance puts a pressure on competing firm. Hess (2005), indicated 
that with the onset of patent expiry, branded drug companies need to opt for more defensive 
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strategies to combat the generic competitors. Narula & Dunning (1998) hiave observed an 
increase in alliances across all of the advanced industrialised economies and the nature of the 
alliances are strategic. 
Alliances are no longer simply undertaken as a means of avoiding transaction and coordination 
costs of markets. Nerkar & Roberts (2004 ) , indicated that the growth and development of a 
firm is dependent on its ability to introduce new products over time which requires 
technological knowledge, the ability to combine knowledge elements into valuable new 
products and complementary assets that facilitate the manufacturing, sales, and distribution of 
those products. They indicate that inventions are the result of combining or recombining 
existing elements of knowledge into new syntheses and an invention becomes a successful 
innovation if it has a marketable use. Eisenhardt & Martin (2000), identified dynamic 
capabilities as a set of specific and identifiable processes such as product development, 
strategic decision making and alliancing, which have significant commonalities across firms 
and are homogeneous, equifinal and substitutable, commonly known as best practices. 
Researchers have theorized that when firms have resources that are valuable, rare, inimitable, 
and non-substitutable (so-called VRIN attributes), they can achieve sustainable compefitive 
advantage by implementing fresh value-creating strategies that cannot be easily duplicated by 
competing firms. Dynamic capabilities are complicated, detailed, analytic processes that rely 
extensively on existing knowledge and linear execution to produce predictable outcomes. They 
indicate that dynamic capabilities are the antecedent organizational and strategic routines by 
which managers alter their resource base—acquire and shed resources, integrate them together, 
and reconnbine them—to generate new value-creating strategies. 
Acquire market access: One of the original motives for alliance formation was to acquire 
market access and/or overcome supply bottlenecks, i.e., to achieve vertical integration where 
such integrafion was not possible through hierarchies. Narula & Dunning (1998), indicate that 
inter-firm alliances are increasingly being undertaken, through various modes, as a direct 
response to pressures brought about by contemporary technological developments and 
globalisation. 
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Rothaermal (2001), indicated that firms entering into alliances look out for 
complementary assets which are advantageous to each other, especially so in the 
biopharmaceutical industry which is technologically very competitive and ever changing. 
Globalization: Contractor & Lorange (2002), attempted to identify the environmental and 
regulatory conditions that have fostered the growth of alliances. They indicate that the fear of 
alliance formation is mitigated by two regulatory and environmental factors: 
1. The global spread of the system of intellectual property protection under the aegis 
of TRIPS, a protocol of the World Trade Organization, which reduces the fear of 
misappropriation. 
2. Greater articulation and codification of knowledge, which reduces the costs of its 
transfer to allies which is aided by broad-based adaptation of information 
technology. 
Harmonization of standards and reciprocal acceptance of data has encouraged some of the 
recent alliances. Consistent application of Intellectual property laws and continuous talks with 
the WTO lead to greater harmonization. This phenomenon is evident in the pharmaceutical 
industry where trials in different nations can be pooled and interpreted, thus allowing nations to 
accept the data collected in different places. Focus on "core-competence" makes it necessary 
for external knowledge acquisition, which is obtained by alliances. They have also indicated 
that alliances can reduce the escalating R&D costs and risks as risks are shared in collaborative 
R&D. 
Cost of research: The process of research is a time consuming and expensive process. 
According to Cohen and Levinthal (1989), the two facets of R&D: it not only generates 
new information but also enhances the firm's ability to assimilate and exploit existing 
information. Thus R&D generates innovations and also develops a firm's ability to identify, 
assimilate and exploit knowledge from the environment thereby enhancing the firm's learning 
and absorptive capacity. 
Relationships: Combined relational capabilities of two firms would determine the alliance or 
acquisition which is dependent not only on the strategic needs of firms to combine their 
resources but also on relevant capabilities. Relational capability of a firm refers to its ability to 
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interact with and manage other firms in inter-firm relationships. Once a firm develops certain 
relational capabilities, it is more likely to exploit them by establishing more interfirm 
relationships with other firms, thereby gaining economic benefits Wang andZajac (2007). 
Collins and Hitt (2006), indicate that in highly competitive industries, firms need to focus on 
proactively managing their icnowledge resources to ensure survival, although the knowledge 
management process may be difficult as it involves tacit knowledge. The transfer of tacit 
knowledge is facilitated by the relational capital between the collaborators. They explain how 
firms use relational capabilities to build relation capital with partners. They acknowledge that 
knowledge transfer is facilitated by repeated interaction among partnering firms and explore the 
need for firms to recognize the importance of inter-personal dynamics involved in the transfer 
of tacit knowledge. Tacit knowledge transfer requires greater trust between partners than does 
explicit knowledge transfer and building relational capital involves development of trust, 
information sharing and joint problem solving. 
High profits from innovations: Roberts (1999), indicated that sustained high profitability 
may result when a firm repeatedly introduces valuable innovations that service previously 
unmet consumer demands. While the returns to the firm from each innovation may erode over 
time, innovation ensures that, overall the firm maintains a high performance position. His 
framework for firm-level profit persistence embraces product innovation, product-market 
competition and more importantly, the prospect that numerous product innovations may be 
embodied within a single firm. Innovation and anti- competifion are identified as two 
explanations for firm level persistent profitability. An innovative new product tends to face low 
competition at the point of introduction and therefore earns relatively high profits. These high 
profits attract imitators, which increase the level of competition faced by the product as time 
passes. According to an anticompetition explanation, a firm may introduce an innovative 
product (or group of products) that is buffered from the competition that otherwise erodes the 
high profits associated with its introduction. On the other hand, an innovation explanation 
recognizes that relatively high profits may persist at the firm level even though competition is 
relatively intense. In such a case, the excess profits associated with any single innovation are 
transitory, but firms successfully introduce multiple innovations over fime. 
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Van Reenen (1993), suggested that firms experience relatively high profits from innovations. 
They have also observed that profit margins of innovating firms are less sensitive to cyclical 
downturns than those of non innovators. They have observed that innovators are likely to be 
quicker, more flexible, more capable and more adaptable in dealing with market pressures. 
Dynamic Technological changes: Rothaermal (2001) indicated that radical technological 
breakthrough is the reason when incumbent firms are forced to adapt to survive. Incumbent 
firms acquire the new technology through licensing agreements, strategic alliances, joint 
ventures and acquisifions. Nerkar and Roberts (2004) have suggested that the growth and 
development of a firm depends on the ability to introduce new products, whose success is 
dependent upon superior technological knowledge and marketing capabilities. 
McCutchen Jr.& Swamidass (2004), conducted an exploratory study to investigate the 
motivations of strategic alliances among small and large pharmaceutical and biotech 
licensors and licensees. They have referred to many reasons that motivate the formation of 
strategic alliances, including the aspect of synergy where the alliance is a symbiotic 
relationship between two firms. 
The most critical outcome of the research is that their results were in consistent with 
Hagedoom (1993), where the primary motive for an alliance was concluded to be technology. 
R&D time - span reduction and financial aspects were the other identified reasons for alliances 
in the pharmaceutical industry. Some of the conclusions drawn throw light on the unique 
disposition of the small firms in the pharmaceutical industry. They have demonstrated that the 
licensees seek new products to improve their competitive position and gain access to new 
markets. Pharmaceutical industry's small firms are often technologically advanced and may 
have a small scale of operation when compared to large firm. Their findings show that firm size, 
which serves as a proxy for firm capabilities, has a significant Influence on the motivations for 
strategic alliances in this industry. They also conclude that the ownership of technology 
(licensor vs. licensee) also Influences the motivations for strategic alliances. 
According to Katila and Mang (2003), factors that speed up collaboration in the 
biopharmaceutical industry includes: patent protection, high intensity of Research and 
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Development of the discovering firm, partnering firms' prior exposure to alliance and finally 
the infrastructure in the industry. Government initiatives to promote entrepreneurial activifies in 
the pharma-biotech sector have been effective as they have also indirectly influenced the 
infrastructure development like building of biotech parks and increasing intellectual property 
protection. 
To summarize, the factors that have influenced the alliance formation among 
companies are represented in the table below. (Adapted from: Contractor and Lorange , 
2002) 
Illustration 4 : Reasons for Alliances 
1. Governmental Policy related factors 
i. Intellectual properties 
ii. Deregulation and Economic liberalization 
2. Gaining competitive advantage 
i. Growth strategy 
ii. Mimic competition 
iii. Gain access to key attributes 
3. Globalization 
i. New market access 
ii. International harmonization of standards 
4.Cost related aspects 
i. Cost of production 
ii. Cost of R&D 
iii. Cost of marketing and distribution 
5. Innovations 
i. Achieve high profits 
ii. Achieve vertical integration 
6. Technology and knowledge management related 
i. Rapid advances in technology - related to lifescience 
ii. Increasing role of information technology 
iii. Strategic importance of speed 
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3.4 Impact of Strategic Alliances 
Alliances, which are a consequence of growth strategy and which are clearly envisioned 
and implemented, can prove to be beneficial to both the alliance partners. This is especially 
the case when there is a transfer of resource from a parent firm to a host firm. James (2002), 
discusses the resource based view which has led to positive outcomes of alliances. Firm 
specific assets, which are distinctive and accumulated over time, can be exchanged which can 
lead to business benefits. Innovafions are often a result of combined capabilities of alliancing 
firms. Hamel (1991), described that in competitive collaboration, the primary objective of the 
strategic alliance is to internalize the partner skills. He proposed that the alliance partner who 
understand the co-relation between inter-partner learning, bargaining power and 
competitiveness will view the alliance as a learning ground. Two major determinants of 
learning are transparency and receptiveness. 
Research and Technology •.Porter (1996), indicated that management tools and techniques: 
total quality management, benchmarking, time based competition, outsourcing, partnering, re-
engineering, change management, have resulted in dramatic operational improvement across 
the globe. This is especially true in high technology industries like pharmaceuticals. Positive 
aspects namely global generation of innovations which results from R&D and innovative 
activities both in the home and host countries are outcomes of strategic alliances, 
Archibugi and Pietrobelli(2002). Additionally, strategic alliances help in the global techno-
scientific collaborations involving joint scientific projects and R&D network. 
Marketing 
Marketing is one of the reasons which has prompted the formation of alliances in the 
pharmaceutical industry. The pharmaceutical R&D companies, who are into discovery, 
develop new and promising molecules. Commercialization of the molecule, generating a 
market, promoting and managing the sales is a completely different aspect, which requires 
skill and resource. Thus big pharmaceutical companies enter into alliance with R&D firms 
where the R&D firms develop new molecules and the big pharmaceutical companies look 
after the commercial aspects. Many companies also enter into alliances for distribution 
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purposes. With respect to the Indian pharmaceutical industry, the alliances have changed the 
scenario of the industry in the last 20 years. The alliances have impacted the way the Indian 
pharmaceutical companies approach marketing. 
New Product Development 
Deeds and Hill (1996), have demonstrated that strategic alliances are positively related to 
new product development. They have built on the premise that new product development 
involves integration of a number of complementary assets and strategic alliances are a quick 
and effective way to achieve them. There is a parabolic relationship, wherein initially strategic 
alliance are viable for firms to gain access to assets that increase their new product 
development, however if the firm enters into too many alliances, negative results may set in. 
Competitive Advantage 
5fl/fl a«J iS'flgoo (2000), have studied the impact of patents on the availability and prices of 
essential drugs in developing countries. Competition in the pharmaceutical market brings 
down prices as the originator firm will bring down prices to compete with the local generic firm. 
Thus when more and more firms are involved in alliances and build their capacity, there 
will be a positive effect on the price of the pharmaceutical drugs. Za«/oww(2005) has given 
evidence that show high levels of patent protection encourages the launch of innovative 
products, especially in countries where MNCs have to encounter local technical capacities. 
Patent protection indirectly aids alliance formation, which aids in enhancing the production 
of the molecule and indirectly impacts price and availability of the molecule. 
Shrank et al (2006), demonstrated that for chronic ailments, generic pharmaceutical 
products have proven to be having less amount of patient drop outs. Thus pointing to a 
fact that it becomes very critical for an originator firm to look at generic options if the 
patients need to be "locked into" the therapy. Drews(2003), has indicated that producfivity 
of the pharmaceutical industry has fallen short dramatically, that is the number of novel 
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compounds are depleting thus pushing big pharmaceutical companies to come together 
trough alliances to acquire new product lines to strengthen their portfolio. 
With the aspects of globalization and certain typical challenges that is faced by the 
pharmaceutical industry, marketing skills and practices stems from the central organization 
and is transferred to local affdiates. The transference is a product of training which 
involves both technical aspects as well as skills development. 
Chandon (2004), has described the strategic options available to a innovator firm after the 
patent expiry. Divesting is strategy adopted where the brand is not supported but 
generates revenue due to the inertia of doctors to switch to new generics. Innovation is 
another strategy that can be adopted by offering new and better services, new dosage 
combinations, new delivery systems etc. Introducing generic products either directly or by 
licensing is also a approach taken by innovator companies, to make the most out of the 
scenario. 
Thus the impact of alliances on the can be summarized as follows 
Illustration 5 : Impact of Alliances on Business Aspects of Pharmaceutical Companies 
1. Product 
i. New product development 
ii. New product launches - domestic and international markets 
iii. Enhanced product portfolio 
2. Marketing 
i. Access to new markets 
ii. Enhanced sales promotional activities and spend 
iii. New distribution channels 
3 Technology 
i. Access to new technology 
ii. R&D capability 
iii. GMP manufacturing facilities knowhow 
4 Manufacturing 
i. Cost optimization 
ii. Quality management techniques 
iii. Common asset and operational synergy 
5 Competitive advantage 
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i. Increased market share 
ii. Increased profitability 
iii. Intellectual and managerial skills 
3.5 Success Factors for Alliances 
Two types of uncertainties in alliances: uncertainty regarding future events and uncertainty 
regarding partner's responses to those future events. Alliances involve considerable investment 
of resources and need to be nurtured and managed well, if they are to be successful. Trust 
between partners forms the basis of any successful alliance. Trust is defined as the mutual 
confidence that neither party will exploit another's vulnerabilities; violation of expected 
behaviours can cause disruption of trust leading to profound confusion. Distrust arises when 
there is suspicion of intentional violation of expectations. A weak trust is developed when there 
are limited opportunities for opportunism wherein, the partners can have the mutual confidence 
that others will not exploit their vulnerabilities because they have no significant vulnerabilities. 
Semi-strong levels of trust, emerges even when significant vulnerabilities exist, if parties to an 
alliance are protected through various governance devices. Strong form trust emerges in the 
face of significant vulnerabilities, independent of whether or not elaborate social and economic 
governance devices exist, because opportunisfic behavior would violate values, principles, and 
standards of behavior that have been internalized by alliance partners. Parkhe (1998), indicates 
that trust plays a dominant role in successful alliances. Successful adaptation calls for a delicate 
balance between the twin virtues of reliability and flexibility. Flexibility is necessary for 
partners to have a viable relationship in the face of changing circumstances, yet unlimited 
flexibility affords companies the opportunity and incentive to cheat, reducing the partners trust 
on each other. 
Hyder and Ghauri (2000),haye indicated that during the early stages of the alliance, there 
exists a lot of uncertainties among the alliancing firms, as they are gauging each others 
capabilities. Resources are committed when the 2 parties establish a relationship with each 
other. Relationship is strengthened through openness and access to each other's re.sources. Two 
attributes that affect post-formation dynamics are the scope of collaborative activity and 
division of labour among partners (iJeweranJ Zollo, 2000). 
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Doz(1996), identified four factors which are key determinants of an evolving partnership: the 
definition of the tasks to be jointly performed by the organizations, the alliancing firms' 
respective organizational routines, the interface between the alliancing firms and finally the 
expectation each firm has on the alliance. 
Developing relationships between the partners is critical as this is can involve formal and 
informal transfer of knowledge which is an important factor determining the success of an 
alliance. Highly competitive industries, firms need to focus on proactively managing their 
knowledge resources to ensure survival, although the knowledge management process may be 
difficult as it involves tacit knowledge, Collins and Hitt (2006). The transfer of tacit knowledge 
is facilitated by the relational capital between the collaborators. They explain how finns use 
relational capabilities to build relation capital with partners. They acknowledge that knowledge 
transfer is facilitated by repeated interaction among partnering firms and explore the need for 
firms to recognize the importance of inter-personal dynamics involved in the transfer of tacit 
knowledge. Tacit knowledge transfer requires greater trust between partners than does explicit 
knowledge transfer and building relational capital involves development of trust, information 
sharing and joint problem solving. Specific governance changes firms make in strategic 
alliances and explore some of the factors affecting parent firms' interventions in their 
collaborafive agreements, Reuer and Zollo (2000). They indicated that like acquisifions, many 
alliances falter at the juncture between alliance formation and implementation. They indicate 
that governance changes in strategic alliances are a critical factor that influences alliance 
termination and parent firm's intervention in collaborative agreement. Governance changes in 
alliances can stem from intense competition or changes in rivalry. Other factors that affect the 
post formation dynamics of alliances are scope of collaborative activity and division of 
labor among partners. 
Liberalization of restrictions on foreign direct investment has historically been one reason 
behind equity changes in market entry of international joint ventures in developing countries. 
Foreign exchange rate movements can be another source of instability in alliances. Prior 
alliances with a partner, for instance, allow firms to better understand partners' routines for 
managing collaborative processes. 
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Baker, Gibbons and Murphy (2008), have illustrated that two important factors that determine 
the form and performance of strategic alliances are - spillovers from joint project into parents 
and the need for governance. Serapio and Cascio(1996), have found that alliances are 
terminated for one or more of six reasons: 
• Differences between partners, people and managerial styles 
• Unsuccessful venture 
• Breach of agreement 
• Nonfitment of goals and strategies 
• Financial difficulties 
• Achieving the original objective of the alliance 
Douma et al(2000), identify different aspects of fit and their interrelationships, as well as 
provides an insight into the drivers for fit. Alliances are knowledge intensive and have moved 
away from the traditional cost-driven model. Inspite of this many alliances do not deliver the 
value expected by the strategic partners. Alliance success depends on an effective and efficient 
alignment (in other words, fit) between the partners involved. Fit is very much related to 
concepts such as complementary balance, mutual benefits, harmony. They have idenfified five 
aspects of mutual relationship: Strategic fit, Organizational fit. Cultural fit, Operational fit and 
Human fit. 
Strategic fit involves six drivers, sharing a common vision, having a compatibility of 
strategies, mutual dependency, market acceptability of the alliances, should add value for the 
partners and their customers, and finally the alliance should be of strategic importance to 
both the partners. The drivers for organizafional fit includes: addressing organizational 
similarities and differences in the alliance, providing for strategic and organizational 
flexibility, reducing the design complexity, enabling effective management control by both 
partners, overcoming potenfial strategic conflicts and enabling partners achieve their 
strategic objectives. 
James (2.002) has indicated that there are challenges of managing resources and 
capabilities in an alliance, which stems from organizational and cultural barriers. Alliances 
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especially mergers and acquisitions, do extract a heavy price from the on going business 
activities, due to disruptions caused by loss of staff, break up of teams, dip in morale and 
loss of business due to lack of focus. Management of the integration process is critical for the 
success of any alliance. Imperfect information of the various aspects of the organization can 
influence the integration process. Sense of inertia and a propensity to hold on to original 
beliefs on the employees part can often create barriers in the integration process which will 
eventually delay the process. Alliances can cause cultural clashes and intra- organizational 
battles between competing business and executives, which can lead to the exit of 
manpower. 
Thus alliance is not an end by itself, the success of an alliance is an elaborate procedure, 
which involves involvement of management at all levels. Trust is the most important factor 
which determines the success of the alliance. Understanding the fit and strategic goal is critical 
for the success of the alliance. Day to day functioning and governance need to be handled 
effectively as they would impact the smooth functioning of the organization. In addition, 
external factors like regulation and liberalization may also play a role in the continuance 
of an alliance. 
Illustration 6 : Factors Affecting the Success of Alliances 
1. Exterinai factors 
i. Legal and regulatory policies 
ii. Currency related aspects 
2. Strategic fit 
i. Strategic fit 
ii. Organisational fit 
iii. Cultural fit 
3. Governance 
i. Day to day operations 
ii. Communication 
4. Trust 
i. Formal and informal relationships 
ii. Collaborative activities 
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3.6 Conclusion and Research Gaps: 
Strategic alliance between Indian and foreign pharmaceuticals is a phenomenon that is here to 
stay for many more years in the future. Literature has discussed extensively the driving factors 
for the alliances and the trend of alliances in the 5 decades starting from 1960 till 2010. 
Research gaps that have been identified are as follows: Considerable literature is available on 
the strategic alliances that have taken place among pharmaceutical companies abroad. The 
studies have analyzed the reasons for the alliances, the trends and outcome of the alliances. 
There is no study available on the outcome of the alliances on various factors like 
business, customers and employees. The alliances are considered to be beneficial as they 
are formed to meet a business objective and after the objective is realized, they are 
termed as successful. However the impact on employees is not studied in depth. 
When it comes to the context of the Indian pharmaceutical companies, the gaps in the 
literature are far more ohv\ous. Beena, Smith, Pradhati, Greene, Langley are some of the 
researchers who have contributed in understanding the trends in strategic alliances in India 
and the factors that have led to the formation of alliances. For instance, many of them refer 
to the liberalization policy of 1991, and the accession to TRIPS are two important 
reasons. There is no study available which discussed the impact of the alliances on the 
Indian companies. Companies have grown, achieving high turnovers, accruing huge 
investments, diversifying into contract research and R&D, are these the outcomes of alliances, 
or natural transition of Indian pharmaceutical companies? With regards to the reasons for 
the formation of alliances between Indian and foreign pharmaceutical companies, many 
causes have been identified. Literature has given a number of evidences like reduced costs, 
scientific talent etc. However there is no formal study which pinpoints the actual reason 
for the alliances. Additionally, the kind of alliance undertaken by a particular enterprise is 
critical. Small pharmaceutical company may undertake alliance with a foreign partner for a 
completely different reason in comparison to a large innovator Indian pharmaceutical 
firm. There is no correlation between the kind of company and the alliance undertaken. 
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The study attempts to understand and analyze the trends on strategic alliances between Indian 
and foreign pharmaceutical companies. Although many researchers have commented on this 
topic, the data is limited up to 2006 only. Many alliances have happened post 2006, which 
needs to be considered as well. There is no study which traces the objectives of alliance 
that have happened in each decade starting from 1950 with regards to Indian 
pharmaceutical companies. 
The first objective of the study is to analyze the various factors that have led to the formation of 
alliances between Indian and foreign pharmaceutical companies. There are a number of 
factors like economic factors, technological aspects that have contributed to the alliances. 
Although there are many literature references to the politico - legal situation which opened 
up the economy and made business lucrative in India, there are no studies which actually 
discusses this. There are indications on some critical aspects that have led to alliance 
formation between Indian and foreign pharmaceutical companies like : Products, Marketing, 
Manufacturing, Technology and Competitive advantage. There is no formal study 
incorporating aspects of these 5 areas into strategic alliances. 
The second objective of the study aims at understanding the business implications of the 
strategic alliances between Indian and foreign pharmaceutical companies. There are many 
researches that have discussed the alliances and their formation, however implications of 
the alliances is a subject with very little work. This is especially so in case of Indian 
scenario. There is no study which discusses the major business area that is impacted the 
most during an alliance. The most important stake holder namely the employee and the 
impact the alliance has on him is again a topic with no available literature. The alliances 
that have occurred in the Indian pharmaceutical industry has been beneficial to a large 
extent. They also have some negative implications. There is no available literature that 
discusses these crucial aspects. One of the research questions is to address the benefits and 
detriments of the alliances that have occurred between Indian and foreign pharmaceutical 
companies. 
The third objective of the study is to understand and evaluate the factors that are critical for a 
successful alliance. Alliances are the outcome of a strategic business objective and involve 
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investments. Hence their objective success is critical for every organization that is part of the 
alliance. Although there are literature which have referred to critical success factors of an 
alliance, literature with respect to success factors for alliance between Indian and foreign 
pharmaceutical companies is not available. ' 
Thus to summarize, the literature gaps identified are depicted in the table as follows. 
Illustration 7: Literature Gaps 
sj^jrHire Gaps. 
1. Trends Strategic alliances between Indian and foreign pharmaceutical companies 
i. No decade wise analysis 
ii. Data is available till 2006 only 
iii. No study on the objectives of the alliances is available 
2. Factors that have led to formation of alliances between Indian and foreign pharmaceutical firms 
i. Role of technological factors in alliance formation 
ii. Role of economic factors in alliance formation 
iii. Role of competitive advantage related aspects in alliance formation 
3. Business implications of strategic alliances between Indian and foreign pharmaceutical firms 
i. The major business area impacted during an alliance 
ii. Impact of alliance on marketing elements 
iii. Impact of alliances on the People of the firms who have formed an alliance 
4. Factors that are critical for a successful alliance between Indian and foreign pharmaceutical firms 
i. Critical success factors with respect to Indian context 
ii. Beneficial aspects of alliances to Indian firms 
iii. Negative fallouts of alliances with regards to Indian pharmaceutical industry 
This study will address the above identified research gaps through both primary and 
secondary data evaluation. The primary data will be collected by the elements on whom 
the alliance has an impact, namely employees and customers. 
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CHAPTER 4 
RESEARCH METHODOLOGY 
CHAPTER 4: RESEARCH METHODOLOGY 
This chapter describes the research methodology adopted in the thesis "Study of the strategic 
alliances between Indian and foreign pharmaceutical companies in India, with reference to the 
Indian pharmaceutical industry." 
4.1 Research Objectives 
The research objectives are derived from the gaps in literature review. The research questions 
are some of the key aspects to which the answers need to be sought. Both the aspects of the 
research are illustrated in the table below. • 
1. To study the factors that influence Indian pharmaceutical companies to form 
strategic alliances with foreign pharmaceutical firms. 
2. To study the impact of the strategic alliances between Indian and foreign 
pharmaceutical companies on various business aspects of the Indian pharmaceutical 
firm. 
3. To formulate strategies for Indian pharmaceutical companies to avail maximum 
benefit, from the alliances undertaken with foreign pharmaceutical companies. 
4.2 Scope of the Research 
The research study analyses the alliances that have happened between Indian and foreign 
pharmaceutical companies. The period under consideration is the last 5 decades that is, 
from 1950-2009. It traces the evolution of the Indian pharmaceutical industry over the 
years and also draws a comparison with the global pharmaceutical firms. The study tracks 
the alliances of 10 major Indian pharmaceutical companies, along with the reason for the 
alliance. Empirical study is conducted to understand the impact of alliances on various 
aspects of the business: Product, Marketing, Technology, Manufacturing and Competitive 
Advantage. Personal interviews of four CEOs/ MDs of Indian pharmaceutical companies, 
who are involved in strategic alliances with foreign pharmaceutical companies gave an 
framework to the various critical parameters that impact alliance formation and the areas 
that are impacted during an alliance. 
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The study does not discuss the alHances happening in other countries, especially between 
firms in developed countries. The study does not study each of the alliance in detail and 
analyze the success or failure of the alliance. It does not discuss the alliance outcomes in 
relation to business goal achievements, impact on turnover etc. 
4.3 Research Questions 
What are the factors that influence the formation of strategic 
alliance between Indian and foreign pharmaceutical firms ? 
What are the major business implications of strategic alliances 
between Indian and foreign pharmaceutical alliances? 
What are the hindrances for strategic alliances between Indian 
and foreign pharmaceutical companies? 
Primary data 
Primary data 
Primary data 
4.4 Identification of Variables 
The variables selected to answer the research questions involve: 
• factors that motivate the Indian pharmaceutical companies to form alliances with 
foreign companies 
• the impact of strategic alliance between Indian and foreign pharmaceutical companies 
on various aspects of the business. 
• Factors that influence the success of the strategic alliances between Indian and 
foreign pharmaceutical companies 
The factors are identified from various existing literatures. 
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Illustration 8 : Variables and Literature References 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
Access to global markets 
Access to new technology 
Access to foreign distribution network 
Access to USFDA approved manufacturing 
facilities 
Strengthen product portfolio 
Acquire marketing knowhow 
Access to highly regulated markets 
Collaborative R&D 
Overall cost minimization 
ImproVe market positions 
Exploit common assets 
Develop financial strength 
Establish a brand name abroad 
Access to worldwide information on latest 
technology and products 
Managerial knowhow - access to superior 
managerial skills 
Access to superior Quality management 
systems 
1 form Alliances with Foreign Companies 
V Literature References r i j t 
Pradhan Jaya Prakash (2007), Pradhan and Abraham 
(2005), Parvatiyar Atul and Gupta P. Yash (1994), Smith 
Sean Eric (2000) 
Greene William (2007), Feinberg e. Susan andMajumdar 
K. Sumit(200l), Chaturvedi Kalpana and Chataway Joanna 
(2006), Parvatiyar Atul and Gupta P. Yash (1994) , Smith 
Sean Eric (2000) 
Parvatiyar Atul and Gupta P. Yash (1994) 
Greene William (2007), 
Pradhan and Abraham (2005 
NerkarAtul and Roberts Peter (2004), Mueller M. Janice 
(2007) 
Smith Sean Eric (2000) 
Pradhan JayaPrakash(2005), Pradhan and Abraham (2005 
R. Narula and J. H. Dunning (1998), Chaturvedi Kalpana 
and Chataway Joanna (2006) 
Smith Eric (2000), Pradhan Jaya Prakash (2007) 
Hess Jon (2005), Brian S Silverman, Joel A C Baum (2002) 
Mowery C. David, Oxley E. Joanne, Silverman S. Brian 
(1996), Pradhan Jaya Prakash (2007) 
Chaturvedi Kalpana and Chataway Joanna (2006) 
Pradhan Jaya Prakash (2007) 
Parvatiyar /. tul and Gupta P. Yash (1994) 
Parvatiyar Atul and Gupta P. Yash (1994) 
Parvatiyar Atul and Gupta P. Yash (1994) 
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1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
(foreign Phannaceiitjcal Companies 
'; Literature References . .•••••ii 
Launch new patented molecules 
Launch new generic molecules in the 
foreign markets 
Gain access to highly regulated market 
Achieved R&D capability 
Gain access to new technology 
Gain capability to invest in marketing and 
sales promotional activities 
Gain GMP compliant manufacturing 
capabilities 
Achieve cost minimization 
Achieve increased market share 
Achieve increased profitability 
Exploit common assets 
Gain enhanced product portfolio 
Establish a brand name abroad 
Access to worldwide information - latest 
advancements in technology and products 
Enabled Managerial knowhow - access to 
superior management systems 
Access to superior Quality systems 
NerkarAtul land Roberts Peter (2004), Mueller M. Janice 
(2007), Kiran Ravi and Mishra Sunita (2009) 
Smith Eric (2000), Mueller M. Janice (2007), Gehl Sampath 
(2005) 
Greene William (2007), Parvatiyar Atul and Gupta P. Yash 
(1994), Gehl Sampath (2005) 
Linton Katherine Connor and Corrado Nicholas (2007), Kiran 
Ravi and Mishra Sunita (2009), Bower D. Jane and Sulej C. 
Julian (2007), Gehl Sampath (2005) 
Feinberg E. Susan and Majumdar K. Sumit(2001), Parvatiyar 
Atul and Gupta P. Yash (1994), Kiran Ravi and Mishra Sunita 
(2009) 
Chitoor Raveendra, Ray Sougata, Aulakh s. Preet, Sarkar M. B. 
(2008) 
Parvatiyar Atul and Gupta P. Yash (1994), Gehl Sampath 
(2005) 
Linton Katherine Connor and Corrado Nicholas (2007) 
Pradhan and Abraham (2005), Chaturvedi Kalpana and 
Chataway Joanna (2006), Parvatiyar Atul and Gupta P. Yash 
(1994) 
Chitoor Raveendra, Ray Sougata, Aulakh s. Preet, Sarkar M. B. 
(2008), Kiran Ravi and Mishra Sunita (2009), Bower D. Jane 
and Sulej C Julian (2007) 
Pradhan and Abraham (2005), Gehl Sampath (2005) 
Pradhan JayaPrakash (2007), NerkarAtul and Roberts Peter 
(2004), Mueller M. Janice (2007) 
Pradhan Jay a Prakash (2007) 
Parvatiyar Atul and Gupta P. Yash (1994) 
Parvatiyar Atul and Gupta P. Yash (1994) 
Parvatiyar Atul and Gupta P. Yash (1994) 
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4.5. Research Hypotheses 
A comprehensive literature review and the scheduling study which was conducted with CEOs 
of Indian firms who have entered into strategic alliances with foreign firms formed the base 
for the Hypotheses formulation. 
Hypotheses 
1 : RELATED TO IMPACT ON PRODUCTS 
Impact of Strategic alliances between Indian and foreign pharmaceutical companies on the 
launch of new patented molecules. 
HOI: There is no significant difference in the mean value of launch of new patented molecules 
as an area if impact of strategic alliances between Indian and foreign pharmaceutical companies 
across the types of Indian pharmaceutical companies. 
H02: There is no significant difference in the mean value of launch of patented molecules 
as an area of impact of strategic alliances between Indian an foreign pharmaceutical 
companies , across the types of activity undertaken by Indian pharmaceutical companies. 
H03: There is no significant difference in the mean value of launch of patented molecules as 
an area of impact of strategic alliances between foreign pharmaceutical companies, across 
Indian pharmaceutical companies of differing turnover. 
Impact of Strategic alliances between Indian and foreign pharmaceutical companies on the 
launch of generic pharmaceutical products in India. 
H04: There is no significant difference in the mean value of launch of generic pharmaceutical 
products abroad as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across all types of Indian pharmaceutical companies. 
H05: There is no significant difference in the mean value of launch of generic pharmaceutical 
products abroad as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across the types of activity undertaken by Indian pharmaceutical 
companies. 
H06: There is no significant difference in the mean value of launch of generic pharmaceutical 
products abroad as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies of varying turnover. 
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Impact of Strategic Alliances between Indian and foreign pharmaceutical companies on the 
launch of generic pharmaceutical products abroad. 
H07: There is no significant difference in the mean value of launch of new generic 
pharmaceutical products in the domestic market as an area of impact of strategic alliances 
between Indian and foreign pharmaceutical companies on the, across the types of Indian 
pharmaceutical companies. 
H08: There is no significant difference in the mean value of launch of new generic 
pharmaceutical products in the domestic market as an area of impact of strategic alliances 
between Indian and foreign pharmaceutical companies across the types of activity undertaken 
by Indian pharmaceutical companies. 
H09: There is no significant difference in the mean value of launch of new generic 
pharmaceutical products in the domestic market as an area of impact of strategic alliances 
between foreign pharmaceutical companies, across Indian pharmaceutical companies with 
different turnovers. 
Impact of Strategic alliances with foreign pharmaceutical companies on gaining a wider 
product portfolio 
HOlO: There is no significant difference in the mean value of expansion of product portfolio 
as an area impact of strategic alliances between Indian and foreign pharmaceutical 
companies, across all types of Indian pharmaceutical companies. 
HOll: There is no significant difference in the mean value of expansion of product portfolio as 
an area of impact of strategic alliances between Indian and foreign pharmaceutical 
companies, across Indian pharmaceutical companies indulging in various activities. 
H012: There is no significant difference in the mean value of expansion of product portfolio as 
an area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across Indian pharmaceutical companies of varying turnover. 
2: RELATED TO IMPACT ON MARKETING ASPECTS 
Impact of Strategic Alliances between Indian and foreign pharmaceutical companies on 
gaining access to highly regulated markets abroad 
H013: There is no significant difference in the mean value of gaining access to highly 
regulated markets abroad as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across all types of Indian pharmaceutical companies. 
H014: There is no significant difference in the mean value of gaining access to highly 
regulated markets abroad as an area of impact of strategic alliances between Indian and 
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foreign pharmaceutical companies, across Indian pharmaceutical companies undertaking 
different activities 
HOI 5: There is no significant difference in the mean value of gaining access to highly 
regulated markets abroad as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies across Indian pharmaceutical companies of different turnover 
Impact of Strategic Alliances between Indian and foreign pharmaceutical companies on 
gaining capability to invest in sales and marketing. 
H016: There is no significant difference in the mean value of gaining investment capability 
into sales and marketing as an area of impact of strategic alliances between Indian and 
foreign pharmaceutical companies, across all types of Indian pharmaceutical companies. 
H017: There is no significant difference in the mean value of gaining investment capability 
into sales and marketing , as an area of impact of strategic alliances between Indian and 
foreign pharmaceutical companies, across Indian pharmaceutical with varying business 
activities. 
H018: There is no significant difference in the mean value of gaining investment capability 
into sales and marketing, as an area of impact of strategic alliances between Indian and 
foreign pharmaceutical companies, across Indian pharmaceutical companies with varying 
turnover 
Impact of Strategic Alliances between Indian pharmaceutical companies on gaining 
access into foreign distribution networks abroad. 
H019: There is no significant difference in the mean value of gaining access to foreign 
distribution networks abroad as an area of impact of strategic alliances between Indian and 
foreign pharmaceutical companies, across all types of Indian pharmaceutical companies. 
H020: There is no significant difference in the mean value of gaining access to foreign 
distribution networks abroad as an area of impact of strategic alliances between Indian and 
foreign pharmaceutical companies, across Indian pharmaceutical companies with differing 
turnover 
H021: There is no significant difference in the mean value of gaining access to foreign 
distribution networks abroad as an area of impact of strategic alliances between Indian and 
foreign pharmaceutical companies, Indian pharmaceutical companies undertaking different 
activities 
3: RELATED TO IMPACT ON TECHNOLOGY 
Impact of Strategic Alliances between Indian and foreign pharmaceutical companies on 
gaining access to new technology, 
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H022: There is no significant difference in the mean value of gaining technological 
competency as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across all types of Indian pharmaceutical companies. 
H023: There is no significant difference in the mean value of gaining technological 
competency as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies indulging in various 
activities. 
H024: There is no significant difference in the mean value of gaining technological 
competency as an area impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies of varying turnover. 
Impact of Strategic Alliances between Indian and foreign pharmaceutical companies on 
achieving R&D capability. 
H025: There is no significant difference in the mean value of achieving R&D capability, as an 
area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across all types of Indian pharmaceutical companies 
H026: There is no significant difference in the mean value of achieving R&D capability, as an 
area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across Indian pharmaceutical companies indulging in various activities. 
H027: There is no significant difference in the mean value of achieving R&D capability, as an 
area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across Indian pharmaceutical companies of varying turnover. 
Impact of Strategic alliances between Indian and foreign pharmaceutical companies on 
gaining access to the latest information on technological and product related upgrades. 
H028: There is no significant difference in the mean value of accessibility of Indian 
companies to latest technological and product related upgrades as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies on, across all types 
of Indian pharmaceutical companies. 
H029: There is no significant difference in the mean value of accessibility of Indian 
companies to latest technological and product related upgrades as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies, across Indian 
pharmaceutical companies of different turnover. 
H()30: There is no significant difference in the mean value of accessibility of Indian 
companies to latest technological and product related upgrades as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies, across Indian 
pharmaceutical companies with different activities. 
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Impact of Strategic alliances between Indian and foreign pharmaceutical companies on 
gaining GMP compliant manufacturing sites. 
H031: There is no significant difference in the mean value of development of GMP 
compliant production capacities by Indian pharmaceutical companies as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies, across all types of 
Indian pharmaceutical companies. 
H032: There is no significant difference in the mean value of development of GMP 
compliant production capacities by Indian pharmaceutical companies as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies, across Indian 
pharmaceutical companies performing different activities. 
H033: There is no significant difference in the mean value of development of GMP 
compliant production capacities by Indian pharmaceutical companies as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies, across Indian 
pharmaceutical companies of different turnover. 
4: RELATED TO IMPACT ON MANUFACTURING 
Impact of Strategic Alliances between Indian pharmaceutical companies on cost 
optimization. 
H034: There is no significant difference in the mean value of cost optimization as an area of 
impact of strategic alliances between Indian and foreign pharmaceutical companies across the 
types of Indian pharmaceutical companies. 
H035: There is no significant difference in the mean value of cost optimization as an area of 
impact of strategic alliances between Indian and foreign pharmaceutical companies across the 
types of activity undertaken by Indian pharmaceutical companies. 
H036: There is no significant difference in the mean value of cost optimization as an area of 
impact of strategic alliances between Indian and foreign pharmaceutical companies across 
Indian pharmaceutical companies of varying turnover. 
Impact of Strategic Alliances between Indian pharmaceutical companies on exploiting 
common assets. 
H037: There is no significant difference in the mean value of achieving operational synergy as 
an area of impact of strategic alliances between Indian and foreign pharmaceutical companies 
across the types of Indian pharmaceutical companies. 
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H038: There is no significant difference in the mean value of achieving operational synergy as 
an area of impact of strategic alliances between Indian and foreign pharmaceutical companies 
across the types of activity undertaken by Indian pharmaceutical companies.. 
H039: There is no significant difference in the mean value of achieving operational synergy as 
an area of impact of strategic alliances between Indian and foreign pharmaceutical companies 
across Indian pharmaceutical companies of varying turnover. 
Impact of Strategic Alliances between Indian and foreign pharmaceutical companies on 
gaining superior quality management skills. 
H040: There is no significant difference in the mean value of quality related skills acquired 
by Indian pharmaceutical companies, as an area of impact of strategic alliances between 
Indian and foreign pharmaceutical companies, across all types of Indian pharmaceutical 
companies. 
HO-^ l: There is no significant difference in the mean value of quality related skills acquired 
by Indian pharmaceutical companies, as an area of impact of strategic alliances between 
Indian and foreign pharmaceutical companies, across Indian pharmaceutical companies of 
different turnover. 
H042: There is no significant difference in the mean value of quality related skills acquired 
by Indian pharmaceutical companies, as an area of impact of strategic alliances between 
Indian and foreign pharmaceutical companies, across Indian pharmaceutical companies with 
different activities. 
5: RELATED TO IMPACT ON COMPEimVE ADVANTAGE 
Impact of Strategic Alliance between Indian and foreign pharmaceutical companies on 
increased market shares, 
H043: There is no significant difference in the mean values of increased market share as an 
area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across all types of Indian pharmaceutical companies. 
H044: There is no significant difference in the mean values of increased market share as an 
area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across Indian pharmaceutical companies indulging in various activities. 
H045: There is no significant difference in the mean value of increased market share as an 
area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across Indian pharmaceutical companies of differing turnovers. 
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Impact of Strategic Alliances between Indian and fofefgn pharmaceutical companies on 
increase in overall profitability. 
H046: There is no significant difference in the mean value of on enhanced profitability as an 
area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across Indian pharmaceutical companies of differing company types. 
H047: There is no significant difference in the mean value of on enhanced profitability as an 
area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across Indian pharmaceutical companies indulging in various activities. 
H048: There is no significant difference in the mean value of on enhanced profitability as an 
area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across Indian pharmaceutical companies of differing turnovers. 
Impact of Strategic Alliances between Indian and foreign pharmaceutical companies on 
establishing new brands in the global market, 
H049:There is no significant difference in the mean value of establishment of Indian 
pharmaceutical brand names in the global market as an area o/impact of strategic alliances 
between Indian and foreign pharmaceutical companies, across the types of activities 
undertaken by Indian pharmaceutical companies. 
H050: There is no significant difference in the mean value of establishment of Indian 
pharmaceutical brand names in the global market as an area of impact of strategic alliances 
between Indian and foreign pharmaceutical companies, across the types of Indian 
pharmaceutical companies. 
H051:There is no significant difference in the mean value of establishment of Indian 
pharmaceutical brand names in the global market as an area of impact of strategic alliances 
between Indian and foreign pharmaceutical companies, across Indian pharmaceutical 
companies of varying turnover. 
Impact of Strategic alliances between Indian and foreign pharmaceutical companies on 
acquiring superior managerial skills. 
H052: There is no significant difference in the mean values of acquisition of management 
skills by Indian pharmaceutical companies as an area of impact of strategic alliances between 
Indian and foreign pharmaceutical companies on the, across all types of Indian 
pharmaceutical companies. 
H053: There is no significant difference in the mean value of acquisition of management 
skills by Indian pharmaceutical companies as an area of impact of strategic alliances between 
Indian and foreign pharmaceutical companies, across Indian pharmaceutical companies of 
different turnover. 
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H054: There is no significant difference in the mean value of acquisition of management 
slcills by Indian pharmaceutical companies as an area of impact of strategic alliances between 
Indian and foreign pharmaceutical companies, across pharmaceutical companies indulging in 
various activities. 
4.6 Research Design 
The study of strategic alliances between Indian and foreign pharmaceutical companies is fairly 
new topic with little available literature.Hence the research design consists of clearly two stages: 
• An initial exploratory stage aimed at crystallization of research questions and, 
• A formal study involving statistical tools and procedures to test the hypotheses. 
Objectives of the exploratory study: 
The exploratory study was conducted with the following objectives in mind, 
• Establish the research questions 
• Establish the hypotheses 
Method of exploratory study: 
Here the exploratory research is qualitative in nature and was executed by: 
• Secondary data analysis 
• Experience survey 
Secondary data analysis involved extensive literature review which includes articles and 
publication which were related to the study topic. Additionally annual reports of Indian 
companies, news paper articles, reports from business consultants like KPMG and McKinsey 
became sources of information which helped to crystallize the research questions. 
Experience surveys which were designed to seek out important ideas and concepts on the 
strategic alliances between Indian and foreign pharmaceutical companies was undertaken. The 
participants in the exploratory surveys were the top executives of Indian pharmaceutical 
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companies who had undertaken alliances with foreign pharmaceutical companies. The sample 
size was limited to 4 participants only. The data collection was done through individual 
structured interviews. 
This study helped understand aspects on the reasons for strategic alliances. Some suggested 
factors include : cost related factors , access to new markets, acquisition of technology and 
knowhow, quality related aspects and the need to reduce time and efforts. 
The impact of strategic alliances between Indian and foreign pharmaceutical companies, 
according to them, was high on products, competitive aspects and marketing strategies of 
Indian pharmaceutical companies. 
Clarity on the intent of the alliance, good communication , cultural fit and compatibility, a 
well oriented alliance steering committee are some of the factors that can influence the 
success of strategic alliances between Indian and foreign pharmaceutical companies. 
Descriptive study: 
The primary objective of the descriptive or formal study is to test the hypotheses and answer 
the posed research questions. The second objective is to establish a correlation among various 
variables that are responsible for the alliances between Indian and foreign pharmaceutical 
companies. 
4.6.1 Questionnaire Development 
The primary data is collected with the help of a specific questionnaire. The questionnaire is 
designed to gather the reasons for alliances between Indian and foreign pharmaceutical 
companies and understand the outcome of the alliances. The questionnaire is divided into 4 
sections. 
The 1st section has 15 variables. Each variable corresponds to each factor that has 
influenced the formation of strategic alliances between Indian and foreign pharmaceutical 
companies. The variables are derived from literature references. 
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The 2" section has 18 variables. This is aimed at gathering data from the responding 
pharmaceutical firms on their experience with strategic alliances that they have undertaken with 
foreign pharmaceutical companies. 
The 3'^ '' section, has 6 factors which are identified as the possible hindrances in the formation of 
strategic alliances in the Indian context. 
The 4 section aims at gathering firm specific data. The descriptive analyses of the 
responding firm, will contain data relating to the Type of company, type of activity of the 
responding company and turnover of the responding company. 
Scale and Design: 
The instrument is intended to be a tool for the study of strategic alliances between Indian 
and foreign pharmaceutical companies with the objective of understanding the factors that 
have contributed to the formation of alliances between Indian and foreign pharmaceutical 
companies. Additionally it aims at gathering firm specific experiences with respect to the 
outcomes of the strategic alliances. 
For this study, the existing components from literature and the components suggested by the 
scheduling research by the industry experts were considered. Convergent and discriminant 
validity of the scales were verified through two rounds of scrutiny by judges and the 
items from the various scales were sorted under appropriate buckets. Weak and bad items 
from the original construct were redefined. The resulfing construct was subjected to 
preliminary test followed by a pilot scale field test. 
The Questionnaire is designed as per Likert scale, thus the level of variables are ordinal. The 
data scale has order but no magnitude and is a categorical data. The Non parametric tests will 
be used for hypotheses testing. 
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4.6.2. Questionnaire Administration 
The sample population for this study is derived from the list of Indian pharmaceutical 
companies registered in recognized databases namely IDMA. The IDMA has 300 registered 
members and includes companies dealing with pharmaceutical manufacturing. It also includes 
pharmaceutical companies who are involved in contract research, research and contract 
manufacturing. Many of these registered pharmaceutical companies have undertaken strategic 
alliances with other pharmaceutical firms. The sample would consist of firms which have 
undergone strategic alliances with another foreign firm. The respondents will be: Top 
executives of pharmaceutical companies in India 
Top executives here refers to the senior managers in Marketing , CEO, MD, Heads of R&D , 
Heads of Production, Executives from Strategy and Development and other functions who 
are privy to high level activities like alliances and acquisitions. The inputs from the top 
executives of pharmaceutical companies in India, gives a complete perspective of the strategic 
alliances between Indian and foreign pharmaceutical companies. 
Sample frame: 
The sample frame for the top executives in pharmaceutical companies of Indian origin extends 
to across India irrespective of the turnover, type and activity of the company. The database was 
acquired from the Indian Drug Manufacturer's Association (IDMA), which is a registry for 
Indian pharmaceutical companies. 
Sampling method: 
The database of firms that have undertaken strategic alliance was created. This included a 
number of 250 Indian companies. From this overall number companies were selected randomly 
to administer the questionnaire. However the representation in the survey depends upon the 
permission granted by the company to get included in the survey. 
Sample size: 
•• To calculate the sample size, the following informafion is critical. 
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Precision desired i 95% confidence level 
Size of the interval estimate 
Central tendency 
±5 
Population Dispersion j Selective 
Source : Cooper and Schindler- Business Research Methods 
Sample size is computed as: The appropriate sample size for a population based survey is 
determined by three factors: 
• Expected frequency value or prevalence of variables of interest, assumed to be 50 % (p) 
• Desired level of confidence, which at 95% is a standard value of 1.96 (t) 
• Acceptable margin of error, which for a standard value of 0.05 is 5% (m) 
Sample size (n) is computed as follows (CEO / Sr. Managers) 
Precision: 95%) confidence 
Expected Frequency: 99%) (p) 
n = t-xp(l-p) n = 1.96 ^x 0.99(1-0.99) n= 15 
m' 0.05^  
The questionnaire was administered to 250 companies. The total responses received was 73. 
Thus the overall sample size considered for this study is 73. 
4.6.3. Pilot study 
In this stage a pilot study of the entire questionnaire was conducted with a small sample 
size comprising of 06 top executives from Indian pharmaceutical companies. The samples 
were selected purely on convenience. 
The first aim of the pilot test was to ensure that the mechanics of questionnaire response 
and compilation were adequate. This was accomplished by having the respondents complete 
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the questionnaire and comment on the length, wording, instructions and complexity of the 
questionnaire. 
The second aim is to establish the reliability of the scales. This was achieved by conducting a 
Cronbach's alpha where the reliabilities for this study were set around 0.7 and 0.8 range. 
During this analysis, the variances of the items and the scales were inspected and the change in 
Cronbach's alpha when an item would be deleted from the scale was noted. The table below 
illustrates the alpha values for the set of data. 
Reliability coefficients of the pilot study: 
Variables relating to the Reasons for strategic alliance and Impact of Strategic Alliance 
between Indian and foreign pharmaceutical companies 
Table No. 12: Reliability Coefficients of Pilot Study 
Reasons for strategic alliance 
Impact of strategic alliance 
Cronbach's Alpha 
.780 
.737 
Cronbach's Alpha Based on 
Standardized Items 
.784 
.727 
N of Items 
10 
18 
The alpha coefficient for the four items is .780, suggesting that the items have relatively high 
internal consistency. 
The alpha coefficient for the four items is .737, suggesting that the items have relatively high 
internal consistency. 
Conclusions of the Pilot Study; 
The following conclusions can be drawn with respect to the results of the pilot study. 
The instrument that was designed to collect data to prove the hypotheses fulfils the 
reliability requirements. Additionally based on the feedback of the respondents the instrument 
has proven to be adequate in terms of: 
• Clarity of questions 
• Flow 
• Ease of answering 
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• Language 
• Constructs 
A univariate analyses of tiie responses indicates tiiat the hypotheses can be tested with the 
questionnaire. 
The coefficient of reliability - chronbach alpha is >0.7 indicating consistency of responses. 
4.6.4. Method of Analysis and Justification 
The scale of measurement for the data collected is nominal in nature, and hence non-
parametric. Random sampling method was used for data collection. 
Hypotheses were tested using single and multiple variables. 
The variables chosen were: 
• Type of pharmaceutical companies (API, Formulations, R&D, Clinical Research) 
• Type of activities of the pharmaceutical companies (Manufacturing, R&D , Contract 
Research, Distribution) 
• Turnover of the pharmaceutical companies (<100 cr, 100-300Cr, 300-500 cr, >500cr 
annually) 
The groups are independent, that is presence of the members in one group is not dependent 
upon membership in another. The statistical techniques that were used are: 
• Non parametric tests which assesses the population distribution 
• One sample tests to understand the aspects which drive strategic alliances 
between Indian and foreign pharmaceutical companies 
• K- sample tests to evaluate the variables for the three groups from the population 
o One way Analysis of Variance (ANOVA) 
• Correlation to assess the correlation between scale variables 
• Regression to predict a model fit 
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4.7 Limitations of the Research 
The study does have certain limitations which are enumerated as follows: 
• Time span: The research considers the strategic alliance between Indian and foreign 
pharmaceutical companies in the last 4 decades till 2010. Although passing references 
are made, alliances made in 2011 and 2012 are not considered. The trends from 2011 
are not extrapolated, although this can be an interesting study as alliances are still being 
considered and some alliances have been successful and some have fallen apart (Pfizer 
and Biocon). 
• Sampling limitations: Inadequate representations under the various categories of the 
pharmaceutical companies. 
• Gaps in data: In India there is no single database which records all the alliances 
that have happened in the Indian pharmaceutical industry in the last few decades. The 
compilation was done through secondary data from journals, newspapers and articles. 
There are possibilities that all the alliances between companies may not have been 
recorded. 
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CHAPTER 5 
DATA ANALYSIS 
CHAPTER 5: DATA ANALYSIS 
5.1: Overview 
The first objective of tiie analyses is to find out the relevant reasons that influence the alliance 
formation between Indian and foreign pharmaceutical companies. The mean and SD are 
calculated to bring out the critical factors. 
The second objective is to understand the impact of strategic alliances between Indian and 
foreign pharmaceutical companies in various business aspects. The data is analyzed and 
reasons categorized under three areas: Type of company; Type of activity undertaken by the 
company; Turnover of the company. The significance is calculated using ANOVA in SPSS. 
Based on the significance the hypotheses is supported or not supported. 
The third objective is to understand the external and internal hindrances which impact the 
success of strategic alliances between Indian and foreign pharmaceutical companies. Mean and 
Standard deviations are calculated to ascertain the important factors. 
Correlation test is done to identify the factor thereby evaluating a linear relation. The model 
feasibility and fit is evaluated through regression analyses. 
Reliability coefficient test for final data 
Table No. 13: Reliability Coefficients of Final Data 
W t '111"iTjiffWraMMlll^MlilliliM m. *^""fl^ iP 
Reasons for alliance 73 
Business impact of strategic alliances 73 
Hindrances for strategic alliances 73 
1 
IBCron bach's 
Alpha 
I .755 
i 
.867 
.701 
IVo. of 
Hems 
15 
18 
6 
Outcome 
High internal 
consistency 
High internal 
consistency 
High internal 
consistency 
Since the data is tested for consistency and proved to be consistent further analyses was 
conducted. 
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5.2 Reasons for Strategic Alliances between Indian and Foreign Pharmaceutical Companies 
The reasons which have encouraged the formation of strategic alliances between Indian and 
foreign pharmaceutical companies can be categorized under 5 reasons: 
• Product related 
• Marketing and Distribution related 
• Technology 
• Manufacturing 
• Gain Competitive advantage 
5.2.1. Product Related 
Product related reasons as driving factors for the formation of strategic alliances between 
Indian and foreign pharmaceutical companies. { 
Table No. 14: Test Statistics for Product Related Factors for Strategic Alliance 
T 
Product -Strengthen product portfolio 
Product -Establish brand and products abroad 
Product -Launch new products in domestic and 
foreign markets 
Product 
.._...,N«... . ..... 
73 
73 
73 
Mean 
3.83 
3.94 
3.76 
3.84 
8td. 
Deviadon 
.62 
.76 
.71 
Mill 
2.00 
1.00 
2.00 
^ ^ ^ 
5.00 
5.00 
5.00 
Inference : There is a strong evidence to suggest that one of the Important reasons that have 
led to the formation of strategic alliances between Indian and foreign pharmaceutical 
companies, is the need to develop new products, introduce them in new markets and 
enhance the product portfolio basket. 
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5.2.2 Marketing Related 
Marketing related reasons as driving factors for the formation of strategic alliances between 
Indian and foreign pharmaceutical companies 
Table No. 15 Test Statistics for Marketing Related Factors for Strategic Alliance 
fn 'ir^ 
Marketing-Global emerging markets 
Marketing-Regulated markets 
Marketing-Distribution channels abroad 
Marketing 
73 
73 
73 
3.83 
3.94 
3.76 
3.84 
.62 
.76 
.71 
2.00 
1.00 
2.00 
5.00 
5.00 
5.00 
Inference: There is strong evidence to indicate that marketing related factors influence the 
formation of strategic alliances between Indian and foreign pharmaceutical companies. Entry 
to new global emerging markets, entry into regulated markets, access to new distribution 
channels abroad are some of the critical factors that drive alliances. 
5.2.3 Technology related 
Technology related reasons as driving factors for the formation of strategic alliances 
between Indian and foreign pharmaceutical companies 
Table No. 16: Test Statistics for Technology Related Factors for Strategic Alliance 
^ ^ ^ ^ ^ ^ ^ 
Technology-Access new technology 
Technology-Collaborative R&D 
Technology-USFDA approvals 
Technology 
HHHB 
73 
73 
73 
Mean 
3.32 
3.30 
3.17 
3.26 
Std. 
Deviiition 
.65 
.90 
.93 
Min 
1.00 
1.00 
1.00 
Maxl ; 
4.00 
5.00 
5.00 
Inference: There is strong evidence to indicate that technology is a strong motivator for 
the formation of strategic alliances between Indian and foreign pharmaceutical countries. 
Access to technology and opportunity to undertake collaborative researches are two strong 
reasons under the technology related features. In addition gaining knowledge about GMP and 
USFDA approved facilities and the access to new technological advancements are 
considered to be strong motivators for the formation of strategic alliances between Indian 
and foreign pharmaceutical companies. 
5.2.4 Manufacturing Related 
Manufacturing related reasons as driving factors for the formation of strategic alliances 
between Indian and foreign pharmaceutical companies. 
Table No. 17: Test Statistics for Manufacturing Related Factors for Strategic Alliance 
Manufacturing-Cost minimization 
Manufacturing-Common assets 
Manufacturing-Quality management 
Manufacturing 
JVA,,,,,-.., 
73 
73 
73 
/ ! » j . ' . ' ! S ^ : . ' * * s S i S ^ ^ - * ' • > --;:;>; 
2.92 
2.86 
3.29 
3.03 
Std. 
.........ttep t^iott,.,,,,. 
.91 
.92 
.68 
.„,„„|tj|jn „.„,...,,, 
1.00 
1.00 
1.00 
•>,yA-y-,',-" •,:;:iSM. **M',yiB-' - s s a 
5.00 
5.00 
5.00 
Inference: There is strong evidence to indicate that manufacturing related factors influence the 
formation of strategic alliances between Indian and foreign pharmaceutical countries. 
Minimizing manufacturing costs, achieving operational synergy by utilizing common assets 
and attaining quality management systems are some of the critical factors that are considered 
to be the reasons that drive strategic alliances between Indian and foreign pharmaceutical 
companies. 
5.2.5 Competitive Advantage Related 
Competitive advantage as driving factors for the formation of strategic alliances between 
Indian and foreign pharmaceutical companies 
Table No. 18: Test Statistics for Competitive Advantage Related Factors for Strategic Alliance 
Competitive Advantage-Marlcet position 
Competitive Advantage-Financial power 
Competitive Advantage-Image 
Competitive Advantage 
wm No. 
73 
73 
73 
3.92 
3.99 
4.04 
3.97 
.72 
.69 
.72 
Minimum 
1.00 
2.00 
1.00 
Maxim 
uni 
5.00 
5.00 
5.00 
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Inference: There is significant evidence to indicate that gaining competitive advantage is 
one of the key drivers that encourage the formation of strategic alliances between Indian 
and foreign companies. Gaining competitive advantage includes gaining market positions, 
achieving financial power and enhancing the image of the organizations through various 
alliances and collaborations, thereby gaining an edge over competition. 
5.3 Impact of Strategic Alliances between Indian and Foreign Pharmaceutical Companies 
on Products 
Description of the groups: 
The sample can be categorized into 3 different groups based on: 
• Type of company 
• Type of activity undertaken by the company 
• Turnover of the company 
Type of company: 
The 73 respondents are grouped under the various heads based on the primary activity of the 
company. 40% (29) of the respondents are from API manufacturing companies. 15% (11) of 
the respondents are from the Formulations category. 34% (25) of the respondents are from 
companies who consider being of both API and Formulations category. A% (3) of the 
respondents are from the Clinical Research type of companies. 7%) (5) of the respondents are 
from the R&D type of companies. 
Type of activity undertaken: 
The 73 respondents are grouped under the various heads based on the key activities undertaken 
by the company. 44.5% (34) of the respondents are manufacturing companies who undertake 
manufacturing activities. 6.8% (05) of the respondents are R&D companies whose core 
activity is R&D. 32.8%) (24) of the respondents are from companies who started off as 
manufacturing companies but today are also giving equal importance to R&D related 
activities. 10.9% (08) of the respondents are from the companies whose core activity is 
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Contract manufacturing. 2.7% (02) of the respondents are from the companies whose core 
activity is Distribution. 
Turnover of the company: 
The 73 respondents are grouped under the various heads based on the key activities undertaken 
by the company. 21.9% (16) of the respondents from pharmaceutical companies with an annual 
turnover <100 Crores annually. 10.9% (08) of the respondents are from pharmaceutical 
companies whose turnover is between 100 and 300 crores annually. 24.8% (18) of the 
respondents are from pharmaceutical companies whose turnover is between 301 and 500 crores 
annually. 42.4%) (31) of the respondents are from pharmaceutical companies whose turnover 
exceeds 500 crores annually. 
Analytical test: 
Assumptions for ANOVA 
- The population sample must be normal 
- The observations must be independent in each sample 
- There is homogeneity of variances 
The one-way analysis of variance (ANOVA) is used to determine whether there are significant 
differences between the means of three or more independent (unrelated) groups. This test helps 
in testing the Null Hypotheses. 
The Levene's test result indicates the homogeneity of variances. If the Levene's test result is 
statistically significant with a p<= .05, then it is interpreted as the data does not show 
homogeneity of variance. If the Levene's statistics is not significant (p>0.05), then the 
assumption is that the data demonstrates homogeneity of variance. 
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5.3.1 Strategic Alliances and Launch of Patented Molecules 
5.3.1. a. Strategic Alliances and launch of patented molecules - all types of pharmaceutical 
companies 
HOI: There is no significant difference in the mean value of launch of new patented molecules 
as an area of impact of strategic alliances between Indian and foreign pharmaceutical companies 
across the types of Indian pharmaceutical companies 
Table No. 19a: Test Statistics for Strategic Alliances and Launch of Patented 
Molecules - All types of Indian pharmaceutical companies 
API 
Formulations 
API & Formulations 
Clinical Research 
R&D 
Total 
29 
11 
25 
3 
5 
73 
3.14 
3.09 
3.56 
2.67 
4.00 
3.32 
aPi^M • ^ 
.79 
.83 
.87 
1.15 
.71 
.86 
- V , >^4,.^^^^^-^..^ 
2.367 .061 
Lcven's dfl df2 
statistic 
.556 4 68 .695 
The Levene's statistic is not significant (p >0.05) 0.695 indicating the homogeneity of 
variances. Level of significance is 0.061 (p=0.061). There is no statisfically significant 
difference between groups as determined by one-way ANOVA (F (4, 68) =2.367, p =0.061). 
Inference: The null hypothesis is supported. 
5.3.1.h. Strategic Alliances and launch of patented molecules - across different activities of 
Pharmaceutical companies 
H02: There is no significant difference in the mean value of launch of patented molecules 
as an area of impact of strategic alliances between Indian an foreign pharmaceutical 
companies, across the types of activity undertaken by Indian pharmaceutical companies 
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Table No. 19b: Test Statistics for Strategic Alliances and Launch 
Mniccvles - across different activities of Indian pharmaceutical co 
1 
of Patented 
mpanies 
^^ P' f^prnpany, Activity 
Manufacturing 34 3.24 .69 
R&D 5 3.60 1.14 
Manufacturing / R&D 24 3.67 .82 
Contract Manufacturing 8 2.87 .83 
Distribution 2 1.50 .70 
Total 73 3.31 .86 
4.744 .002 
Statistic dfl dO Sig, 
.524 68 .in 
The Levene's statistic is not significant (p >0.05) 0.718 indicating the homogeneity of 
variances. There is statistically significant difference between groups as determined by one-
way ANOVA (F (4, 68) = 4.744, p = 0.002). A Tukey post-hoc HSD test indicated that the 
mean score for the impact of alliances on launching new patented products by the Indian 
pharmaceutical companies undertaking strategic alliances with foreign pharmaceutical 
companies is significant in three instances: 
Indian pharmaceutical companies undertaking distribution activities and companies 
undertaking manufacturing (Mean difference, 1.735 and p, 0.027), Indian pharmaceutical 
companies undertaking distribution activities and companies involved in R&D (Mean 
difference, 2.100 and p, 0.018) and Indian pharmaceutical companies undertaking distribution 
activities and companies with both manufacturing and R&D companies (Mean difference, 
2.1666 and p, 0.003). 
Inference: The null hypotheses is not supported. 
5.3.1.C Strategic Alliances and launch of patented molecules - across turnovers of Indian 
pharmaceutical companies 
H03: There is no significant difference in the mean value of launch of patented molecules as 
an area of impact of strategic alliances between foreign pharmaceutical companies, across 
Indian pharmaceutical companies of differing turnover 
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Table No. 19c: Test Statistics for Strategic Alliances and Launch oj 
Piitentecl Molecules - across turnovers of Indian pharmaceutical companies 
'iStTtWi^. 
<100Cr. 
IOO-300Cr. 
301-500 Cr. 
>500 Cr. 
Total 
16 
8 
18 
31 
73 
• 
Pieaii 
2.75 
3.00 
3.44 
3.61 
3.31 
Std. 
Deviati<« 
1.064 
.75 
.51 
.80 
.86 
F Sig. 
mmHn^^ 
4.597 .005 
Levene k 
Statistic dfl dfl 
69 .087 
The Levene's statistic is not significant (p >0.05) 0.087 indicating the homogeneity of 
variances.There is statistically significant difference between groups as determined by one-way 
ANOVA (F (3,69)=4.597, p =0.005). A Tu]<ey post- hoc test revealed that mean difference is 
significant at 0.005 level for companies with turnovers <100 cr. and >500 cr (Mean difference, 
0.8629 and p, 0.005). 
Inference: The null hypotheses is not supported. 
5.3.2. Strategic Alliances and Launch of Generic Products Abroad 
5.3.2. a. Strategic Alliances and launch of generic products abroad - types of pharmaceutical 
companies 
H04: There is no significant difference in the mean value of launch of generic pharmaceutical 
products abroad as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across all types of Indian pharmaceutical companies. 
Table No. 20a: Test Statistics for Strategic Alliances and Launch of generic 
products abroad- all types of Indian pharmaceutical companies 
•rics abroad 
API 
Formulations 
API & Formulations 
Clinical Research 
R&D 
Total 
.>i Mean 
29 3.55 
3.36 
25 3.96 
3 2.66 
5 3.60 
73 3.63 
Deviatis 
.90 
.78 
1.15 
.54 
.92 
2.016 .102 
94 
101 68 
The Levene's statistic is not significant (p > 0.05) 0.363 indicating the homogeneity of 
variances. Level of significance is 0.102 ip=0.\02) which is above 0.05 hence there is no 
statistically significant difference. There is no statistically significant difference between 
groups as determined by one-way ANOVA (F (4, 68) =2.016, p = 0.102)). 
Inference: The null hypotheses is supported. 
5.3.2.h. Strategic Alliances and launch of generic products abroad 
pharmaceutical companies 
activities of 
H05: There is no significant difference in the mean value of launch of generic pharmaceutical 
products abroad as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies indulging in various 
activities. 
Table No. 20b: Test Statistics for Strategic Alliances and Launch oj 
generic products abroad - across different activities of Indian 
? 
Manufacturing 
R&D 
Manufacturing & R&D 
Contract Manufacturing 
Distribution 
Total 
34 
5 
24 
8 
2 
73 
3.44 
3.20 
4.12 
3.50 
2.50 
3.63 
I 
i J 
'viation 
.990 
.836 
.679 
.755 
.707 
.920 
3.618 .010 
isLevene 
IStatistic 
1.404 
(Ifl 
4 
(112 
68 
% . , . ; „ : 
.242 
The Levene's statistic is not significant (p >0.05) 0.242 indicating the homogeneity of 
variances. Level of significance is 0.010 (/?= 0.010) which is below 0.05 hence there is a 
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statistically significant difference. There is a statistically significant difference between groups 
as determined by one-way ANOVA (F (4, 68) = 3.618, p = 0.010). 
A Tukey post-hoc test revealed that mean difference (0.68382) is significant at 0.03 llevel 
for Indian Pharmaceutical companies with only Manufacturing as their core activities and 
companies with both Manufacturing and R&D as their core activities. 
Inference: The null hypothesis is not supported. 
5.3.2.C. Strategic Alliances and launch of generic products abroad - across turnovers of 
pharmaceutical companies 
H06: There is no significant difference in the mean value of launch of generic pharmaceutical 
products abroad as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies of varying turnover 
Table No. 20c : 
products abroad 
1 .. , 
<100Cr. 
100-300Cr. 
301-500 Cr. 
>500 Cr. 
Total 
Test Statistics for Strategic Alliances and Launch of generic 
- across turnover of Indian pliarmaceutical companies 
16 2.93 1.12 
8 3.50 .92 
18 3.61 .69 
31 4.03 .70 
73 3.63 .92 
^%rn 
6.125 .001 
I.evene 
Statistic dfl df2 Sia. 
2.138 3 69 .103 
The Levene's statistic is not significant (p >0.05) 0.103 indicating the homogeneity of 
variances.Level of significance is 0.001 (p=0.001) which is below 0.05 hence there is a 
statistically significant difference. There is a statistically significant difference between groups 
as determined by one-way ANOVA (F (3, 69) =6.125, p =0.001). 
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A Tukey post- hoc test revealed that mean difference (1.09476) is significant at 0.000 level for 
Indian pharmaceutical companies with turnovers <100 cr. and >500 cr. (Mean difference, 
1.09476 and p,0.000). 
Inference: The results indicate that the null hypothesis is not supported. 
5.3.3. Strategic Alliances and Launch of Generic Products in Domestic Market 
5.3.3.a. Strategic Alliances and launch of generic products in domestic market - across all 
types pharmaceutical companies 
H07: There is no significant difference in the mean value of launch of new generic 
pharmaceutical products in the domestic market as an area of impact of strategic alliances 
between Indian and foreign pharmaceutical companies, across the types of Indian 
pharmaceutical companies.. 
Table No. 21a : Test Statistics for Strategic Alliances and Launch of Generic 
Products in Domestic Market - all types of pharmaceutical companies 
1 
API 
Formulations 
API & Formulations 
Clinical Research 
R&D 
Total 
29 
11 
25 
3 
5 
73 
3.34 
3.36 
3.72 
2.66 
3.60 
3.46 
1 
DeviaQon^^ ~'" "^B l i l 
.66 
.92 
.84 
1.15 
1.14 
.83 
1.537 .201 
1 
Levene 
Statistic dfl df2 Sis'. 
.748 4 68 .563 
The Levene's stafistic is not significant (p >0.05) 0.563 indicating the homogeneity of 
variances. Level of significance is 0.201 (p=0.201) which is above 0.05 hence there is no 
statistically significant difference. There is no statistically significant difference between 
groups as determined by one-way ANOVA (F (4, 68) =1.537, p =0.201)). 
Inference: The null hypothesis is supported. 
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5.3.3.b. Strategic Alliances and launch of generic products in domestic market- by 
pharmaceutical companies across all activities 
H08: There is no significant difference in the mean value of launch of new generic 
pharmaceutical products in the domestic market as an area of impact of strategic alliances 
between Indian and foreign pharmaceutical companies across the types of activity undertaken 
by Indian pharmaceutical companies. 
Table No. 21 b: Test statistics for Strategic Alliances and Launch of Generic 
Products in Domestic Market - across different activities pharmaceutical 
companies 
Manufacturing 
R&D 
Manufacturing / R&D 
Contract Manufacturing 
Distribution 
Total 
34 
5 
24 
8 
2 
73 
3.35 
3.20 
3.83 
3.25 
2.50 
3.46 
. ; ,,,.,..,. 
f Deviation 
.77 
1.30 
.76 
.70 
.70 
.83 
w 
2.427 .056 
Levcne 
Statistic dfl dt2 
1.273 68 .289 
The Levene's statistic is not significant (p >0.05) 0.289 indicating the homogeneity of 
variances. Level of significance is 0.056 (p=0.056) which is above 0.05 hence there is no 
statistically significant difference. There is no statistically significant difference between 
groups as determined by one-way ANOVA (F (4, 68) =2.427, p =0.056). 
Inference: The null hypothesis is supported. 
5.3.S.C. Strategic Alliances and launch of generic products in domestic market-pharmaceutical 
companies of different turnover. 
H09: There is no significant difference in the mean value of launch of new generic 
pharmaceutical products in the domestic market as an area of impact of strategic alliances 
between Indian and foreign pharmaceutical companies, across Indian pharmaceutical 
companies with different turnovers. 
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Table No. 21 c: Test Statistics for Strategic Alliances and Launch of Generic 
Products in Domestic Market - across turnovers of Indian pharmaceutical 
companies 
w^H flws«:>i^B|||| 
<100Cr. 
100-300 Cr. 
301-500 Cr. 
>500 Cr. 
Total 
16 
8 
18 
31 
73 
3.00 
3.37 
3.50 
3.70 
3.46 
.96 
.74 
.70 
.78 
.83 
WKP 
2.716 .048 
Leveue 
Statistic dfl dfi 
.343 69 .795 
The Levene's statistic is not significant (p >0.05) 0.795 indicating the homogeneity of 
variances. 
Level of significance is 0.048 (p=0.048) which is below 0.05 hence there is a statistically 
significant difference. There is a statistically significant difference between groups as 
determined by one-way ANOVA (F (3, 69) = 2.776p =0.048). A Tukey post- hoc test revealed 
that mean difference is significant between Indian pharmaceutical companies with turnover 
<100 cr. and Indian pharmaceutical companies with turnover between > 500 cr. (mean 
difference 0.70968 and p= 0.028) 
Inference : The null hypothesis is not supported. 
5.3.4. Strategic A lliances and Enhanced Product Portfolio 
5.3.4. a. Strategic Alliances and enhanced product porifolio - across all types pharmaceutical 
companies 
HOlO: There is no significant difference in the mean value of expansion of product portfolio 
as an area impact of strategic alliances between Indian and foreign pharmaceutical 
companies, across all types of Indian pharmaceutical companies. 
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Table No.22 a: Test Statistics for Strategic Alliances and Enhanced Product 
Porlfolio - all types pharmaceutical counumi's 
API 
Formulations 
API & Formulations 
Clinical Research 
R&D 
Total 
29 3.68 
I I 3.72 
25 4.08 
3.66 
4.20 
73 3.86 
.54 
.46 
.75 
1.52 
.44 
.67 
1.680 .165 
Le\cne 
Statistic dfl df2 Sie. 
3.072 68 .022 
The Levene's statistic is significant (p >0.05) 3.072, liowever literature indicates ANOVA can 
be done on tiie data. Level of significance is 0.165 (/7=0.165) which is above 0.05 hence there 
is no statistically significant difference. There is no statistically significant difference between 
groups as determined by one-way ANOVA (F (4,68)=1.680,p =0.165). 
Inference: The null hypothesis is supported. 
5.3.4. b. Strategic Alliances and enhanced product portfolio - all activities of pharmaceutical 
companies \ 
HOll: There is no significant difference in the mean value of expansion of product portfolio as 
an area of impact of strategic alliances between Indian and foreign pharmaceutical 
companies, across Indian pharmaceutical companies indulging in various activities. 
Table No.22b: Test Statistics for Strategic Alliances and Enhanced Product 
Portfolio - across different activities of pharmaceutical companies 
iM»*»„v#mR:». .DfwHI 
Manufacturing 34 3.58 .55 
R&D 5 4.40 .54 
Manufacturing / R&D 24 4.16 .70 
Contract Manufacturing 8 3.75 .70 
Distribution 2 4.00 .00 
Total 73 3.86 .67 
.^  ,^i-, Sig. 
4.117 .005 
1 
Levene 
Statistic dtl df2 Sis. 
1.405 4 68 .242 
100 
The Levene's statistic is not significant (p >0.05) 0.242 indicating the homogeneity of 
variances Level of significance is 0.005 (p=0.005) which is below 0.05 hence there is a 
statistically significant difference. There is a statistically significant difference between groups 
as determined by one-way ANOVA (F (4.68)=4.117,p =0.005). A Tukey post- hoc test 
revealed that mean difference is significant at 0.007 level for Indian pharmaceutical 
companies whose core activity includes only manufacturing versus Indian pharmaceutical 
companies whose core activities include manufacturing and R&D (Mean difference, 0.57843 
and p,0.007). [ 
! 
Inference: The null hypotheses is not supported. 
5.3.4.C. Strategic Alliances and enhanced product portfolio - turnover pharmaceutical 
companies j 
H012: There is no significant difference in the mean value of expansion of product portfolio 
as an area of impact of strategic alliances between Indian and foreign pharmaceutical 
companies, across Indian pharmaceutical companies of varying turnover. 
Table No. 22c: Test Statistics for Strategic Alliances and Enhanced Product 
Portfolio —across turnovers of Indian pharmaceutical companies. 
1 1 
urnoyet 
<100Cr. 
100 - 300 Cr. 
301-500 Cr. 
>500 Cr. 
Total 
:^_,_„_7 „^ ^ Std. ._ F Si 
16 3.81 .54 
8 3.50 .75 
18 3.72 .66 
31 4.06 .67 
73 3.86 .67 
,^ 
2.084 .110 
The Levene's statistic is not significant (p >0.05) 0.679 indicating the homogeneity of 
variances. Level of significance is 0.110 (p=0.110) which is above 0.05 hence there is no 
statistically significant difference. There is no statistically significant difference between 
groups as determined by one-way ANOVA (F (3, 69) =2.084,p =0.110)). 
Inference: The null hypothesis is supported. 
101 
5.4: Impact of Strategic Alliances between Indian and Foreign Pharmaceutical Companies 
on Marketing 
5.4.1. Strategic Alliances and Access to Regulated Markets 
5.4. La. Strategic alliances and access to regulated markets- type of pharmaceutical 
companies 
H013: There is no significant difference in the mean value of access to highly regulated 
markets abroad as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies , across all types of Indian pharmaceutical companies 
Table No. 23 a: Test statistics for Strategic Alliances and Access to 
Regulated Markets - all 
1 • 
1 
API 
Formulations 
API & Formulations 
Clinical Research 
R&D 
Total 
type of pharmaceutical companies 
Std. 
29 3.62 .62 
11 3.54 .68 
25 3.84 .68 
3 3.66 .57 
5 3.80 .83 
73 3.69 .66 
0.553 .697 
j 
! 
The Levene's statistic is not significant (p >0.05) 0.884 indicating the homogeneity of 
variances Level of significance is 0.697 (p=0.697) which is above 0.05 hence there is no 
statistically significant difference. There is no statistically significant difference between 
groups as determined by one-way ANOVA (F (4, 68) =0.553, p =0.697)). 
Inference: The null hypothesis is supported. 
5.4. Lb. Strategic alliances and access to regulated markets- activities of pharmaceutical 
companies 
H014: There is no significant difference in the mean value of access to highly regulated 
markets abroad as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies undertaking different 
activities. 
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Table No. 23 b: Test statistics for 
Markets -across different activitic 
^^mmms'^am^mmm 
market ...,:..,:,.«,,,„«-» 
Manufacturing 34 
R&D 5 
Manufacturing / R&D 24 
Contract Manufacturing 8 
Distribution 2 
Total 73 
Strategic Alliances and Access to 
s of pharmaceutical companies 
,, .Msntj. 
3.47 
3.80 
3.91 
3.87 
4.00 
3.69 
l^:.. 5;|(j 
,,,.,.|)^v|itioiL,,^,,,,£„.,. 
.66 
.83 
.65 
.35 
.00 
.66 
2.060 
Regulated 
Sig. 
.096 
L«vene 
Statistic dfl ifl Sia. 
2.887 68 .029 
The Levene's statistic is not significant (p >0.05) 2.887 indicating the homogeneity of 
variancesLevel of significance is 0.096 (/7=0.096) which is above 0.05 hence there is no 
statistically significant difference. There is no statistically significant difference between 
groups as determined by one-way ANOVA (F (4, 68) =0.2.060, p =0.096). 
i 
Inference: The null hypothesis is not supported. 
5.4. I.e. Strategic alliances and access to regulated markets-turnover of pharmaceutical 
companies \ 
H015: There is no significant difference in the mean value of access to highly regulated 
markets abroad as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies across Indian pharmaceutical companies of different turnover. 
Table No. 23c: Test statistics for Strategic Alliances 
Markets -across turnovers of Indian pharmaceutical 
f" •• Turnover "•• 
.^^^^Pi 
Peviation 
<100Cr. 16 3.43 .62 
100-300 Cr. 8 3.62 .51 
301-500 Cr. 18 3.66 .68 
>500Cr. 31 3.87 .67 
Total 73 3.69 .66 
and Access to 
companies 
j 
1.628 
Regulated 
Sig. 
.191 
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iiStKistiCi: dfi .dSL, 
.393 3 69 
«-SJg,„s 
.758 
The Levene's statistic is not significant (p >0.05) 0.393 indicating the homogeneity of 
variances Level of significance is 0.191 (p=0.191) which is above 0.05 hence there is no 
statistically significant difference. There is no statistically significant difference between 
groups as determined by one-way ANOVA (F (3, 69) =1.628, p =0.191). 
Inference: The null hypothesis is not supported. 
5.4.2. Strategic Alliances and Investment in Sales and Marketing 
5.4.2. a Strategic alliances and investment in sales and marketing-across all types of 
pharmaceutical companies 
H016: There is no significant difference in the mean value gaining investment capability into 
sales and marketing as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across all types of Indian pharmaceutical companies. 
Table No. 24a: Test Statistics for Strategic Alliances and Investment in 
Sales and Marketing - all types of pharmaceutical companies 
M aMestment 
API 
Formulations 
API & Formulations 
Clinical Research 
R&D 
Total 
N 
29 
11 
25 
3 
5 
73 
Mean 
3.55 
3.27 
4.20 
4.33 
4.20 
3.80 
Deviation * 
.57 
.46 
.76 
.57 
.83 
.73 
m P *~^ 'o-
K W^^^mm 
6.190 .000 
1 
1 
Levene 
Statistic dfl dC Jig,; 
1.544 68 .199 
The Levene's statistic is not significant (p >0.05) 0.199 indicating the homogeneity of 
variances Level of significance is 0.000 (p=0.000) which is belowO.05 hence there is a 
statistically significant difference. There is statistically significant difference between groups as 
determined by one-way ANOVA (F (4,68)=6.190 ,p =0.000). 
A Tukey post- hoc test revealed that mean difference is significant in two 
instances :between Indian API companies and Indian pharmaceutical companies which are 
104 
both API and Formulations type (mean difference 0.648 and p= 0.005) and Indian 
Formulation companies and Indian pharmaceutical companies which are of both API and 
formulations type (mean difference 0.927 and p=0.002 ) 
Inference: The null hypothesis is not supported. { 
5.4.2. b. Strategic alliances and investment in sales and marketing-across all activities 
pharmaceutical companies 
H017: There is no significant difference in the mean value of gaining investment capability 
into sales and marketing, as an area of impact of strategic alliances between Indian and 
foreign pharmaceutical companies, across Indian pharmaceutical with varying business 
activities. ) 
Table No. 24 b: Test Statistics for Strategic Alliances and Investment in 
SaL's and Marketing - across different activities pharmaceutical Cpmpanies 
2,.:jV%rketiog-Investmeiit 
Manufacturing 34 
R&D 5 
Manufacturing / R&D 24 
Contract Manufacturing 8 
Distribution 2 
Total 73 
StdP"'-""' ''' 
Mean Deviation 
3.35 .48 
4.40 .54 
4.33 .70 
3.87 .64 
3.50 .70 
3.80 .73 
n.2ii .000 
Stati.stic dfl df2 Sig 
1.489 4 68 .215 
The Levene's statistic is not significant (p >0.05) 0.215 indicating the homogeneity of 
variances Level of significance is 0.000 (/7=0.000) which is belowO.05 hence there is a 
statistically significant difference. There is statistically significant difference between groups as 
determined by one-way ANOVA (F (4,68)= 11.233 ,p =0.000). 
A Tukey post- hoc test revealed that mean difference is significant in two 
instances :between Indian pharmaceutical companies with manufacturing as their core activity 
and Indian pharmaceutical companies with R&D as their core activity(mean difference 1.04 
and p= 0.004) and, between Indian pharmaceutical companies with manufacturing as their 
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core activity and companies with both manufacturing and R&D activities (mean difference 
0.9803 and p=0.000). { 
Inference: The null hypothesis Is not supported \ 
5.4.2. c. Strategic alliances and investment in sales and marketing- across all turnovers 
pharmaceutical companies j 
H018: There is no significant difference in the mean value of gaining investment capability 
into sales and marketing, as an area of impact of strategic alliances between Indian and 
foreign pharmaceutical companies, across Indian pharmaceutical companies with varying 
turnover. 
Table No. 24 c: Test Statistics for Strategic Alliances and Investment in 
Sales and Marketing - across turnovers of Indian pharmaceutical 
p 
<100Cr. 
100-300 Cr. 
301-500 Cr. 
>500 Cr. 
Total 
16 
8 
18 
31 
73 
3.50 
3.37 
3.61 
4.19 
3.80 
.63 
.74 
.60 
.70 
.73 
^^^H^^^^^^^^^H^^^^H 
6.177 .001 
1 
Levcnc 
Statistic 
.028 
dfl df2 
3 69 .994 
The Levene's statistic is not significant (p >0.05) 0.994 indicating the homogeneity of 
variances Level of significance is 0.001 (/>=0.001) which is below 0.05 hence there is a 
statistically significant difference. There is statistically significant difference between groups as 
determined by one-way ANOVA (F (3,69)=6.177 , p =0.001). 
. A Tukey post- hoc test revealed that mean difference is significant in three instances 
between pharmaceutical companies with manufacturing with an annual turnover <100 cr. 
and >500 cr. (mean difference 0.693 and p= 0.007), between pharmaceutical companies with 
manufacturing with an annual turnover between 100 and 300cr . and >500 cr. (mean 
difference 0.818 and p= 0.015) and between pharmaceutical companies with manufacturing 
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with an annual turnover between 30Icr and 500cr. and >500 cr. (mean difference 0.582 and 
p= 0.023). I 
I 
Inference: The null hypothesis is not supported 
5.4.3. Strategic Alliances and Access to Emerging International Markets 
5.4.3. a. Strategic alliances and access to emerging international markets- all types of Indian 
pharmaceutical companies j 
H019. There is no significant difference in the mean value of gaining access to foreign 
distribution networks abroad as an area of impact of strategic alliances between Indian and 
foreign pharmaceutical companies, across all types of Indian pharmaceutical companies. 
Talyle No. 25a: Test Statistics for Strategic Alliances and Access to 
Emerginf^ International Markets - all types of pharmaceutical companies 
mm M i ^ 
API 29 3.65 .66 
Formulations 11 3.00 .77 
API & Formulations 25 4.12 .66 
Clinical Research 3 4.00 .00 
R&D 5 3.80 .83 
Total 73 3.73 .76 
5.347 .001 
Levene 
Statistic dfl df 
1.304 68 .277 
The Levene's statistic is not significant (p >0.05) 0.277 indicating the homogeneity of 
variances Level of significance is 0.001 (p=0.001) which is below 0.05 hence there is a 
statistically significant difference. There is statistically significant difference between groups as 
determined by one-way ANOVA (F (4,68)=5.347 , p =0.001). 
A Tukey post- hoc test revealed that mean difference is significant between Indian 
pharmaceutical formulations companies and Indian pharmaceutical companies who are 
identified as both formulations and API type of companies (mean difference 1.12 and p= 
0.000) j 
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Inference: The null hypothesis is not supported 
5.4.3. b. Strategic alliances and access to emerging international markets- all turnover Indian 
pharmaceutical companies 
H020: There is no significant difference in the mean value of gaining access to foreign 
distribution networks abroad as an area of impact of strategic alliances between Indian and 
foreign pharmaceutical companies, across Indian pharmaceutical companies with differing 
turnover. 
TiMe No.25b: Test Statistics for Strategic Alliances and Access to Emerging 
International Markets -across turnovers of Indian pharmaceutical companies 
I.-
< 100 Cr. 
100-300 Cr. 
301-500 Cr. 
>500 Cv. 
Total 
16 
8 
18 
31 
73 
3.56 
3.37 
3.50 
4.06 
3.73 
WHWjH| 
.89 
.74 
.70 
.62 
.76 
3.732 .015 
The Levene's statistic is not significant (p >0.05) 0.085 indicating the homogeneity of 
variances. Level of significance is 0.015 (p=0.015) which is below0.05 hence there is a 
statistically significant difference. There is statistically significant difference between groups 
as determined by one-way ANOVA (F (3,69)= 3.732, p =0.015)). 
A Tukey post- hoc test revealed that mean difference is significant Between Indian 
pharmaceutical companies with an annual turnover between 301 and 500 cr , and Indian 
pharmaceutical companies with turnover >500 cr. (mean difference 0.564 and p= 0.050). 
Inference:The null hypothesis is not supported \ 
5.4.3. c. Strategic alliances and access to emerging international markets- all activities Indian 
pharmaceutical companies 
H021: There is no significant difference in the mean value of gaining access to foreign 
distribution networks abroad as an area of impact of strategic alliances between Indian and 
foreign pharmaceutical companies, Indian pharmaceutical companies undertaking different 
activities. 
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Table No.25c: Test Statistics for Strategic Alliances and Access to Emerging 
International Markets - across different activities of Indian pharmaceutical 
Manufacturing 
R&D 
Manufacturing / R&D 
Contract Manufacturing 
Distribution 
Total 
34 
5 
24 
8 
2 
73 
M 
3.32 
4.00 
4.16 
3.87 
4.50 
3.73 
BF 
.72 
.70 
.63 
.35 
.70 
.76 
0.713 .000 
The Levene's statistic is not significant (p >0.05) 0.056 indicating the homogeneity of 
variances . Level of significance is 0.000 (p=0.000) which is below 0.05 hence there is a 
statistically significant difference. There is statistically significant difference between groups as 
determined by one-way ANOVA (F (4,68)= 6.713, p =0.000). 
A Tukey post- hoc test revealed that mean difference is significant between Indian 
pharmaceutical companies with manufacturing as their core activity and Indian 
pharmaceutical companies with both manufacturing and R&D as their core activity (mean 
diperence 0.8431 and p= 0.000). j 
Inference: The null hypothesis is not supported 
5.5: Impact of Strategic Alliances between Indian and Foreign Pharmaceutical Companies 
on Technology 
5.5.1. Strategic Alliances and Access to New Technology 
5.5.1 a. Strategic alliances and access to new technology - company type 
H022: There is no significant difference in the mean value of gaining technological 
competency as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across all types of Indian pharmaceutical companies. 
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Table No. 26a : Test Statistics for Strategic Alliances and Access to 
New Technology - all types of pharmaceutical companies 
•i""""''"-
API 
Formulations 
API & Formulations 
Clinical Research 
R&D 
Total 
l ^ ^ ^ < 
29 
11 
25 
3 
5 
73 
M e a n 
3.24 
3.18 
3.52 
3.66 
3.40 
3.35 
Std. 
Deviation 
.83 
.60 
1.04 
.57 
.54 
.85 
F Sig. 
.562 .691 
Levene 
Statistic df l dt2 Sie, 
1.489 4 68 .215 
The Levene's statistic is negative (p >0.05) 0.215 indicating the homogeneity of variances. 
Level of significance is 0.691 (p=0.691) which is above 0.05 hence there is no statistically 
significant difference. There is no statistically significant difference between groups as 
determined by one-way ANOVA (F (4, 68)= 0.562 , p =0.691). 
Inference: The null hypothesis is supported 
5.5.1 b . Strategic alliances and access to new technology - type of activity 
H023: There is no significant difference in the mean value of gaining technological 
competency as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies indulging in various 
activities. 
Table No. 26b : Test Statistics for Strategic Alliances and Access to New 
Technology - across different activities of Indian pharmaceutical 
companies 
9' SCoftpainy J V c # ^ 
! 
Manufacturing 
R&D 
Manufacturing / R&D 
Contract Manufacturing 
Distribution 
Total 
. . ^ 
34 
5 
24 
8 
2 
73 
3.26 
3.40 
3.50 
3.62 
2.00 
3.35 
»"'" - ' " 'Jt 
r* ""Sid.* 1 
Deviation 
.75 
.54 
1.06 
.51 
.00 
,85 
1 ' -^^^m 
m 
1.799 .139 
1 
The Levene's statistic is not significant (p >0.05) 0.061 indicating the homogeneity of 
variances .Level of significance is 0.139 (p=0.139) which is above 0.05 hence there is no 
statistically significant difference. There is no statistically significant difference between 
groups as determined by one-way ANOVA (F (4, 68)= 1.799 , p =0.139). 
Inference: The null hypothesis is supported j 
5.5.7 c . Strategic alliances and access to new technology - turnover 
H024: There is no significant difference in the mean value of gaining technological 
competency as an area impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies of varying turnover. 
Table No. 26c : Test Statistics for Strategic Alliances and Access to New 
Technology - across turnovers of Indian pharmaceutical companies 
Turnover 
« H I ^ 
< 100 Cr. 
100-300 Cr. 
301-500 Cr. 
>500 Cr. 
Total 
mm^ 
16 
8 
18 
31 
73 
^.,V.^ . . : . 
3,12 
3.75 
3.22 
3.45 
3.35 
Std. 
.71 
.46 
.80 
.99 
.85 
F 
.^^ .a .^..^  
1.242 
Sig. 
• f e s S i s ^ 
.301 
1.895 69 .139 
The Levene's statistic is not significant (p >0.05) 0.139 indicating the homogeneity of 
variances. Level of significance is 0.301 (p=0.301) which is above 0.05 hence there is no 
statistically significant difference. There is statistically significant difference between groups as 
determined by one-way ANOVA (F (3,69)= 1.242 , p =0.301). 
Inference: The null hypothesis is supported 
5.5.2. Strategic Alliances and Achieving R&D Capability 
5.5.2. a. Strategic alliances and achieving R&D capability - types of company 
H025: There is no significant difference in the mean value of achieving R&D capability, as an 
area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across all types of Indian pharmaceutical companies 
Table No. 27a : Test Statistics for Strategic Alliances and 
Capability - all types of pharmaceutical companies 
lnology-R&D S S ^ W 
capability M M M ^ J . Mean Deviation 
API 29 2.79 .94 
Formulations 11 2.63 1.12 
API & Formulations 25 3.52 1.08 
Clinical Research 3 3.66 1.15 
R&D 5 3.40 .54 
Total 73 3.09 1.05 
Achieving R&D 
•^ 
2.674 .039 
Levene 
Statistic dfl 4fL. „,S!& 
.756 68 .557 
The Levene's statistic is not significant (p >0.05) 0.557 indicating the homogeneity of 
variances. Level of significance is 0.039 (/7=0.039) which is below 0.05 hence there is a 
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statistically significant difference. There is statistically significant difference between groups as 
determined by one-way ANOVA (F (4,68 )= 2.674 , p =0.039). 
A Tukey post- hoc test revealed that mean difference is not significant between different 
groups of pharmaceutical companies, which are categorized on the basis of the core company 
type. I 
Inference: The null hypothesis is not supported 
5.5.2. h. Strategic alliances and achieving R&D capability -activities of company 
H026: There is no significant difference in the mean value of achieving R&D capability, as an 
area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across Indian pharmaceutical companies indulging in various activities. 
Table No. 27b: Test Statistics for Strategic Alliances and Achieving R&D 
Capability - ac ro.ys different 
Manufacturing 
R&D 
Manufacturing / R&D 
Contract Manufacturing 
Distribution 
Total 
activities of phi 
:" 'f rH| | 
^ • • • p e a n 
34 2.73 
5 3.40 
24 3.70 
8 3.00 
2 1.50 
73 3.09 
irmaceutical 
DeviatroiT 
.86 
.54 
1.12 
.92 
.70 
1.05 
com/ifanies 
• • I '''' 
5.2 
" 
86 .001 
Levene 
Jteilstic .,MLm,iiS- fjiiim. Si& 
1.521 68 .206 
The Levene's statistic is not significant (p >0.05) 0.206 indicating the homogeneity of 
variances. Level of significance is 0.001 (/?=0.001) which is below 0.05 hence there is a 
statistically significant difference. There is statistically significant difference between groups as 
determined by one-way ANOVA (F (4,68 )= 5.286 , p =0.001). 
A Tukey post- hoc test revealed that mean difference is significant in two instances :between 
pharmaceutical companies with manufacturing as their core activity and Indian 
pharmaceutical companies with both manufacturing and R&D as their core activity (mean 
difference 0.97304 and p= 0.002) and between Indian pharmaceutical companies with 
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manufacturing and R&D as their core activity and pharmaceutical companies with 
Distribution as their core activity (mean difference 2.208 and p= 0.019). 
Inference: The null hypothesis is not supported 
5.5.2. c. Strategic alliances and achieving R&D capability -turnover of company 
H027: There is no significant difference in the mean value of achieving R&D capability, as an 
area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across Indian pharmaceutical companies of varying turnover. 
Table No. 27c: Test Statistics for Strategic Alliances and Achieving R&D 
Capability - across turnovers of Indian pharmaceutical companies 
100-300 Cr. 
301-500 Cr. 
>500 Cr. 
Total 
3.25 .03 
2.94 .63 
31 3.45 .12 
73 3.09 1.05 
Statistic dfl dC Sia. 
4.151 3 69 .009 
The Levene's statistic is significant (p >0.05) 4.151.Level of significance is 0.024 (p-0.024) 
which is below 0.05 hence there is a statistically significant difference. There is statistically 
significant difference between groups as determined by one-way ANOVA (F (3,69)= 3.348 ,p 
=0.024)). 
A Tukey post- hoc test revealed that mean difference is significant between companies with 
turnover <100 cr. and companies with turnover between > 500 cr. (mean difference 0.95161 
and p= 0.016). 
Inference: The null hypothesis is not supported 
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5.5.3. Strategic A lliances and GMP Compliant Production Facilities 
5.5.3. a. Strategic alliances and GMP compliant production Facilities - type of company 
H028: There is no significant difference in the mean value of development of GMP 
compliant production capacities by Indian pharmaceutical companies as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies, across all types of 
Indian pharmaceutical companies. 
Table No. 28a : Test Statistics for Strategic Alliances and GMP 
Compliant Production Capacities -all types of companies 
'Mm^u 
API 
Formulations 
API & Formulations 
Clinical Research 
R&D 
Total 
29 
11 
25 
3 
5 
73 
3.27 
3.09 
3.88 
4.00 
3.40 
3.49 
Weviatioa 
.70 
.83 
.83 
.00 
.54 
.80 
3.398 .014 
Levene 
Statistic dfl dtl Sie. 
.969 68 .431 
The Levene's statistic is not significant (p >0.05) .969 indicating the homogeneity of variances. 
Level of significance is 0.014 (/7=0.014) which is below 0.05 hence there is a statistically 
significant difference. There is statistically a significant difference between groups as 
determined by one-way ANOVA (F (4,68)=3.398 ,p =0.014)). 
-
A Tukey post- hoc test revealed that mean difference is significant in two instances: 
between pharmaceutical API companies and pharmaceutical API and formulation companies 
(mean difference 0.60414and p= 0.035) and, between formulations pharmaceutical companies 
and companies with both API and formulation (mean difference 0.78909 and p= 0.039). 
Inference: The null hypothesis is not supporte 
J.J) 3.b. Strategic Alliances and GMP Compliant Production Facilities -activities of company 
:15 
H029 : There is no significant difference in the mean value of development of GMP 
compliant production capacities by Indian pharmaceutical companies as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies, across Indian 
pharmaceutical companies performing different activities 
Table No. 28b: Test Statistics for Strategic Alliances and GMP Compliant 
Production Capacities - across different activities of companies 
Manufacturing 
R&D 
Manufacturing / R&D 
Contract Manufacturing 
Distribution 
Total 
34 3.20 
3.60 
24 .87 
8 3.62 
3.00 
73 3.49 
.72 
.54 
.85 
.51 
1.41 
.80 
3.026 .023 
Levene 
cStatistic 
.497 
df2 Si.t 
68 .738 
The Levene's statistic is not significant (p >0.05) .497 indicating the homogeneity of variances 
Level of significance is 0.023 (p=0.023) which is below 0.05 hence there is a statistically 
significant difference. There is statistically a significant difference between groups as 
determined by one-way ANOVA (F (4,68)=3.026 , p =0.023). 
A Tukey post- hoc test revealed that mean difference is significant between pharmaceutical 
companies with manufacturing as their core activity and pharmaceutical companies with 
both manufacturing and R&D as their core activity (mean difference 0.66912 and p= 
0.013). 
Inference: The null hypothesis is not supported 
5.5.3. c. Strategic Alliances and GMP Compliant Production Facilities - turnover of company 
H030: There is no significant difference in the mean value of development of GMP 
compliant production capacities by Indian pharmaceutical companies as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies, across Indian 
pharmaceutical companies of different turnover. 
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Table No. 28c : Test Statistics for Strategic Alliances and GMP Compliant 
Production Capacities - across turnovers of Indian pharmaceutical 
companies 
<100Cr. 
100-300Cr. 
301-500 Cr. 
>500 Cr. 
Total 
f 
16 
8 
18 
31 
73 
^mn 
3.18 
3.62 
3.22 
3.77 
3.49 
|K 
Deviation 
.91 
.517 
.54 
.84 
.80 
M i l 
3.043 
Sig. 
.035 
Le\ene 
Statistic dfl dC Sie. 
1.041 69 .380 
The Levene's statistic is not significant (p >0.05) 1.041 indicating the homogeneity of 
variances Level of significance is 0.035 (jj=0.035) which is below 0.05 hence there is a 
statistically significant difference. There is statistically a significant difference between groups 
as determined by one-way ANOVA (F (3,69)=3.043 , p =0.035). 
I 
i 
A Tukey post- hoc test revealed that mean difference is not significant between 
pharmaceutical companies with differing turnovers. | 
Inference: The null hypothesis is not supported 
5.5.4: Strategic Alliances and Access to Information 
5.5.4. a Strategic alliances and access to information - type of companies 
H031: There is no significant difference in the mean value of accessibility of Indian 
companies to latest technological and product related upgrades as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies on, across all types 
of Indian pharmaceutical companies. 
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Table No. 29a : Test Statistics for Strategic Alliances and Access to 
Information -all types of pharmaceutical companies 
iffs:^"'» 
API 
Formulations 
API & Formulations 
Clinical Research 
R&D 
Total 
Mii 
29 
11 
25 
3 
5 
73 
n ^ 
3.27 
3.27 
3.96 
4.33 
4.20 
3.61 
Std. 
Deviation 
.79 
.64 
.61 
.57 
.44 
.77 
F Sig. 
5.697 .001 
1 
The Levene's statistic is negative (p >0.05) 1.031 indicating the homogeneity of variances. 
Level of significance is 0.001 (p=0.001) which is above 0.05 hence there is no statistically 
significant difference. There is statistically no significant difference between groups as 
determined by one-way ANOVA (F (4,68)= 5.697 ,p =0.001)). 
A Tukey post- hoc test revealed that mean difference is significant between pharmaceutical 
API companies and pharmaceutical API and formulation y(mean difference 0.68414and p= 
0.005). j 
Inference: The null hypothesis is not supported 
5.5.4. b, Strategic alliances and access to information - turnover of companies 
H032: There is no significant difference in the mean value of accessibility of Indian 
companies to latest technological and product related upgrades impact of strategic alliances 
between Indian and foreign pharmaceutical companies, across Indian pharmaceutical 
companies of different turnover. 
Table No. 29b : Test Statistics for Strategic Alliances and Access to 
Infnrmaiinn - ocmss turnovers of Indian pharmaceutical companies 
<100Cr. 
100-300 Cr. 
301-500 Cr. 
>500 Cr. 
Total 
3.50 
3.62 
3.27 
31 3.87 
73 3.61 
.89 
.74 
.77 
2.532 .064 
Levene 
Statistic 
1.166 3 69 .329 
The Levene's statistic is non significant (p >0.05) 1.166 indicating the homogeneity of 
variances. Level of significance is 0.064 (p=0.064) which is below 0.05 hence there is a 
statistically significant difference. There is statistically significant difference between groups as 
determined by one-way ANOVA (F (3,69)= 2.532 ,p =0.064)). 
Inference: The null hypothesis is supported 
5.5.4. c. Strategic alliances and access to information - activity of companies 
H033: There is no significant difference in the mean value of accessibility of Indian 
companies to latest technological and product related upgrades as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies, across Indian 
pharmaceutical companies with different activities. 
Table No. 29c : Test Statistics for Strategic Alliances and Access to 
Information - across different activities of pharmaceutical companies 
•> 
Manufacturing 
R&D 
Manufacturing / R&D 
Contract Manufacturing 
Distribution 
Total 
34 
5 
24 
8 
2 
73 
3.20 
4.20 
4.00 
3.87 
3.50 
3.61 
.64 
.44 
.65 
.64 
2.12 
.77 
t « _ 
6.175 .000 
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2.977 4 68 .025 
The Levene's statistic is not significant (p >0.05) 2.977 indicating the homogeneity of 
variances. Level of significance is 0.000 (p=0.000) which is below 0.05 hence there is a 
statistically significant difference. There is statistically significant difference between groups as 
determined by one-way ANOVA (F (4,68)= 6.175 , p =0.000). 
A Tukey post- hoc test revealed that mean difference is significant in two instances: 
between pharmaceutical companies with manufacturing as their core activity and 
pharmaceutical companies with both manufacturing and R&D as their core activity (mean 
difference 0.99412 and p= 0.027) and between pharmaceutical companies with manufacturing 
asa their core activity and companies with both manufacturing and R&D as their core 
activity (mean difference 0.794]2and p= 0.000). | 
Inference : The null hypothesis is not supported 
5.6: Impact of Strategic Alliances Between Indian and Foreign Pharmaceutical Companies 
on Manufacturing 
5.6.1. Strategic Alliances and Cost Optimization 
5.6.1. a. Strategic alliances and cost optimization ~ type of company 
R034: There \s no significant difference in the mean value of cost optimization as an area of 
impact on strategic alliances between Indian and foreign pharmaceutical companies, across 
the types of Indian pharmaceutical companies. 
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Table No.30a : Test Statistics for Strategic Alliances and Cost Optimization 
•all i\iK'\ (if phiirmaceutical companies 
1 
API 
Formulations 
API & Formulations 
Clinical Research 
R&D 
Total 
piK....::»:isa» 
1. 
i r N 
29 
11 
25 
3 
5 
73 
BK-^ 1 
Mean Deviation F 
3.17 
2.90 
2.64 
2.66 
3.00 
2.91 
.80 
1.13 
.95 
.57 
.70 
.90 
1.236 
- ' ^ "^ "^^^^ 
Sig. 
.304 
Levene 
Statistic dfl dC Sia. 
.972 4 68 .428 
The Levene's statistic is not significant (p >0.05) .972 indicating the homogeneity of variances. 
Level of significance is 0.304 (/7=0.304) which is above 0.05 hence there is no statistically 
significant difference. There is no statistically significant difference between groups as 
determined by one-way ANOVA (F (4,68)= 1.236 , p =0.304). 
Inference: The null hypothesis is supported 
5.6. Lb. Strategic alliances and cost optimization ~ activity of company 
H035: There is no significant difference in the mean value of cost optimization as an area of 
impact on strategic alliances between Indian and foreign pharmaceutical companies across the 
types of activity undertaken by Indian pharmaceutical companies. 
Table No.30b: Test Statistics for Strategic Alliances and Cost Optimization -
across different activities of pharmaceutical companies 
Manufacturing 
R&D 
Manufacturing / R&D 
Contract Manufacturing 
Distribution 
Total 
\ .--N, „ 
34 
5 
24 
8 
2 
73 
3.05 
3.00 
2.62 
2.87 
4.00 
2.91 
Deviation 
.91 
.70 
.92 
.64 
1.41 
.90 
1.602 .184 
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1.079 68 .374 
The Levene's statistic is not significant (p >0.05) 1.079 indicating the homogeneity of 
variances. Level of significance is 0.184 (/?=0.184) which is above 0.05 hence there is no 
statistically significant difference. There is no statistically significant difference between 
groups as determined by one-way ANOVA (F (4,68)= 1.602 , p =0.184). 
i 
Inference: The null hypothesis is supported 
5.6.1. c. Strategic alliances and cost optimization - turnover of company 
H036: There is no significant difference in the mean value of cost optimization as an area of 
impact on strategic alliances between Indian and foreign pharmaceutical companies across 
Indian pharmaceutical companies of varying turnover. 
Table No. 30c: Test Statistics for Strategic Alliances and Cost Optimization 
- across ditferent turnover of pharmaceutical companies 
1 '^* 1 ramet""- • 
<100Cr. 
100-300 Cr. 
301-500 Cr. 
>500 Cr. 
Total 
16 
8 
18 
31 
73 
3.00 
3.50 
2.77 
2.80 
2.91 
Std. i 
.96 
.92 
.80 
.90 
.90 
1.462 .232 
1 
1 
Levene 
Siatistic dtl d;2 Sig, 
.108 69 .955 
The Levene's statistic is not significant (p >0.05) 0.108 indicating the homogeneity of 
variances. Level of significance is 0.232 {p=0.232) which is above 0.05 hence there is no 
statistically significant difference. There is no statistically significant difference between 
groups as determined by one-way ANOVA (F (3,69)= 1.462 , p =0.232). 
Inference: The null hypothesis is supported 
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5.6.2. Strategic Alliances and Achieving Operational Synergy 
5.6.2. a. Strategic alliances and achieving operational synergy - type of company 
H037: There is no significant difference in the mean value of achieving operational synergy as 
an area of impact on strategic alliances between Indian and foreign pharmaceutical companies 
across the types of Indian pharmaceutical companies. 
Table No. 31a: Test 
Operational Synergy -
v; iSciuring-
iipaasseti. 
API 
Formulations 
API & Formulations 
Clinical Research 
R&D 
Total 
Statistics for Strategic Alliances and Achieving 
 all types of pharmaceutical companies 
Std. 
29 2.86 1.02 
11 3.09 .70 
25 2.80 .91 
3 2.33 1.15 
5 3.00 .70 
73 2.86 .91 
.463 .763 
Levene 
Statistic dfl df2 Sig. 
.490 68 .743 
The Levene's statistic is not significant (p >0.05) 0.490 indicating the homogeneity of 
variances.Level of significance is 0.763 (p=0.763) which is above 0.05 hence there is no 
statistically significant difference. There is no statistically significant difference between 
groups as determined by one-way ANOVA (F (4,68)= 0.463 , p =0.763). 
Inference: The null hypothesis is supported 
5.6.2. Strategic Alliances and Achieving Operational Synergy 5.6.2.b. Strategic alliances and 
achieving operational synergy ~ activity of company 
H038; There is no significant difference in the mean value of achieving operational synergy as 
an area of impact on strategic alliances between Indian and foreign pharmaceutical companies 
across the types of activity undertaken by Indian pharmaceutical companies. 
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Table No. 31b: Test Statistics for Strategic Alliances and Achieving 
Operational Synergy - type of company 
Manufacturing 
R&D 
Manufacturing / R&D 
Contract Manufacturing 
Distribution 
Total 
34 
5 
24 
8 
2 
73 
2.82 
2.80 
2.79 
3.25 
3.00 
2.86 
i > ^ i ^ = 
.99 
1.09 
.93 
.46 
.00 
.91 
.411 .800 
Statistic dfl df2 Sig. 
1.090 68 .369 
The Levene's statistic is not significant (p >0.05) 1.090 indicating the homogeneity of 
variances. 
Level of significance is 0.800 (p=0.800) which is above 0.05 hence there is no statistically 
significant difference. There is no statistically significant difference between groups as 
determined by one-way ANOVA (F (4,68)= 0.411 ,p =0.800) 
Inference: The null hypothesis is supported 
5.6.2. Strategic Alliances and Achieving Operational Synergy 
5.6.2.C . Strategic alliances and achieving operational synergy - turnover company 
H039: There is no significant difference in the mean value of achieving operational synergy 
as an area of impact on strategic alliances between Indian and foreign pharmaceutical 
companies across Indian pharmaceutical companies of varying turnover. 
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Table No. 31c: Test Statistics for Strategic Alliances and Achieving 
Operational Synergy -across different turnover of Pharmaceutical 
companies 
< lOOCr. 
100-300 Cr. 
301-500 Cr. 
>500 Cr. 
Total 
16 
8 
18 
31 
73 
2.56 1.03 
2.87 .83 
2.94 .80 
2.96 .94 
2.86 .91 
.746 
BnHH 
.528 
The Levene's statistic is not significant (p >0.05) 0..973 indicating the homogeneity of 
variances. Level of significance is 0.528 (p=0.528) which is above 0.05 hence there is no 
statistically significant difference. There is no statistically significant difference between 
groups as determined by one-way ANOVA (F (3,69)= 0.746, p =0.528 ). 
Inference: The null hypothesis is supported 
5.6.3. Strategic Alliances and Quality Management 
5.6.3. a. Strategic alliances and quality management-type of company 
H040: There is no significant difference in the mean value of quality related skills acquired 
by Indian pharmaceutical companies, as an area of impact of strategic alliances between 
Indian and foreign pharmaceutical companies, across all types of Indian pharmaceutical 
companies. 
Table No. 32 a: Test Statistics for Strategic Alliances and Quality 
Management -all types of pharmaceutical companies 
~w"' ,:.M|||^a||MMM| 
API 
Formulations 
API & Formulations 
Clinical Research 
R&D 
Total 
29 
11 
25 
5 
73 
3.37 
3.72 
3.52 
3.00 
3.20 
3.45 
.72 
.46 
.77 
.00 
.83 
.70 
illllllBlll 
1.015 .406 
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2.976 68 .025 
The Levene's statistic is not significant (p >0.05) 2.976 indicating the homogeneity of 
variances. 
Level of significance is 0.406 (j9=0.406) which is above 0.05 hence there is no statistically 
significant difference. There is no statistically significant difference between groups as 
determined by one-way ANOVA (F (4,68)= 1.015, p =0.406). 
Inference: The null hypothesis is supported 
5.6.3. b. Strategic alliances and quality management -turnover of company 
H041: There is no significant difference in the mean value of quality related skills acquired 
by Indian pharmaceutical companies, as an area of impact of strategic alliances between 
Indian and foreign pharmaceutical companies, across Indian pharmaceutical companies of 
different turnover. 
Table No. 32b: : Test Statistics for Strategic Alliances and Quality 
Management -across different turnover of pharmaceutical companies 
[ • • 
< 100 Cr. 
100-300Cr. 
301-500 Cr. 
>500 Cr. 
Total 
16 
8 
18 
31 
73 
dl 
3.43 
3.62 
3.11 
3.22 
3.28 
'"I 
Deviation F Sig. 
.62 
1.18 
.58 
.56 
.67 
1.446 .237 
j 
Lcveiie 
Statistic dfl df2 Sia. 
2.118 69 .106 
The Levene's statistic is not significant (p >0.05) 2.118 indicating the homogeneity of 
variances. Level of significance is 0.237 (;7=0.237) which is above 0.05 hence there is no 
statistically significant difference. There is no statistically significant difference between 
groups as determined by one-way ANOVA (F (3,69)= 1.446, p =0.237). 
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Inference: The null hypothesis is supported 
5.6.3. c. Strategic alliances and quality management - activity of company 
H042: There is no significant difference in the mean value of quality related skills acquired 
by Indian pharmaceutical companies, as an area of impact of strategic alliances between 
Indian and foreign pharmaceutical companies, across Indian pharmaceutical companies with 
different activities. 
Table No. 32c: : Test Statistics for Strategic Alliances and Quality 
Management - across different activities of pharmaceutical companies 
•ill 
Manufacturing 
R&D 
Manufacturing / R&D 
Contract Manufacturing 
Distribution 
Total 
34 
5 
24 
8 
2 
73 
3.38 
3.40 
3.50 
3.50 
4.00 
3.45 
•yiatipnj 
.69 
.54 
.78 
.75 
.00 
.70 
.412 .800 
^Statistic dfl m 
1.620 
The Levene's statistic is not significant (p >0.05) 1.620 indicating the homogeneity of 
variances. Level of significance is 0.800 (/7=0.800) which is above 0.05 hence there is no 
statistically significant difference. There is no statistically significant difference between 
groups as determined by one-way ANOVA (F (4,68)= 0.412 , p =0.800). 
Inference: The null hypothesis is supported 
5.7: Impact of Strategic Alliances between Indian and Foreign Pharmaceutical Companies 
on the Competitive Advantage 
5.7.1. Strategic Alliances and Increased Market Share 
5.7.1. a Strategic alliances and increased market share - type of company 
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H043: There is no significant difference in the mean values of increased market share as an 
area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across all types of Indian pharmaceutical companies. 
Table No. 33a: Test Statistics for Strategic Alliances and Increased 
Market Share ~ all types of pharmaceutical companies 
feermsMl rpatksytore. 
API 
Formulations 
API & Formulations 
Clinical Research 
R&D 
Total 
..M..., 
29 
11 
25 
3 
5 
73 
,„„JVfeaa,. 
3.82 
3.54 
4.16 
4.33 
3.80 
3.91 
Std. 
.71 
1.12 
.55 
.57 
.44 
.74 
1.817 .136 
Levene 
Statistic 
1.971 
dfl 
4 
df2 
68 
Sin. 
.109 
The Levene's statistic is not significant (p >0.05) 1.971 indicating the homogeneity of 
variances Level of significance is 0.136 (/7=0.136) which is above 0.05 hence there is no 
statistically significant difference. There is no statistically significant difference between 
groups as determined by one-way ANOVA (F (4,68)= 1.817 , p =0.136). 
Inference: The null hypothesis is supported 
5.7.1. Strategic Alliances and Increased Market Share 
5.7.1. b. Strategic alliances and increased market share - activity of company 
H044: There is no significant difference in the mean values of increased market share as an 
area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across Indian pharmaceutical companies indulging in various activities. 
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Table No. 33b : Test Statistics for Strategic Alliances and Increased Market 
Share - across different activities 
: ^^ ^ Increased market share. 
Manufacturing 
R&D 
Manufacturing / R&D 
Contract Manufacturing 
Distribution 
Total 
ofpha 
N 
34 
5 
24 
8 
2 
73 
rmaceuti 
Mean 
3.76 
3.80 
4.20 
3.75 
4.00 
3.91 
cat companies 
Sid. 
Deviation F Sig. 
.88 
.44 
.58 
.46 
.00 
.74 
1.463 .223 
Levene 
Statistic dfl df2 Siu. 
1.601 68 .184 
The Levene's statistic is not significant (p >0.05) 1.601 indicating the homogeneity of 
variances. Level of significance is 0.223 (p=0.223) which is above 0.05 hence there is no 
statistically significant difference. There is no statistically significant difference between 
groups as determined by one-way ANOVA (F (4,68)== 1.463 , p =0.223). 
Inference: The null hypothesis is supported , 
5.7.1. c. Strategic alliances and increased market share - turnover of company 
H045: There is no significant difference in the mean value of increased market share as an 
area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across Indian pharmaceutical companies of differing turnovers. 
Table No. 33 c: Test Statistics for Strategic Alliances and Increased Market 
Share - across different turnover of pharmaceutical companies 
^iH^HHH 
<Mii,.:„P«iati«n.. im,^.3.^ 
<100Cr. 16 3.75 .85 
100-300 Cr. 8 3.62 1.18 
301-500 Cr. 18 3.83 .51 
>500Cr. 31 4.12 .61 
Total 73 3.91 .74 
1.65 
.. * .^Sifc.,3;,, 
2 .185 
Statistic dfl dO Siai. 
1.951 3 69 .129 
The Levene's statistic is not significant (p >0.05) 1.951 indicating the homogeneity of 
variances Level of significance is 0.185 (p=0.185) which is above 0.05 hence there is no 
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statistically significant difference. There is no statistically significant difference between 
groups as determined by one-way ANOVA (F (3, 69) = 1.652, p =0.185). 
Inference: The null hypothesis is supported 
5.7.2. Strategic Alliances and Increased Overall Profitability 
5.7.2. a. Strategic alliances and increased overall profitability -type of company 
H046: There is no significant difference in the mean value of on enhanced profitability as an 
area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across Indian pharmaceutical companies of differing company types. 
Table No. 34a: Test Statistics for Strategic Alliances and Overall 
Profitability - all types of pharmaceutical companies 
API 
Formulations 
API & Formulations 
Clinical Research 
R&D 
Total 
29 
11 
25 
3 
5 
73 
' S 
3.82 
3.36 
4.36 
4.00 
4.20 
3.97 
Deviation 
.75 
1.02 
.70 
.00 
.44 
.81 
F Sig. 
3.770 .008 
Levene 
Statistic 
2.905 
df2 Si 
68 .028 
The Levene's statistic is not significant (p >0.05) 2.905 indicating the homogeneity of 
variances There is statistically significant difference between groups as determined by one-
way ANOVA (F (4,68)= 3.770 ,p =0.008)). 
A Tukey post- hoc test revealed that mean difference is significant between pharmaceutical 
API companies and pharmaceutical API and formulation (MD 0.99636 and p= 0.005). 
Inference: The null hypothesis is not supported 
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5.7.2. h. Strategic alliances and increased overall profitability - type of activity 
H047: There is no significant difference in the mean vdlue of on enhanced profitability as an 
area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across Indian pharmaceutical companies indulging in various activities. 
Table No. 34 b: Test Statistics for Strategic Alliances and Overall 
Profitability - across different activities of pharmaceutical companies 
fitplivlty 
* * Wi^V-i%\"^ti i l£i!*-V'l&M 
Manufacturing 
R&D 
Manufacturing / R&D 
Contract Manufacturing 
Distribution 
Total 
34 
5 
24 
8 
2 
73 
3.70 
4.20 
4.37 
3.62 
4.50 
3.97 
Std. 
.87 
.44 
.71 
.51 
.70 
.81 
3.449 .013 
The Levene's statistic is not significant (p >0.05) 1.613 indicating the homogeneity of 
variances. Level of significance is 0.013 (;7=0.013) which is below 0.05 hence there is a 
statistically significant difference. There is statistically significant difference between groups 
as determined by one-way ANOVA (F (4,68)= 3.449 ,p =0.013). 
A Tukey post- hoc test revealed that mean difference is significant between pharmaceutical 
companies with manufacturing as their core activity and pharmaceutical companies with 
both manufacturing and R&D as their core activity (mean difference 0.66912 and p= 
0.014). 
Inference: The null hypothesis is not supported 
5.7.2. c. Strategic alliances and increased overall profitability - turnover 
H048: There is no significant difference in the mean value of on enhanced profitability as an 
area of impact of strategic alliances between Indian and foreign pharmaceutical companies, 
across Indian pharmaceutical companies of differing turnovers. 
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Table No. 34 c: Test 
Profhahllitv - (/L'/V;,SV Jiffci 
<100Cr. 
100-300 Cr. 
301-500 Cr. 
>500 Cr. 
Total 
Statistics for Strategic Alliances and Overall 
cut turnover of pharmaceutical companies 
H... 
16 
8 
18 
31 
73 
.Mean , ,^_,_Dg j^atio|ij.„i;.: _ F^^ .,. ....Sig..,,,, 
3.62 .95 
4.12 .99 
3.61 .60 
4.32 .65 
3.97 .81 
4.793 .004 
The Levene's statistic is not significant (p >0.05) 1.498 indicating tiie homogeneity of 
variances. Level of significance is 0.004 (p=0.004) which is below 0.05 hence there is a 
statistically significant difference. There is statistically significant difference between groups 
as determined by one-way ANOVA (F (3,69)= 4.793 ,p =0.004 . 
Tukey post- hoc test revealed that mean difference is significant between pharmaceutical 
companies with differing turnovers 301-500 cr. and >500 cr. (mean difference 0.54122 and 
p= 0.042). 
Inference: The null hypothesis is not supported 
5.7.3. Strategic Alliances and Brand Building j 
5.7.3. a. Strategic alliances and brand building - Activity of company 
H049: There is no significant difference in the mean value of establishment of Indian 
pharmaceutical brand names in the global maricet as an area o/impact of strategic alliances 
between Indian and foreign pharmaceutical companies, across the types of activities 
undertaken by Indian pharmaceutical companies. 
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Table No. 35a: Test Statistics for Strategic Alliances and Brand 
Buildiiii^- Across different Activities of pharmaceutical cf^mpanies 
.:; E.slablishcd new brands 
Manufacturing 
R&D 
Manufacturing / R&D 
Contract Manufacturing 
Distribution 
Total 
K 
34 
5 
24 
8 
2 
73 
Mean 
3.6471 
3.8000 
4.1667 
3.8750 
4.5000 
3.8767 
D<iviation 
.73371 
.44721 
.63702 
.64087 
.70711 
.70603 
>' Sig. 
2.510 .050 
Levene 
Statistic dfi „df2. 
1.193 68 .322 
The Levene's statistic is not significant (p >0.05) 1.193 indicating the homogeneity of 
variances. Level of significance is 0.050 (p=0.050) which is equal 0.05 hence there is no 
statistically significant difference. There is statistically significant difference between groups 
as determined by one-way ANOVA (F (4,68)= 2.510 ,p =0.050). 
i 
Inference: The null hypothesis is supported 
5.7.3. b. Strategic alliances and brand building - Type of company 
H050: There is no significant difference in the mean value of establishment of Indian 
pharmaceutical brand names in the global market as an area of impact of strategic alliances 
between Indian and foreign pharmaceutical companies, across the types of Indian 
pharmaceutical companies. 
Table No. 35b: Test Statistics for Strategic Alliances and Brand Building -all 
types of pharmaceutical companies 
" 
jt it ive Advantage-i 
i^isli new brands 
API 
Formulations 
API & Formulations 
Clinical Research 
R&D 
Total 
>^  
29 
11 
25 
3 
5 
73 
Mean 
3.75 
3.54 
4.12 
4.33 
3.80 
3.87 
w 
Std. 
Deviation 
.63 
.93 
.66 
.57 
.44 
.70 
F Siii,. 
1.981 .107 
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Levene 
1.550 
,1 
4 68 .198 
The Levene's statistic is not significant (p >0.05) 1.550 indicating the homogeneity of 
variances. Level of significance is 0.107 (p=0.\07) which is above 0.05 hence there is no 
statistically significant difference. There is no statistically significant difference between 
groups as determined by one-way ANOVA (F (4,68)= 1.981 ,p =0.107 ). 
Inference: The null hypothesis Is supported 
5.7.3. c. Strategic alliances and brand building - Turnover of company 
H051: There is no significant difference in the mean value of establishment of Indian 
pharmaceutical brand names in the global market as an area of impact of strategic alliances 
between Indian and foreign pharmaceutical companies, across Indian pharmaceutical 
companies of varying turnover. 
Table No. 35c: Test Statistics for Strategic Alliances and Brand Building ~ 
across ui/jt^rtni iurno\ 
<100Cr. 
100-300 Cr. 
301-500 Cr. 
>500 Cr. 
Total 
er uj pnurmace 
16 
8 
18 
31 
73 
micai 
eati 
3.68 
4.12 
3.55 
4.09 
3.87 
cumpumes 
Std, 
Deviation 
.87 
.64 
.51 
.65 
.70 
3.2333 .027 
1 
I.evene 
Slatistic dfl df: 
1.855 3 69 .145 
The Levene's statistic is not significant (p >0.05) 1.855 indicating the homogeneity of 
variancesLevel of significance is 0.027 (p=0.027) which is below 0.05 hence there is a 
statistically significant difference. There is statistically significant difference between groups as 
determined by one-way ANOVA (F (3,69)= 3.233 ,p =0.027). 
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A Tukey post- hoc test revealed that mean difference is significant between pharmaceutical 
companies with differing turnovers 301 -500 cr. and >500 cr. (mean difference 0.66912 and 
p= 0.014). 
1 
Inference: The null hypothesis is not supported 
5.7.4. Strategic Alliances and Acquiring Superior Managerial Skills 
5.7.4. a. Strategic alliances and acquiring superior managerial skills - company activity 
H052: There is no significant difference in the mean values of acquisition of management 
skills by Indian pharmaceutical companies as an area of impact of strategic alliances between 
Indian and foreign pharmaceutical companies on the, across all types of Indian 
pharmaceutical companies. 
Table No. 36 a: Test Statistics for Strategic Alliances and Acquiring 
Superior Managerial Skills - all types of ptiarmaceiitical companies 
^ ^ ^ ^ • K i m h i l itieR 
API 
Formulations 
API & Formulations 
Clinical Research 
R&D 
Total 
N 
29 
11 
25 
3 
5 
73 
Mean 
3.58 
3.45 
3.88 
4.33 
4.00 
3.72 
Deviation 
.68 
.68 
.78 
.57 
.70 
.73 
F , S i " . • 
1.673 .166 
The Levene's statistic is not significant (p >0.05) .307 indicating the homogeneity of 
variances Level of significance is 0.166 (p=^0.166) which is above 0.05 hence there is no 
statistically significant difference. There is no statistically significant difference between 
groups as determined by one-way ANOVA (F (4,68)= 1.673 ,p =0.166). 
Inference: The null hypothesis is supported 
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5.7.4. b. Strategic alliances and acquiring superior managerial skills - company turnover 
H053: There is no significant difference in the mean value of acquisition of management 
skills by Indian pharmaceutical companies as an area of impact of strategic alliances between 
Indian and foreign pharmaceutical companies, across Indian pharmaceutical companies of 
different turnover. 
Table No. 36b: Test Statistics for Strategic Alliances and Acquiring 
Superior Managerial Skills - across different turnovers of 
pharmaceutical companies 
<100Cr. 
100-300Cr. 
301-500 Cr. 
>500 Cr. 
Total 
16 3.62 .80 
8 3.62 .74 
18 3.50 .61 
31 3.93 .72 
73 3.72 .73 
1.613 .194 
The Levene's statistic is not significant (p >0.05) .721 indicating the homogeneity of 
variances Level of significance is 0.194 (p=0.194) which is above 0.05 hence there is no 
statistically significant difference. There is no statistically significant difference between 
groups as determined by one-way ANOVA (F (3,69)= 1.613 ,p =0.194). 
Inference: The null hypothesis is supported 
5.7.4. c. Strategic alliances and acquiring superior managerial skills - company activity 
H054: There is- no significant difference in the mean value of acquisition of management 
skills by Indian pharmaceutical companies as an area of impact of strategic alliances between 
Indian and foreign pharmaceutical companies, across pharmaceutical companies indulging in 
various activities. 1 
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Table No. 36c : Test Statistics for Strategic Alliances and Acquiring 
Superior Managerial Skills -Across different activities of pharmaceutical 
companii • 
Manufacturing 
R&D 
Manufacturing / R&D 
Contract Manufacturing 
Distribution 
Total 
34 
5 
24 
8 
2 
73 
3.47 
4.20 
4.00 
3.50 
4.50 
3.72 
1 
.66 
.44 
.78 
.53 
.70 
.73 
3.612 .010 
! 
Levene 
Statistic dfl dC Sig. 
.538 4 68 .708 
The Levene's statistic is not significant (p >0.05) .538 indicating the homogeneity of 
variances. Level of significance is 0.010 (p=0.0\0) which is below 0.05 hence there is a 
statistically significant difference. There is statistically significant difference between groups 
as determined by one-way ANOVA (F (4, 68 )= 3.612 ,p =0.010 )). 
A Tukey post- hoc test revealed that mean difference is significant between pharmaceutical 
companies with manufacturing as their core activity and pharmaceutical companies with 
both manufacturing and R&D as their core activity (mean difference 0.52941 and p= 
0.038). 1 
Inference: The null hypothesis is not support 
5.8 Hindrances for Strategic Alliance 
Table 3 7 Test statistics -Hindrances for Strategic alliance 
External Hindrances 
Lack of Information 
Govt, policies 
73 
73 
Mean Deviation 
3.38 
3.52 
.98 
.80 
137 
Internal Hindrances 
Unclear objectives 
Lack of communication 
Non monitoring of alliance 
Lack of trust 
73 
73 
73 
73 
3.34 
3.71 
3.68 
3.79 
.73 
.73 
.66 
.79 
Inference: 
Lack of information pertaining to companies, their core activities is a strong de-motivator for 
the formation of strategic alliances between Indian and foreign pharmaceutical companies. L 
ack of governmental policies on strategic alliances is a strong demotivator for the formation 
of strategic alliances between Indian and foreign pharmaceutical companies. Unclear and 
loosely defined objective is a strong internal reason for failures of alliances between Indian 
and foreign pharmaceutical companies Lack of communication between the alliancing 
partners is a strong internal reason for failures of alliances between Indian and foreign 
pharmaceutical companies Non monitoring of the progress of the alliance is a strong internal 
reason for failures of alliances between Indian and foreign pharmaceutical companies Lack of 
trust between the two alliancing companies is a strong internal reason for failures of 
alliances between Indian and foreign pharmaceutical companies. 
5.9 Summary 
Reasons for the Formation of Alliances between Indian and Foreign Pharmaceutical 
Companies 
. S' 
1 
2 
J 
4 
5 
Strengthen product portfolio 
Establishing brands abroad 
Launching new product lines 
Entering global emerging markets 
Entering regulated markets 
Klean 
3.83 
3.94 
3.76 
3.83 
3.94 
SD"" 
.62 
.76 
.71 
.62 
.76 
Rank 
6 
4 
8 
7 
3 
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6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
Establishing distribution channels abroad 
Accessing new technology 
Undertaking collaborative R&D 
Obtaining USFDA approved 
Cost minimization 
Achieving operational synergy 
Achieving quality management 
Achieving market position 
Achieving financial power 
Enhancing company image 
3.76 
3.32 
3.30 
3.17 
2.91 
2.86 
3.28 
3.91 
3.98 
4.04 
.71 
.64 
.90 
.93 
.90 
.91 
.67 
.72 
.69 
.71 
9 
10 
11 
13 
14 
15 
12 
5 
2 
1 
Impact of Strategic Alliances between Indian and Foreign Pharmaceutical Companies on 
Indian Pharmaceutical Companies 
Level of Outcome 
Si'> 
HOI There is no significant difference in the mean value! of launch of new patented 
molecules as an area if impact of strategic alliances between Indian and foreign 
pharmaceutical companies across the types of Indian pharmaceutical companies 
0.061 Supported 
H02 There is no significant difference in the mean value of launch of patented 
molecules as an area of impact of strategic alliances between Indian an 
foreign pharmaceutical companies, across the types of activity undertaken by 
Indian pharmaceutical companies 
0.002 Not 
supported 
H03 There is no significant difference in the mean value of launch of patented 
molecules as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies of differing 
turnover 
0.005 Not 
supported 
H04 There is no significant difference in the mean value of launch of generic 
pharmaceutical products abroad as an area of impact of strategic alliances 
between Indian and foreign pharmaceutical companies, across all types of 
Indian pharmaceutical companies 
0.102 Supported 
H05 There is no significant difference in the mean value of launch of generic 
pharmaceutical products abroad as an area of impact of strategic alliances 
between Indian and foreign pharmaceutical companies, across Indian 
pharmaceutical companies indulging in various activities 
0.010 Not 
supported 
H06 There is no significant difference in the mean value of launch of generic 
pharmaceutical products abroad as an area of impact of strategic alliances 
between Indian and foreign pharmaceutical companies, across Indian 
pharmaceutical companies of varying turnover 
0.001 Not 
supported 
H07 There is no significant difference in the mean value of launch of new generic 
pharmaceutical products in the domestic market as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies, 
across the types of Indian pharmaceutical companies 
0.201 Supported 
H08 There is no significant difference in the mean value of launch of new generic 
pharmaceutical products in the domestic market as an area of impact of strategic 
alliances between Indian and foreign pharmaceutical companies across the types 
of activity undertaken by Indian pharmaceutical companies 
0.056 Supported 
H09 There is no significant difference in the mean value of launch of new generic 
pharmaceutical products in the domestic market as an area of impact of strategic 
alliances between Indian and foreign pharmaceutical companies, across Indian 
pharmaceutical companies with different turnovers 
0.048 Not 
supported 
HOIQ There is no significant difference in the mean value of expansion of product 0.165 Supported 
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portfolio as an area impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across all types of Indian pharmaceutical companies 
HO 11 There is no significant difference in the mean value of expansion of product 0.005 
portfolio as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies indulging 
in various activities 
H022 There is no significant difference in the mean value of gaining technological 
competency as an area of impact of strategic alliances between Indian and 
foreign pharmaceutical companies, across all types of Indian pharmaceutical 
companies 
H023 There is no significant difference in the mean value of gaining technological 
competency as an area of impact of strategic alliances between Indian and 
foreign pharmaceutical companies, across Indian pharmaceutical companies 
indulging in various activities 
Not 
supported 
0.110 Supported 
0.697 Supported 
0.096 Supported 
0.191 Supported 
HO 12 There is no significant difference in the mean value of expansion of product 
portfolio as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies of varying 
turnover 
HOI3 There is no significant difference in the mean value of access to highly 
regulated markets abroad as an area of impact of strategic alliances between 
Indian and foreign pharmaceutical companies, across all types of Indian 
pharmaceutical companies 
H014 There is no significant difference in the mean value of access to highly regulated 
markets abroad as an area of impact of strategic alliances between Indian and 
foreign pharmaceutical companies, across Indian pharmaceutical companies 
undertaking different activities 
HOIS There is no significant difference in the mean value of access to highly regulated 
markets abroad as an area of impact of strategic alliances between Indian and 
foreign pharmaceutical companies across Indian pharmaceutical companies of 
different turnover ^ 
HOI6 There is no significant difference in the mean value gaining investment capability 0.000 Not 
into sales and marketing as an area of impact of strategic alliances between supported 
Indian and foreign pharmaceutical companies, across all types of Indian 
pharmaceutical companies 
HO 17 There is no significant difference in the mean value of gaining investment 0.000 Not 
capability into sales and marketing, as an area of impact of strategic alliances supported 
between Indian and foreign pharmaceutical companies, across Indian 
pharmaceutical with varying business activities 
HOI8 There is no significant difference in the mean value of gaining investment O.OOI Not 
capability into sales and marketing, as an area of impact of strategic alliances supported 
between Indian and foreign pharmaceutical companies, across Indian 
pharmaceutical companies with varying turnover 
HO 19 There is no significant difference in the mean value of gaining access to 0.001 Not 
foreign distribution networks abroad as an area of impact of strategic alliances supported 
between Indian and foreign pharmaceutical companies, across all types of 
Indian pharmaceutical companies 
H020 There is no significant difference in the mean value of gaining access to foreign 0.015 Not 
distribution networks abroad as an area of impact of strategic alliances between supported 
Indian and foreign pharmaceutical companies, across Indian pharmaceutical 
companies with differing turnover 
H02I There is no significant difference in the mean value of gaining access to foreign 0.000 Not 
distribution networks abroad as an area of impact of strategic alliances between supported 
Indian and foreign pharmaceutical companies, Indian pharmaceutical 
companies undertaking different activities 
0.691 Supported 
0.139 Supported 
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0.301 Supported H024 There is no significant difference in the mean value of gaining technological 
competency as an area impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies of varying 
turnover 
H025 There is no significant difference in the mean value of achieving R&D 0.039 Not 
capability, as an area of impact of strategic alliances between Indian and supported 
foreign pharmaceutical companies, across all types of Indian pharmaceutical 
companies 
H026 There is no significant difference in the mean value of achieving R&D capability, 0.001 Not 
as an area of impact of strategic alliances between Indian and foreign supported 
pharmaceutical companies, across Indian pharmaceutical companies indulging 
in various activities ____^___ 
H027 There is no significant difference in the mean value of achieving R&D capability, 0.024 Not 
as an area of impact of strategic alliances between Indian and foreign supported 
pharmaceutical companies, across Indian pharmaceutical companies of varying 
turnover 
H028 There is no significant difference in the mean value of development ofGMP 0.014 Not 
compliant production capacities by Indian pharmaceutical companies as an area supported 
of impact of strategic alliances between Indian and foreign pharmaceutical 
companies, across all types of Indian pharmaceutical companies 
H029 There is no significant difference in the mean value of development ofGMP 0.023 Not 
compliant production capacities by Indian pharmaceutical companies as an area supported 
of impact of strategic alliances between Indian and foreign pharmaceutical 
companies, across Indian pharmaceutical companies performing different 
activities 
H030 There is no significant difference in the mean value of development ofGMP 0.035 Not 
compliant production capacities by Indian pharmaceutical companies as an area supported 
of impact of strategic alliances between Indian and foreign pharmaceutical 
companies, across Indian pharmaceutical companies of different turnover 
H031 There is no significant difference in the mean value of accessibility of Indian 0.001 Not 
companies to latest technological and product related upgrades as an area of supported 
impact of strategic alliances between Indian and foreign pharmaceutical 
companies on, across all types of Indian pharmaceutical companies 
H032 There is no significant difference in the mean value of accessibility of Indian 0.064 Supported 
companies to latest technological and product related upgrades impact of 
strategic alliances between Indian and foreign pharmaceutical companies, across 
Indian pharmaceutical companies of different turnover 
H033 There is no significant difference in the mean value of accessibility of Indian 0.000 Not 
companies to latest technological and product related upgrades as an area of supported 
impact of strategic alliances between Indian and foreign pharmaceutical 
companies , across Indian pharmaceutical companies with different activities 
H034 There is no significant difference in the mean value of cost optimizafion as an 
area of impact on strategic alliances between Indian and foreign 
pharmaceutical companies, across the types of Indian pharmaceufical 
companies 
H035 There is no significant difference in the mean value of cost optimization as an 
area of impact on strategic alliances between Indian and foreign pharmaceutical 
companies, across the types of acfivity undertaken by Indian pharmaceutical 
companies 
H036 There is no significant difference in the mean value of cost opdmization as an 
area of impact on strategic alliances between Indian and foreign pharmaceutical 
companies across Indian pharmaceutical companies of varying turnover. 
H037 There is no significant difference in the mean value of achieving operational 
synergy as an area of impact on strategic alliances between Indian and foreign 
0.304 Supported 
0.184 Supported 
0.232 Supported 
0.763 Supported 
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pharmaceutical companies across the types of Indian pharmaceutical companies. 
H038 There is no significant difference in the mean value of achieving operational 
synergy as an area of impact on strategic alliances between Indian and foreign 
pharmaceutical companies across the types of activity undertaken by Indian 
pharmaceutical companies. 
H039 There is no significant difference in the mean value of achieving operational 
synergy as an area of impact on strategic alliances between Indian and foreign 
pharmaceutical companies across Indian pharmaceutical companies of varying 
turnover 
H040 There is no significant difference in the mean value of quality related skills 
acquired by Indian pharmaceutical companies, as an area of impact of strategic 
alliances between Indian and foreign pharmaceutical companies, across all types 
of Indian pharmaceutical companies 
H041 There is no significant difference in the mean value of quality related skills 
acquired by Indian pharmaceutical companies, as an area of impact of strategic 
alliances between Indian and foreign pharmaceutical companies, across Indian 
pharmaceutical companies of different turnover 
H042 There is no significant difference in the mean value of quality related skills 
acquired by Indian pharmaceutical companies, as an area of impact of strategic 
alliances between Indian and foreign pharmaceutical companies, across Indian 
pharmaceutical companies with different activities 
H043 There is no significant difference in the mean values of increased market share as 
an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across all types of Indian pharmaceutical companies 
H044 There is no significant difference in the mean values of increased market share as 
an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies indulging in 
various activities 
H045 There is no significant difference in the mean value of increased market share as 
an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies of differing 
turnovers 
H046 There is no significant difference in the mean value of on enhanced profitability 0.008 
as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies of differing 
company types 
H047 There is no significant difference in the mean value of on enhanced profitability 0.013 
as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies indulging in 
various activities ^ 
H048 There is no significant difference in the mean value of on enhanced profitability 0.004 
as an area of impact of strategic alliances between Indian and foreign 
pharmaceutical companies, across Indian pharmaceutical companies of differing 
turnovers 
H049 
H050 
There is no significant difference in the mean value of establishment of Indian 
pharmaceutical brand names in the global market as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies, 
across the types of activities undertaken by Indian pharmaceutical companies 
There is no significant difference in the mean value of establishment of Indian 
pharmaceutical brand names in the global market as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies, across 
the types of Indian pharmaceutical companies 
0.800 Supported 
0.528 Supported 
0.406 Supported 
0.237 Supported 
0.800 Supported 
0.136 Supported 
0.223 Supported 
0.185 Supported 
Not 
supported 
Not 
supported 
Not 
supported 
0.050 Supported 
0.107 Supported 
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H051 There is no significant difference in the mean value of establishment of Indian 0.027 
pharmaceutical brand names in the global market as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies, 
across Indian pharmaceutical companies of varying turnover 
H052 There is no significant difference in the mean values of acquisition of 0.166 
management skills by Indian pharmaceutical companies as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies on the, 
across all types of Indian pharmaceutical companies 
H053 There is no significant difference in the mean value of acquisition of 0.194 
management skills by Indian pharmaceutical companies as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies, across 
Indian pharmaceutical companies of different turnover 
Not 
supported 
Supported 
Supported 
H054 There is no significant difference in the mean value of acquisition of 
management skills by Indian pharmaceutical companies as an area of impact of 
strategic alliances between Indian and foreign pharmaceutical companies, across 
pharmaceutical companies indulging in various activities 
0.010 Not 
supported 
Hindrances for Formation of Strategic Alliances between Indian and Foreign 
Pharmaceutical Companies on Indian Pharmaceutical Companies 
K 
1 
2 
3 
4 
5 
6 
•f' able 
Lack of data related to organizations and their interests 
Lack of governmental policies and 
Unclear alliance objectives of Indian pharmaceutical 
companies regarding alliance formation 
Lack of communication among between alliancing 
Indian and foreign pharmaceutical companies 
Lack of alliance progress monitoring between Indian 
and foreign pharmaceutical companies 
Lack of Trust among alliancing companies 
Mean 
3.38 
3.52 
3.34 
3.71 
3.68 
3.79 
SD 
.98 
.80 
.73 
.73 
.66 
.79 
Rank : 
5 
4 
6 
2 
3 
1 
5.10. Correlation between the Strategic Alliances and the Identified Factors 
This section discusses in detail the relationship that can be drawn with the primary research 
data and the impact of this data on managerial decision making with respect to problems 
related to strategic alliances between Indian and foreign pharmaceutical companies. 
Reasons for strategic alliances 
Ifs well known that foreign MNCs look at India as a high potential market for their products 
and set up alliances with Indian companies to market and launch their products. However 
143 
Indian companies as well seek out foreign collaborations for many reasons. This becomes the 
core objective which drives the strategic alliance. The reasons which have encouraged the 
formation of strategic alliances between Indian and foreign pharmaceutical companies can 
be categorized under 5 reasons: 
• Product related 
• Marketing and Distribution related 
• Technology 
• Manufacturing 
• Gain Competitive advantage 
5.10.1: Strategic Alliance and Product Related Reasons 
Tabic ]S a Test statistics- Product Related Reasons for 
r '" 
r ; . . J : ^ - - •••;••••-.:;-:>•' , ; : . : : ; - • , „ . , ; ^ > - -.• . , . ; ; ; • 
T>pc ol Activiu 
Product-Strengthen product portfolio 
Product-Launch new brands abroad 
Product-Launch new products 
Strategic alliance 
Mean 
2.16 
3.5479 
3.6164 
3.6712 
St(i. Deviation 
1.214 
.88256 
.92241 
.68829 
^ 
73 
73 
73 
73 
The factor launching new products (M = 3.67, SD = 0.688) was stronger than the launching new 
products abroad (M=3.61, SD=0.92) and the factor strengthen product portfolio (M = 3.54, SD = 
0.88). 
Table 38 b Product Related Reasons for Strategic 
Pearson 
Correlation 
Sig. (2-
tailed) 
• • i 
"Cofr&latton 
Type of Activity 
P-Strengthen product portfolio 
P-Launch new brands abroad 
P-Launch new products 
Type of Activity 
P-Strengthen product portfolio 
P-Launch new brands abroad 
P-Launch new products 
alliance-Correlation 
Type of 
Activit\ 
1.000 
.343 
.280 
,066 
.002 
.008 
.291 
Strengtlien 
product 
|X>rlfolio 
.343 
1.000 
.637 
.278 
.002 
.000 
.009 
Launch new 
bninds abroad 
.280 
.637 
1.000 
.302 
.008 
.000 
.005 
Liiuncli nsv\ 
products 
.066 
.278 
.302 
1.000 
.291 
.009 
.005 
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A correlation for the data revealed that, There is moderate correlation between 
• strategic alliance formation hetM'een Indian and foreign pharmaceutical companies and 
the need to strengthen product portfolio, r = .343, N = 73, p < .01, 2- tail. 
• strategic alliance formation between Indian and foreign pharmaceutical companies 
pharmaceutical companies and the need to launch new products abroad, r = .283, N 
= 73,p<.01, 2-tail. 
• launching new products domestically and enhancing product portfolio, r = .278, N = 73, 
p < .01, 2- tail. There was a moderate correlation between launching new products 
domestically and launching new products abroad, r = .302, N = 73, p < .01, 2- tail. 
There is no correlation between strategic alliance formation between Indian and foreign 
pharmaceutical companies and launching new products in domestic market, r = .066, N = 73, 
p<.01, 2-tail. 1 
There is a significant correlation between launching new products abroad and enhancing 
product portfolio, r = .637, N =" 73, p < .01, 2- tail. 
Table 38 c Product Related Reasons for Strategic alliance-Model Summary 
Model 
1 
R 
.355^ 
R Square 
.126 
Adjusted R 
Square 
.088 
Std. Error of 
the Estimate 
1,159 
Change Statistics 
R Square 
Change 
.126 
F Change 
3.314 
dfl 
3 
df2 
69 
Sig. F Change 
.025 
Model Coefficients 
1 (Constant) 
P- Strengthen product portfolio 
P-Launch new brands abroad 
P-Launch new products 
Un standardized 
Coefficients 
B 
.547 
.389 
.151 
-.084 
Std. 
Error 
.836 
.202 
.195 
.210 
Standardized 
Coefficients 
Beta 
.283 
.115 
-.048 
t 
.654 
1.924 
.773 
-.400 
Sig. 
.515 
.058 
.442 
.690 
When product related factors for the formation of strategic alliances between Indian and 
foreign pharmaceutical companies was predicted, it was found that need to strengthen product 
portfolio(/3=0.283, p>0.05) need to launch new brands abroad (p = 0.115,p>0.05) and 
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need to launch new products in domestic market (13--0.048, p>0.05) were not significant 
predictors. \ 
-) I 
The overall model fit was R' = 0.126 
Illustration 09 : Product Related Reasons for Strategic Alliances 
The overall model fit was r = 0.126. 
Yl=.389(Pl)+.151(P2)-.084(P3)+.547 
P1-Strengthen product portfolio 
P2-Launch new brands abroad 
P3-Launch new products 
Thus the linear equation can 
be represented as : 
5.10.2: Strategic Alliance and Marketing Related Reasons 
Table 39a Test statistics- Markctiri'z Related Reasons for Strategic Alliances 
s •• •, - i 
Annual Turnover 
Marketing-Global emerging markets 
Marketing-Regulated markets 
Marketing-Distribution channels abroad 
r 
': Mean 2.88 
3.8356 
3.9452 
3.7671 
Sid. iX'vialion 
1.190 
.62391 
.76177 
.71726 
N 
73 
73 
73 
73 
Table 39b Marketing Related Reasons for Strategic Alliances- Correlation 
Pearson 
Correlation 
Annual Turnover 
M-Global emerging markets 
M-Regulated markets 
1.000 
.328 
.345 
.328 
1.000 
,507 
.345 
.507 
1.000 
.259 
.379 
.408 
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Sig.(2-
tailed) 
M-Distribution channels abroad 
Annual Turnover 
M-Global emerging markets 
M-Regulated markets 
M-Distribution channels abroad 
.259 
.002 
.001 
.013 
.379 
.002 
.000 
.000 
.408 
.001 
.000 
.000 
1.000 
.013 
.000 
.000 
A correlation for the data revealed that, there is a moderate correlation between 
• strategic alliance formation between Indian and foreign pharmaceutical companies and 
the need to access the global emerging markets, r = .328, N = 73, p < .05, 2- tail. 
• strategic alliance formation between Indian and foreign pharmaceutical companies and 
need to access the global regulated markets, r = . 345, N = 73, p < . 05, 2- tail. 
• strategic alliance formation between Indian and foreign pharmaceutical companies and 
need to access distribution channels abroad, r = .259, N - 73, p < .05, 2- tail. 
There is a significant correlation between \ 
• accessing global emerging markets and accessing global regulated markets, r = .507, N 
= 73,p<.01, 2-tail. 
• accessing global emerging markets and accessing distribution channels abroad, r 
= .379, N= 73, p<.01, 2-tail. 
• accessing distribution channels abroad and accessing global regulated markets, r 
= .408,N=73,p<.0},2-tail. 
Table 39c Marketing Related Reasons for Strategic Alliances-Model Summary 
Model 
1 
R 
.399' 
R Square 
.159 
Adjusted R 
Square 
.123 
Std. Error of 
the Estimate 
1.114 
Change Statistics 
R Square 
Change 
.159 
F Change 
4.352 
dn 
3 
df2 
69 
Sig.F 
Change 
.007 
Model coefficients 
1 (Constant) 
M-Global emerging markets 
M-Regulated markets 
M-Distribution channels abroad 
Unstandardized 
Coefficients 
B 
-.399 
.347 
.328 
.173 
Std. Error 
.941 
.250 
.208 
.206 
Standardized 
Coefficients 
Beta 
.182 
.210 
.104 
t 
-.424 
1.386 
1.580 
.840 
Si?. 
.673 
.170 
.119 
.404 
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When Marketing related factors for the formation of strategic alliances between Indian and 
foreign pharmaceutical companies was predicted, it was found that need to access global 
emerging markets (P=0.182, p>0.05) need to access regulated markets (P = 0.210, p>0.05) 
and need to launch distribution channels abroad (P= 104, p>0.05) were not significant 
predictors. 
The overall model fit is R~ = 0.159. 
Illustration 10 : Marketing Related Reasons for Strategic Alliances 
MKTG1 
MKTG2 
MKTG3 
SA 
MKTG1 -Global emerging markets 
MKTG2-Regulated markets 
MKTGS-Distribution channels abroac 
The overall model fit 
was R^  = 0.159. Thus 
the linear equation 
can be represented as : 
Y2=.347(MKTG1) +.328(MKTG2) +.173(MKTG3) -.399 
5.10.3: Strategic Alliance and Technology Related Reasons 
Table 40a Test statistics— Technology Related Reasons for Strategic Alliances 
Type of Company 
Technology-Access new technology 
Technology-Collaborative R&D 
Technology-USFDA approvals 
Mean 
2.23 
3.3288 
3.3014 
3.1781 
Ski. DcviiUioft 
1.219 
.64668 
.90806 
.93307 
: • • . 
73 
73 
73 
73 
Table JOb Technnjog}- Related Reasons 
Pearson 
Correlation 
Z.'T^ B 
Type of Company 
T-Access new technology 
T-Collaborative R&D 
T-USFDA approvals 
for Strategic Alliances- (Correlation 
^^' lypt'of new Coli 
1.000 .025 
.025 1.000 
.300 ,113 
.134 .477 
^m. ,.. 
.300 
.113 
1.000 
.247 
^BUSFDA apnro\aIs 
.134 
.477 
.247 
1.000 
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Sig. (2-tailed) Type of Company 
T-Access new technology 
T-Collaborative R&D 
T- USFDA approvals 
.417 
.005 
.129 
.417 
.171 
.000 
.005 
.171 
.017 
.129 
.000 
.017 
A correlation for the data revealed that, there is no significant correlation between 
• strategic alliance formation between Indian and foreign pharmaceutical companies and 
the need to access new technology, r = .025, N = 73, p> .05, 2- tail. 
• accessing new technology and collaborative R&D, r = .113, N ^ 73, p < .01, 2- tail. 
There is a moderate correlation between 
• strategic alliance formation between Indian and foreign pharmaceutical companies 
and the need for collaborative R&D, r = .300, N = 73, p < .05, 2- tail. 
• strategic alliance formation between Indian and foreign pharmaceutical companies 
and need the for USFDA approved facilities, r = . 134, N = 73, p >.05, 2- tail. 
• collaborative R&D and the need to access USFDA approved facility, r = .247, N = 73, 
p<.01,2-tail. 
• There is a significant correlation between USFDA approved facility and need to access 
new technology, r = .477, N = 73, p < .01, 2- tail. 
Table 40c Technology Related Reasons for Strategic Alliances- Model Summary 
Model 
1 
R 
.309" 
R Square 
.095 
Adjusted R 
Square 
.056 
Std. Error of 
the Estimate 
1.185 
Change Statistics 
R Square 
Change 
.095 
F Change 
2.424 
dfl 
3 
df2 
69 
Sig.F 
Change 
.073 
Model 
1 (Constant) 
T- Access new technology 
T-Collaborative R&D 
f-USFDA approvals 
Unstandardized 
Coefficients 
B 
.920 
-.092 
.381 
.114 
Std. Error 
.850 
.246 
.159 
.175 
Standardized 
Coefficients 
Beta 
-.049 
.283 
.087 
t 
1.082 
-.373 
2.399 
.652 
Sig. 
.283 
.710 
.019 
.517 
When Technology related factors for the formation of strategic alliances between Indian and 
foreign pharmaceutical companies was predicted, it was found that need to access new 
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technology (/3=-0.049, p>0.05) and the need for USFDA approved facilities (P 
= .087,p>0.05) were not significant predictors. However Collaborative R&D ( P=.283 , p< 
0.05) is a significant predictor. 
The overall model fit was R' = 0.095 
Illustration 11: Technology Related Reasons for Strategic Alliances 
SA 
TECH1 -Access new technology 
TECH2-Collaborative R&D 
TECH3-USFDA approvals 
The overall model fit was 
R^  = 0.095. Thus the 
linear equation can be 
represented as: 
Y3=.381(TECH2) +.114(TECH3) -.092(TECH1) +.920 
5.10.4: Strategic Alliance and Manufacturing Related Reasons 
Table 41a Test statistics- Manufacturing Related Reasons for Strategic Alliances 
Annual lurnover 
Manufacturing-Cost minimization 
Manufacturing-Common assets 
Manufacturing-Quality management 
i.n ' 1.190 
2.9178 .90911 
2.8630 .91765 
3,2877 .67658 
73 
73 
73 
73 
Table 41b - Manufacturing Related Reasons for 
i'eai",son 
Correlation 
Cdmliitions 
1 Annual lumoxer 
Manufacturing-Cost minimization 
Manufacturing-Common assets 
Strategic Alliafices- Correlation 
Annual M-C(>st 
1.000 -.138 
-.138 1.000 
.162 .419 
M-
Common 
assets 
.162 
.419 
1.000 
M-<^ualily 
uianagemiiBtp 
-.162 
.220 
.221 
150 
Sig. (2-tailed) 
Manufacturing-Quality 
management 
Annual Turnover 
Manufacturing-Cost minimization 
Manufacturing-Common assets 
Manufacturing-Quality 
management 
-.162 
.122 
.085 
.085 
.220 
.122 
.000 
,031 
.221 
.085 
.000 
.030 
1.000 
.085 
.031 
.030 
A correlation for the data revealed that, 
There is no significant correlation between 
• strategic alliance formation between Indian and foreign pharmaceutical companies 
and the need to minimise manufacturing costs, r = -. 138, N = 73, p> .05, 2- tail, 
• strategic alliance formation between Indian and foreign pharmaceutical companies the 
need to optimise common assets, r = .162, N = 73, p> .05, 2- tail, 
• strategic alliance formation between Indian and foreign pharmaceutical companies the 
need for quality management processes, r = .162, N = 73, p >.05, 2- tail. 
There is a significant correlation between cost minimisation and optimising common assets 
factors ,r = .419,N=73,p<.01,2- tail. 
There is a moderate correlation between 
• cost minimisation and the need for quality management processes, r=.220, N ^ 73, p 
<.01,2-tail 
• optimising common assets and the need for quality management processes, r = .221, N 
= 73, p<.01, 2-tail 
Table 4 
Model 
1 
'c - Manufacturing 
R 
.328 
R Square 
.108 
Related Reasons for Strategic Alliances- Model Summary 
Adjusted R 
Square 
.069 
Std. Error of 
the Estimate 
1.148 
Change Statistics 
R Square 
Change 
.108 
F Change 
2.775 
dfl 
3 
df2 
69 
Sig. F 
Change 
.048 
Model 
Unstandardized 
Coefficients 
B 
Std. 
Error 
Standardized 
Coefficients 
Beta t Sig. 
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1 (Constant) 
Manufacturing-Cost minimization 
Manufacturing-Common assets 
Manufacturing-Quality management 
3.664 
-.291 
.383 
-.314 
.756 
.166 
.164 
.207 
-.222 
.295 
-.179 
4.845 
-1.757 
2.331 
-1.517 
.000 
.083 
.023 
.134 
When Manufacturing related factors for the formation of strategic alliances between Indian 
and foreign pharmaceutical companies were predicted, it was found that Cost optimization 
( P= -.222, p> 0.05) and Quality management (P= -.179, p>0.05) are not significant 
predictors. However need to optimize common assets (P=-0.295, p<0.05) was a significant 
predictor. The overall model fit was R' = 0.108 
Illustration 12 : Manufacturing Related Reasons for Strategic Alliances 
SA 
Y4- -.291(MFTG1) + .383(MFTG2) - 314(MFTG3) + .3.66 
I 
5.10,5: Competitive A dvantage Related I 
Table Ala Test sintisiics-C'ompetitive Advantage RelatedReaso 
Type of Activity 
Competitive Advantage-Maricet position 
Competitive Advantage-Financial power 
Competitive Advantage-Image 
nsfor Strategic Alliances 
1 
2.16 
3.9178 
3.9863 
4.0411 
Std. Deviation 
1.214 
.72175 
.69708 
.71567 
A' 
73 
73 
73 
73 
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Table 42b Competitive Advantage Related Reasons for Strategic Alliances- Correlation 
• j,., *f,^^^^^^^-)^¥ 
Pearson 
Correlation 
Sig. (2-tailed) 
Type of Activity 
CA-Martcet position 
CA-Financia! power 
CA-Image 
Type of Activity 
CA-Mari^ et position 
CA-Financial power 
CA-Image 
Type of Ad^  aniage-
illlBIIIIMIIIIllllMlilMIIIII* . . . 
[ ^ ^ • I H H K Ma'icct ttosition 
1.000 .063 
,063 1.000 
.315 .301 
.296 .410 
.298 
,298 
,003 .005 
.006 .000 
Compet-'ive 
.Xclvanuigi.--
l-inancial 
power 
.315 
.301 
1.000 
.391 
.003 
,005 
.000 
Compttitivc 
Ativan lage-
.296 
.410 
.391 
1.000 
.006 
.000 
.000 
A correlation for the data revealed that, 
There is no significant correlation between 
strategic alliance formation between Indian and foreign pharmaceutical companies 
and the need to enhance market position, r = . 063, N = 73, p> .05, 2- tail, 
strategic alliance formation between Indian and foreign pharmaceutical companies 
and the need to enhance company image, r = .296, N = 73, p<.05, 2- tail. 
There is moderate correlation between 
strategic alliance formation between Indian and foreign pharmaceutical companies 
and the need to enhance financial power, r = .315, N == 73, p <.05, 2- tail. 
There is a significant correlation between 
• the need for enhancing market position and create financial presence, r = .301, N = 
73,p<.01, 2-tail 
• the need for enhancing market position and enhance corporate image, r = .410, N = 73, 
p< .01, 2-tail. 
• the need for enhancing corporate image and attaining financial capability, r = .391, 
N=73,p<.01,2-tail. 
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Table 42c Competitive Advantage Related Reasons for Strategic Alliances-Model Summary 
Model 
1 
R 
.380^ 
R Square 
.145 
Adjusted R 
Square 
.107 
Std. Error of 
the Estimate 
1.146 
R Square 
Change 
.145 
Change Statistics 
F Change 
3,889 
dfl 
3 
df2 
69 
Sig.F 
Change 
.013 
Model 
1 (Constant) 
CA -Market position 
CA- Financial power 
CA-lmage 
Un standardized 
Coefficients 
B 
-.518 
-.190 
.442 
.412 
Std. 
Error 
1.005 
.208 
.214 
.218 
Standardized 
Coefficients 
Beta 
-.113 
.254 
.243 
t 
-.515 
-.912 
2.067 
1.895 
Sig. 
.608 
.365 
.042 
.062 
When Competitive Advantage related factors for the formation of strategic alliances 
between Indian and foreign pharmaceutical companies was predicted, it was found that 
achieving Market position (fi= -.US , p> 0.05) and enhancing Company image (^=.243, 
p>0.05) are not significant predictors. 
However the need to achieve financial power (P=-0.254 , p<0.05) was a significant 
predictor. 
The overall model fit was R' = 0.145 
Illustration 13 : Competitive Advantage related reasons for Strategic Alliances 
( $ 
SA 
CA1-Market position 
CA2-Financial power 
CA3-lmage 
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The overall model fit was R = 0.145. Thus the linear equation can be represented as: 
Y5= -.190(CA1) + .442(CA2)+.412(CA3) - .518 
5.77. Correlation between the Strategic Alliances and Business Implication 
5.11.1 Strategic Alliance and Implication on Products 
Table 43a Test staiislics- Implications of Strategic Alliance on 
i J) . -- /'rmimmff! 
Annual Turnover 
Products-New patents 
Products-New generics abroad 
Products-New generics domestic 
Products-Wide portfolio 
2.88 
3.3151 
3.6301 
3.4658 
3.8630 
Prf^ducts 
Sid. Deviation 
1.190 
.86405 
.92055 
.83470 
.67320 
N 
73 
73 
73 
73 
73 
Tabk 43b Implications of Strategic Alliance on Products- Correlation 
1 
Feaison 
Correlation 
Sig. (2-
tailed) 
CorreiatioB ' S ^ H i 
Annual Turnover 
Products-New patents 
Products-New generics abroad 
Products-New generics domestic 
Products-Wide portfolio 
Annual Turnover 
Products-New patents 
Products-New generics abroad 
Products-New generics domestic 
Products-Wide portfolio 
Turnover 
1.000 
.403 
.452 
.324 
.187 
.000 
.000 
.003 
.057 
i'rodticis-
Ncw 
paleiit^ 
.403 
1,000 
.358 
.448 
,410 
.000 
.001 
.000 
,000 
I'roducts-
generics 
,452 
,358 
1.000 
.607 
.388 
.000 
.001 
.000 
.000 
Producls-Ncu 
generics 
domestic 
.324 
.448 
.607 
1.000 
.436 
.003 
,000 
.000 
.000 
I'roducts-
Wide 
poi1foli< .^i. 
,187 
.410 
.388 
.436 
1.000 
.057 
.000 
.000 
.000 
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A correlation for the data revealed that, There is no significant correlation between strategic 
alliances between Indian and foreign pharmaceuticals and widening their product portfolio, 
r = .187 ,N=73,p> .05,2-tail. I 
There is moderate correlation between 
• strategic alliances between Indian and foreign pharmaceutical companies and 
launching new generics in domestic market, r = .324, N = 73, p <.05, 2- tail. 
• New patents and launching new generics in foreign market, r = .358, N = 73, p < .05, 
2- tail. 
• gaining Wide portfolio and launching new generics in foreign market, r = .388, N = 
73, p<.05, 2-tail. I 
There is significant correlation between 
• strategic alliances between Indian and foreign pharmaceutical companies and 
launching new generics in the foreign market, r = .452, N = 73, p<.05, 2- tail. 
• strategic alliances between Indian and foreign pharmaceutical companies and launch 
new patents, r = .403, N = 73, p<.05, 2- tail. 
• launching New patents and Launching new generics in the domestic market, r = . 448, 
N=73,p<.05,2-tail 
• New patents and Product portfolio enhancement, r = .410, N = 73, p < .05, 2- tail. 
Table 43c Implications of Strategic Alliance on Products-Model Summary 
Model 
1 
R 
.526' 
R Square 
.111 
Adjusted R 
Square 
.234 
Std. Error of 
the Estimate 
1.041 
Change Statistics 
R Square 
Change 
.277 
F Change 
6.503 
dn 
4 
df2 
68 
Sig.F 
Change 
.000 
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Model 
i (Constant) 
Products-Newpatents 
Products-New generics abroad 
Products-New generics domestic 
Products-Wide portfolio 
Unstandardized 
CoefTicients 
B 
.302 
.418 
.490 
-.009 
-.145 
Std. Error 
.770 
.165 
.171 
.198 
.212 
Standardized 
Coefficients 
Beta 
.304 
.379 
-.006 
-.082 
T 
.392 
2.529 
2.870 
-.044 
-.682 
Sig. 
.696 
.014 
.005 
.965 
.498 
When implication of strategic alliance on product related factors alliances between Indian 
and foreign pharmaceutical companies was predicted, it was found that need to achieve 
launching new patented products (P=-0.304, p<0.05) and launching new generics in the 
foreign market ( P= .379, p> 0.05) were significant predictors. 
However Launching new generics in domestic market ( (5= -. 006, p> 0.05) and enhancing 
Product portfolio (J3'= -.082, p>0.05) are not significant predictors. 
The overall model fit was R- = 0.277 
5.11.2 Strategic Alliance and Implication on Marketing 
Table 44a Test statistics- Implications of Strategic Alliance on Marketing 
. . flll .: *. . . . , . , ,,„ " „ , . _ , . , „ „ „ „ . , M e a j l „ _ „ _ . . 
Type of Activity 2.16 
Marketing-Regulated market 3.6986 
Marketing-Investment capability 3.8082 
Marketing-Foreign distribution 3.7397 
„„,,;„, Std, Deviation , 
1.214 
.66007 
.73895 
.76426 
N :„„: 
73 
73 
73 
73 
Table 44b Implications of Strategic Alliance on Marketing- Correlation 
Pearson Correlation Type of Activity 
Marketing-Regulated market 
Marketing-Investment capability 
Marketing-Foreign distribution 
1.000 
.305 
.423 
.466 
Marketing-
Regulated 
tuarket 
.305 
1.000 
.364 
.448 
Markcting-
Investmeni 
capability 
.423 
.364 
1.000 
.451 
Marketing-
l'( reign 
disti ibution 
.466 
.448 
.451 
1.000 
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Sig. (2-tailed) Type of Activity 
Mariceting-Regulated market 
Marketing-Investment capability 
Marketing-Foreign distribution 
.004 
.000 
.000 
.004 
.001 
.000 
.000 
.001 
.000 
.000 
.000 
.000 
A correlation for the data revealed that, 
There is moderate correlation between strategic alliances between Indian and foreign 
pharmaceutical companies and their entry into regulated markets, r = .305, N = 73, p <.05, 
2- tail. I 
There is strong correlation between 
• .strategic alliances between Indian and foreign pharmaceutical companies their 
enhanced investment capability, r = .423, N = 73, p<.05, 2- tail. 
• strategic alliances between Indian and foreign pharmaceutical companies and 
accessing foreign distribution channel, r = .466, N = 73, p < .01, 2- tail. 
• Entry to regulated markets and enhanced access to foreign distribution channels, r 
= .448, N=^ 73, p<.01,2-tail 
• Enhanced investment capability and enhanced access to foreign distribution channels, 
r = .451,N=73,p<.01,2-tail. 
There is moderately significant correlation between enhanced investment capability and 
access to regulated markets, r=.364,N=73,p<.01, 2- tail. 
Table 44c Implications of Strategic Alliance on Marketing-Model Summary 
Model 
1 
R 
.527" 
R Square 
.278 
Adjusted R 
Square 
.246 
Std. Error of 
the Estimate 
1.054 
Change Statistics 
R Square 
Change 
.278 
F Change 
8.841 
dfl 
3 
df2 
69 
Sig.F 
Change 
.000 
Model 
1 (Constant) 
Mk-Regulated market 
Mk-Investment capability 
Mk-Foreign distribution 
Unstandardized 
Coefficients 
B 
-1.795 
.128 
.415 
.509 
Std. Error 
.843 
.215 
.192 
.194 
Standardized 
Coefficients 
Beta 
.070 
.253 
.321 
t 
-2.128 
.597 
2.158 
2.629 
Sig. 
.037 
.552 
.034 
.011 
158 
When implication of strategic alliance on product related factors alliances between Indian 
and foreign pharmaceutical companies was predicted, it was found that increase in investment 
capability (p=-0.253 , p<0.05) and access to foreign distribution network market ( P= .321 , 
p< 0.05) were significant predictors. 
However access to regulated market ( p= .07, p> 0.05) is not a significant predictor. 
The overall model fit was R- = 0.278 
5.11.3 Strategic Alliance and 
Tabic 45 a Test slalistics—Implicatioi 
' '•l^^^K"' 
Type of Company 
Technology-New technology 
Technology-R&D capability 
Technology-GMP compliance 
Technology-Access to information 
Implication 
IS of Strategic 
fa^.a. 
on Technology 
Alliance on Tephnology 
| i | | | | | | l | iM^HK, 
2.23 
3.3562 
3.0959 
3.4932 
3.6164 
1 
Std. Deviation 
1.219 
.85586 
1.05626 
.80144 
.77514 
N 
73 
73 
73 
73 
73 
Table 45b Imp! 
Pearson 
Correlation 
Sig. (2-tailed) 
cations of Strategic Alliance on 
^ J 
Type of Company 
Technology-New technology 
Technology-R&D capability 
Technology-GMP compliance 
Technology-Access to information 
Type of Company 
Technology-New technology 
Technology-R&D capability 
Technology-GMP compliance 
Technology-Access to information 
Technology- Correlation 
Type of 
CoiDpany 
1.000 
.132 
.295 
.250 
.463 
.132 
.006 
.016 
.000 
l-Ncu 
technoldg 
.132 
1,000 
.423 
.388 
.334 
.132 
.000 
.000 
.002 
••IF" ^ 
T-R&D 
capability 
.295 
.423 
1.000 
.567 
.470 
.006 
.000 
.000 
.000 
•|-(iMP i 
compliance 
.250 
.388 
.567 
1.000 
.510 
.016 
.000 
.000 
.000 
-.\cccssi 
(0 
ilonmiti 
on 
.463 
.334 
.470 
.510 
1.000 
.000 
.002 
.000 
.000 
A correlation for the data revealed that, 
There is no correlation between strategic alliances between Indian and foreign 
pharmaceutical companies and their access to new technologies, r = .132, N = 73, p> .05, 2-
tail. I 
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There is moderate correlation behveen 
• pharmaceutical companies with differing activities and enhanced R&D capabilities, r 
= .295,N=73,p<.05,2-tail. 
• strategic alliances behveen Indian and foreign pharmaceutical companies and 
acquiring GMP compliant manufacturing facilities, r = .250, N = 73, p <.05, 2- tail 
Table 45c Implications of Strategic Alliance on Technology- Model Summary 
Model 
1 
R 
.475' 
R Square 
.226 
Adjusted R 
Square 
.180 
Std. Error of 
the Estimate 
1.104 
Change Statistics 
R Square 
Change 
.226 
F Change 
4.951 
dfl 
4 
df2 
68 
Sig.F 
Change 
.001 
There is strong correlation between 
• strategic alliances between Indian and foreign pharmaceutical companies and their 
enhanced access to information, r = .463, N = 73, p <.05, 2- tail 
• Accessing new technology and enhanced R&D capabilities, r = .423 , N = 73, p <.05, 
2- tail. 
• enhanced R&D capabilities and achieving GMP compliant manufacturing facilities, r 
= .567,N= 73,p<.05,2-tail. 
• achieving GMP compliant manufacturing facilities and Accessing new information, r 
= .5I0,N=73,p<.05,2-tail. 
There is moderate correlation between 
• Accessing new technology and achieving GMP compliant manufacturing facilities , r 
= .388,N=73,p<.05,2-tail 
• Accessing new technology and Accessing new information , r = .334 , N = 73, p <.05, 
2- tail 
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IVhen implication of strategic alliance on technology related factors alliances between 
Indian and foreign pharmaceutical companies was predicted, it was found that ability to 
access new information ((3=0.433 , p<0.05) was significant predictor. 
However achieving Accessing new technology ( (3= -.059, p> 0.05) , Achieving R&D 
capability (([3= .128, p>0.05 )and accessing GMP compliant facilities (P= -.021, p>0.05) 
are not significant predictors. The overall model fit was R^ = 0.226 
5.11.4 Strategic Alliance and Implication on Manufacturing 
Table 46a Test statistics- Implications 
Annual Turnover 
Manufacturing-Cost optimization 
Manufacturing-Common assets 
Manufacturing-Quality management 
of Strategic Alliance on Manufacturing 
2.88 
3.0959 
3.0959 
3.4521 
1.190 
.71033 
.95981 
.70791 
73 
73 
73 
73 
TiihL' 46b Implications of Strategic Alliance or, \tiiniifactiiring- Correlation 
M- Cost M-Commoi M-(.)ualil\ 
Pearson 
Correlation 
Sig. (2-tailed) 
Annual Turnover 
Manufacturing-Cost optimization 
Manufacturing-Common assets 
Manufacturing-Quality management 
Annual Turnover 
Manufacturing-Cost optimization 
Manufacturing-Common assets 
Manufacturing-Quality management 
1 umovcr 
1.000 
.261 
.120 
-.164 
.013 
.156 
.083 
opitinj/auon 
.261 
1.000 
.475 
.272 
.013 
.000 
.010 
assets 
.120 
.475 
1.000 
.487 
.156 
.000 
.000 
mamigeroent 
-.164 
.272 
.487 
1.000 
.083 
.010 
.000 
A correlation for the data revealed that. 
There is moderate correlation between strategic alliances between Indian and foreign 
pharmaceutical companies and Cost optimization, r = .261, N = 73, p <.05, 2- tail. 
There is no correlation between 
• strategic alliances between Indian and foreign pharmaceutical companies the need to 
optimization of common assets, r = . 120, N = 73, p>.05, 2- tail. 
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• strategic alliances between Indian and foreign pharmaceutical companies and Quality 
Management, r = -.164, N = 73, p> .05, 2- tail. 
• Quality management and Cost optimization among pharmaceutical companies, r=.272, 
N=73,p< 0.05,2 -tail 
There is a strong correlation between 
• Optimizing common assets and Cost optimization among pharmaceutical companies, 
r=.475,N=73,p <0.000, 2- tail 
• Quality management and Optimizing common assets among pharmaceutical companies, 
r=.487,N=73, p<0.05, 2-tail 
Table 46c Implications of Strategic Alliance on Manufacturing- Model Summary 
Model 
1 
R 
.373" 
R Square 
.139 
Adjusted R 
Square 
.102 
Std. Error of 
the Estimate 
1.127 
Change Statistics 
R Square 
Change 
.139 
F Change 
3.721 
dn 
3 
df2 
69 
Sig.F 
Chang 
e 
.015 
Model 
Un standardized Coefficients 
Std. Error 
Standardized 
Coefficients 
Beta t Sig. 
(Constant) 
M-Cost optimization 
M-Common assets 
M-Quality management 
2.682 
.467 
.169 
-.514 
.784 
.213 
.174 
.215 
.279 
.137 
-.306 
3.421 
2.195 
.975 
-2.390 
.001 
.032 
.333 
.020 
When implication of strategic alliance on Manufacturing related factors alliances between 
Indian and foreign pharmaceutical companies was predicted, it was found that need for cost 
optimization ((5=-0.279, p<0.05) was significant predictors. 
However achieving Utilization of common assets ( P~ -137, p> 0.05) and Enhancing 
Quality management capability ((fi= -.306, p<0.05 ) are not significant predictors. The 
overall model fit was R-^0.13 
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5.11.5 Strategic Alliance and Implication Competitive Advantage 
Table 47a Test statistics—Implications of Strategic Alliance on Competitive Advantage 
1 . 
Type of Activity 
CA- Increased market share 
CA-Increased profits 
CA-Established new brands 
CA-Manageria! capabilities 
2.16 
3.9178 
3.9726 
3.8767 
3.7260 
« „ESll-JJsxiatiQa,„,, „ 
1.214 
.74075 
.81603 
.70603 
.73144 
^ nl:z 
73 
73 
73 
73 
73 
Table 47b Implications of Strategic Alliance on Compel'. 
p ^ ^ — ' 7 5 ™ ^ • ....::••••• r 
:e-Correlation 
'.'".•s '-"---rr-
Pearson 
Correlation 
Sig. 
(2-tailed) 
Type of Activity 
CA-lncreased market share 
CA- Increased profits 
CA-Established new brands 
CA-Managerial capabilities 
Type of Activity 
CA-Increased market share 
CA-Increasedprofits 
CA-Established new brands 
CA-Managerial capabilities 
1.000 
.154 
.229 
.300 
.255 
.096 
.026 
.005 
.015 
.154 
1.000 
.571 
.379 
.317 
.096 
.000 
.000 
.003 
.229 
.571 
1.000 
.500 
.546 
.026 
.000 
.000 
.000 
^tablished 
,n$K.bt«pds-
.300 
.379 
.500 
1.000 
.472 
.005 
.000 
.000 
.000 
CA- a 
.255 
.317 
.546 
.472 
1.000 
.015 
.003 
.000 
.000 
A correlation for the data revealed that, 
There is no correlation between strategic alliances between Indian and foreign 
pharmaceutical companies and the need to enhance market position, r = .154, N = 73, p > .05, 
2- tail. 
There is moderate correlation between 
strategic alliances between Indian and foreign pharmaceutical companies and the need 
to increase profits, r = .229, N = 73, p <.05, 2- tail. 
strategic alliances between Indian and foreign between pharmaceutical companies and 
the need to enhance managerial capabilities, r = .255, N = 73, p<.05, 2- tail, 
strategic alliances between Indian and foreign pharmaceutical companies and need to 
establish new brands, r = .300, N = 73, p < .05, 2- tail 
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Table 47c 
Model 
1 
Implications of Strategic Alliance 
R 
.329" 
R 
Square 
.108 
Adjusted R 
Square 
.056 
on Compe 
Std. Error of 
the Estimate 
1.179 
Model 
1 (Constant) 
Competitive Advantage-Increased 
maricet share 
Competitive Advantage-Increased 
profits 
Competitive Advantage-
Established new brands 
Competitive Advantage-
Managerial capabilities 
Htive Advantage - Model Summary 
Change Statistics 
R Square 
Change 
.108 
Un standardized 
Coefficients 
B 
-.362 
.007 
.077 
.366 
.207 
Std. Error 
.967 
[231 
.241 
.239 
.236 
F Change 
2.062 
dn 
4 
Standardized 
Coefficients 
Beta 
.005 
.052 
.213 
.125 
df2 
68 
t 
-.374 
.032 
.319 
1.536 
.877 
Sig.F 
Change 
.095 
Sig. 
.710 
.974 
.751 
.129 
.384 
When the implication of strategic alliance on Competitive Advantage related factors 
alliances between Indian and foreign pharmaceutical companies was predicted, it was found 
that need for establishing new brands (P= 0.213, p>0.05) was moderately significant 
predictor. 
However achieving Increase market shares ( (5= .005, p> 0.05) and Increase profits 
((f^= .052, p<0.05 ) and Enhance Managerial capabilities (7?= .256, p> 0.05) are not 
significant predictors. 
The overall model fit was R^ = 0.108. 
5.12. Correlation Between the Strategic Alliances and Identified Hindrances for Strategic 
Alliances 
5.12. External and Internal Hindrances for strategic alliances between Indian and foreign 
pharmaceutical companies 
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Table 48a Test statistics- External and Internal Hindrances for Strategic Alliance 
Deviation 
Annual Turnover 
External Hindrances-Information 
External Hindrances-Govt. policies 
Internal Hindrances-Unclear objectives 
Internal Hindrances-Lack of communication 
Internal Hindrances-Non monitoring of alliance 
Internal Hindrances-Lack of trust 
2.88 
3.3836 
3.5205 
3.3425 
3.7123 
3.6849 
3.7945 
1.190 
.98079 
.80121 
.73066 
.73559 
.66409 
.79859 
73 
73 
73 
73 
73 
73 
73 
Table 4Hb External and Internal Hindrances for Strategic Alliance- correlation 
Pearson 
Correlation 
Sig. (2-tailed) 
Annual Turnover 
E- Information 
E-Govt. policies 
I-Unclear objectives 
I-Lack of communication 
I-Non monitoring of alliance 
I-Lack of trust 
Annual Turnover 
E-lnformation 
E-Govt. policies 
I-Unclear objectives 
I-Lack of communication 
I-Non monitoring of alliance 
1-Lack of trust 
1.000 
-.126 
-.063 
.193 
.102 
-.243 
-.012 
.145 
.299 
.051 
.196 
,019 
.458 
-.126 
1.000 
.679 
.085 
.251 
.060 
.084 
.145 
.000 
.236 
.016 
.307 
.239 
ft/ '^ 
-.063 
.679 
1.000 
.071 
.187 
.130 
.191 
.299 
.000 
.276 
.057 
.137 
.053 
- J " " J ^ 
.193 
.085 
.071 
1.000 
.625 
.397 
.241 
.051 
.236 
.276 
.000 
.000 
.020 
.102 
.251 
.187 
.625 
1.000 
.381 
.465 
.196 
.016 
.057 
.000 
.000 
.000 
(-Non 
monttoring 
Dfailiaijcc 
-.243 
.060 
.130 
.397 
.381 
1.000 
.531 
.019 
.307 
.137 
.000 
.000 
.000 
-.012 
.084 
.191 
.241 
.465 
.531 
1.000 
.458 
.239 
.053 
.020 
.000 
.000 
A correlation for the data revealed that, There is a no significant correlation between 
strategic alliances between Indian and foreign pharmaceutical companies and 
external hindrance namely lack of information, r = -. 126, N = 73, p > .05, 2- tail. 
strategic alliance between Indian and foreign pharmaceutical companies and external 
hindrance namely government policies, r = -.063, N = 73, p >.05, 2- tail. 
strategic alliances between Indian and foreign pharmaceutical companies and 
internal hindrance of unclear objectives, r = .193, N = 73, p >.05, 2- tail. 
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strategic alliance between Indian and foreign pharmaceutical companies and 
internal hindrance of lack of communication, r = .102, N = 73, p >.05, 2- tail, 
strategic alliance between Indian and foreign pharmaceutical companies and 
internal hindrance of mm monitoring of alliance, r = -.243, N = 73, p <.05, 2- tail, 
between strategic alliance between Indian and foreign pharmaceutical companies 
pharmaceutical companies and internal hindrance of lack of trust, r = -. 012, N = 73, 
p>.05,2-tail. 
Table 48c External and Internal Hindrances for Strategic Alliance- Mode 
Model 
1 
R 
.445' 
R Square 
.198 
Adjusted R 
Square 
.125 
Std. Error of 
the Estimate 
1.113 
' Summary 
Chan 
R Square 
Change 
.198 
F 
Change 
2.715 
ge Statistics 
dn 
6 
df2 
66 
Sig.F 
Change 
.020 
Model 
1 (Constant) 
Ext-lnformation 
Ext-Govt. policies 
Int-Unclear objectives 
Int-Lack of communication 
Int-Non monitoring of alliance 
Int-Lack of trust 
Unstandardized 
Coefficients 
B 
3.526 
-.242 
• 111 
.530 
.076 
-.822 
.199 
Std. Error 
.976 
.188 
.228 
.241 
.260 
.247 
.212 
Standardized 
Coefficients 
Beta 
-.200 
.075 
.326 
.047 
-.459 
.133 
t 
3.613 
-1.289 
.489 
2.197 
.292 
-3.330 
.935 
Sig. 
.001 
.202 
.626 
.032 
.771 
.001 
.353 
When External Hindrances to strategic alliance was predicted, it was found that need for lack 
of information (/3= -0.200 , p>0.05) and Government policies (p=-0.075 , p>0.05) are 
not significant predictor. 
When Internal Hindrances to strategic alliance was predicted, it was found that Unclear 
Objectives (fi^ .326 , p< 0.05) is a significant predictor. 
However, Lack of communication ({3= .047 , p>0.05), and Lack of Trust (P= . 133 , p> 
0.05) are not significant factors . 
Non monitoring of alliance (P= -.459 , p< 0.05) has a strong negative correlation. 
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5.13. Summary: Correlation 
a. Factors that influence Indian pharmaceutical companies to form strategic alliances with foreign 
pharmaceutical firms. 
Table 49 - Summary of Reasons for Strategic Alliances 
Product 
Marketing 
Technology 
Manufacturing 
Competitive Advantage 
Strengthen product portfolio 
Establish brands abroad 
Launch new products 
Global emerging markets 
Regulated markets 
Distribution channels abroad 
Access new technology 
Collaborative R&D 
USFDA approvals 
Cost minimization 
Common assets 
Quality management 
Market position 
Financial power 
Image 
Coireladon 
.343 
.280 
.066 
.328 
.345 
.259 
.025 
.300 
.134 
-.138 
.162 
-.162 
.063 
.315 
.296 
fijflueuce 
Moderate 
Moderate 
Low 
Moderate 
Moderate 
Moderate 
Low 
Moderate 
Low 
Low 
Low 
Low 
Low 
Moderate 
Moderate 
R square 
.126 
.159 
.095 
.108 
.145 
b. Impact of the strategic alliances between Indian and foreign pharmaceutical companies on various 
business aspects of the Indian pharmaceutical firm. i 
Table 50 - Summary of Implications of Strategic Alliances 
Product 
Marketing 
Technology 
Manufacturing 
New patents 
New generics abroad 
New generics domestic 
Wide portfolio 
Regulated market 
Investment capability 
Foreign distribution 
New technology 
R&D capability 
GMP compliance 
Access to information 
Cost optimization 
p^ri-elation 
.403 
.452 
.324 
.187 
.305 
.423 
.466 
.132 
.295 
.250 
.463 
.261 
Impact 
High 
High 
Moderate 
Low 
Moderate 
High 
High 
Low 
Moderate 
Moderate 
High 
Moderate 
R stjuare 
.277 
.278 
.226 
.139 
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Competitive Advantage 
Common assets 
Quality management 
Increased market share 
Increased profits 
Established new brands 
Managerial capabilities 
.120 
-.164 
.154 
.229 
.300 
.255 
Low 
Low 
Low 
Moderate 
Moderate 
Moderate 
.108 
c. External and Internal hindrances for the formation of strategic alliances between Indian and foreign 
pharmaceutical companies. 
Table 51 - Summary of Hindrances for Strategic Alliance 
I 
L.xtema! 
Internal 
Intorniation 
Govt, policies 
Unclear objectives 
Lack of communication 
Non monitoring of alliance 
Lack of trust 
-.126 
-.063 
.193 
.102 
-.243 
-.012 
Negative 
Negative 
Low 
Low 
Negative 
Negative 
.198 
5.14. Proposed Model for Strategic Alliance between Indian and Foreign Pharmaceutical 
Companies 
lustration 14: Proposed Model 
Reasons for Strategic Alliance 
PRODUCT 
MARKETING 
TECHNOLOGY 
MANUFACTURING 
COMPETITIVE 
ADVANTAGE 
Hindrances 
External 
STRATEGIC 
ALLIANCES 
'i A A. 
Internal 
Impact of Strategic Alliance 
1i 
,.:f 
• 
""•A 
''< 
PRODUCT 
MARKETING 
TECHNOLOGY 
MANUFACTURING 1 
COMPETITIVE 
ADVANTAGE 
The model depicts three aspects, the reasons for strategic alliance between Indian and 
foreign pharmaceutical companies, the impact of the alliance on business and the factors that 
hinder the formation and success of the alliances. All the five factors namely, product, 
marketing, technology, manufacturing and competitive advantage play a role in the 
formation of strategic alliances between Indian and foreign pharmaceutical companies. The 
level of influence is dependent on the type of company, its activities and business objectives of 
growth. Positive impact of strategic alliances between Indian and foreign pharmaceutical 
companies is observed on various aspects of the business namely, product, marketing, 
technology, manufacturing and competitive advantage. The impact of the alliances would 
depend on the focus of the company going for the alliance. The model depicts the influence of 
factors both external and internal which can prove to be hindrance for the .success of the 
strategic alliance between Indian and foreign pharmaceutical companies 
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CHAPTER 6 
CONCLUSIONS AND RECOMMENDATIONS 
CHAPTER 6: CONCLUSIONS, RECOMMENDATIONS AND DIRECTIONS FOR 
FUTURE RESEARCH 
6.1 Conclusions for the Main Research Problem 
After analyzing the primary data, the following conclusions can be drawn with reference 
to reasons for strategic alliances, impact of strategic alliances and the hindrances for 
strategic alliance between Indian and foreign pharmaceutical companies. However the 
expected outcome of these factors differs from company to company. 
6.1.1 Conclusions Relating to Reasons for Strategic Alliance between Indian and Foreign 
Pharmaceutical Companies: 
• Strengthen product portfolio 
This research work has indicated that for Indian pharmaceutical companies a driving factor 
for the formation of Strategic alliances between Indian and foreign pharmaceutical companies 
is the need to strengthen the existing product portfolio of Indian companies. Mueller (2007) 
had identified this as a reason for strategic alliances among pharmaceutical companies. Dr. 
Reddy's which started off as an API and bulk drugs manufacturing company is foraying 
today into the biosimilar segments, with an alliance with Merck Serono to co develop new 
molecules for the oncology segment. 
• Establish new brands abroad 
Primary research indicates that Indian pharmaceutical companies look at strategic alliances 
with foreign pharmaceutical companies, to establish their products and brands in the foreign 
market. This is also substantiated by Pradhan (2007). Ipca has entered into a strategic alliance 
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with Heritage Pharmaceuticals (USA) for the development, supply and marketing of generic 
pharmaceutical products to the US prescription drug market. 
• Launch new product lines 
Research indicates that Indian companies seek alliances with foreign pharmaceutical firms to 
enable them launch new products in the market. Alliances help companies launch product 
faster to meet the growing demands. Panacea Biotech's alliance with Kremers Urban (USA) 
includes launch of 11 high barrier generic compounds, the first one being Tacrolimus 
capsules. 
• Enter global emerging markets 
Expanding the market by entering new emerging markets is a strong driver for Indian 
pharmaceutical companies to form strategic alliances with foreign pharmaceutical 
companies. Pradhan (2007), Parvatiyar and Gupta(199$), Smith (2000) have indicated this 
to be a key reason for staretgic alliances. Indoco Remedies and Aspen have inked an 
alliance to supply of ophthalmic products for 30emerging markets in 2012. Dr Reddy's and 
GSK have entered into an alliance to develop & market branded generics for emerging market 
• Enter regulated markets 
Indian pharmaceutical companies consider entry into regulated market like US, UK, 
European Union as the third most important reason which drives strategic alliances between 
Indian and foreign pharmaceutical companies. This is also evidenced by the fact that many 
Indian pharmaceutical companies have acquired pharmaceutical companies in the desired 
markets and created their own subsidiaries. Cipla's alliance with Watson pharma (USA) 
focused on 60 generic products to be developed and launched in the US market. 
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• Establish distribution channels abroad 
The need to establish new distribution channels in foreign market which will eventually 
help in marketing the products, drives strategic alliances between Indian and foreign 
pharmaceutical companies. Parvatiyaribnd Gupta(1994) have established this as a key 
reason for alliances. 
• Access new technology 
Research indicates that Indian pharmaceutical companies consider gaining access to new 
technology as a reason that can drive strategic alliances between Indian and foreign 
pharmaceutical companies. Greene(2007), Smith (2000),Chaturvedi and Chataway(2006), 
concluded that one of the key motivators for strategic alliances between firms is to access 
new technology. 
• Undertake collaborative R&D 
Indian companies consider collaborative R&D as a driver for strategic alliances between Indian 
and foreign pharmaceutical companies. Narula and Dunning (1998), have indicated that 
collaborative R&D encourages Alliances. However this reason may not hold good for all 
Indian pharmaceutical companies, as R&D costs in India are much lower and not all Indian 
pharmaceutical companies have the orientation towards R&D. DRL has launched a drug 
discovery program by creation Dr. Reddy's Research Foundation in 1992, to boost R&D. The 
first NCE that came out of India was a molecule called DRF- 2725, which was licensed 
out to Nova Nordisk for trials and was launched in 2011. 
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• Obtain USFDA approved manufacturing facilities 
Pharmaceutical companies in India look at strategic alliances with foreign pharmaceutical 
companies to gain access to USFDA approved manufacturing facilities. Although Greene 
(2007)and Pradhan and Abraham (2005) indicated this to be a driver, it is s not a very 
strong driving force among Indian pharmaceutical companies and may be limited to firm 
specific driver. 
• Cost minimization 
Research indicates that cost minimization is a factor that can influence the formation of 
strategic alliances between Indian and foreign pharmaceutical companies. However not all 
pharmaceutical companies consider this to be a driving factor especially with reference to the 
Indian pharmaceutical companies. 
• Achieve operational synergy 
Achieving operational synergy may be a reason for strategic alliances between two firms, 
however with respect to Indian and foreign pharmaceutical companies, this is not a strong 
driving factor for Indian pharmaceutical companies to look at strategic alliances with 
foreign pharmaceutical companies. 
• Achieve quality management 
Gaining knowledge on quality related aspects and managing overall quality is a driver for 
strategic alliances. However with respect to Indian pharmaceutical companies, this is not a very 
critical driver for strategic alliances with foreign pharmaceutical companies. 
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• Achieve market position 
This research has indicated that achieving high market position is a key factor which 
drives Indian pharmaceutical companies to form strategic alliances with foreign 
pharmaceutical companies. This also stems from the fact that achieving high market 
position is a growth objective of a company, and strategic alliances can help achieve high 
growth objectives. Companies like Ranbaxy, Piramal lifescience, Glenmark, Sun Pharma, DRL, 
APL and Lupin have achieved high market positions over the years 
• Achieve financial power 
The need to have adequate financial power through high profits is a strong driver for 
Indian pharmaceutical; companies to form strategic alliances with foreign pharmaceutical 
companies. Cipla and Ranbaxy have become top pharmaceutical companies in India thanks to 
many alliances which has helped them gain higher sales turnover, which has helped them 
gather high financial power. 
• Enhance company image 
This research indicates that Indian pharmaceutical companies feel that the primary reason for 
strategic alliances between Indian and foreign pharmaceutical companies is the need to 
enhance the company image and score on competitive advantage. This will eventually 
influence the profitability and stocks of the Indian pharmaceufical companies. 
6.1.2 Conclusions Relating to Impact of Strategic Alliance 
Analysis of the primary data from Indian pharmaceutical companies indicate that strategic 
alliances between Indian and foreign companies has a direct impact on new patent filing and 
new product launches from Indian pharmaceutical companies. 
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• Strategic alliances and introduction of new patents from Indian pharmaceutical 
companies 
The response from the Indian companies indicates that there is a strong impact of strategic 
alliances with foreign pharmaceutical companies on the introduction of new patents by the 
Indian pharmaceutical companies. Nerkar and Roberts(2004) and Mueller (2007), have 
established that strategic alliances have a positive effect on the launch of patented 
molecules among pharmaceutical companies. Indian pharmaceutical companies undertaking 
various activities like manufacturing, R&D, contract manufacturing and distribution and 
across size of company, have implied impact of strategic alliance with foreign 
pharmaceutical companies on new patents from Indian pharmaceutical companies. 
• Strategic alliances and launch of generic products abroad 
This research indicates that there is a strong impact of strategic alliances with foreign 
pharmaceutical companies on the launch of generic products abroad in foreign markets. Gehl 
Sampath(2005), established the contribution of strategic alliances on launch of generic 
molecules abroad. Companies like Cipla, Ranbaxy, Lupin and Glenmark have made their 
mark in the international market with high quality generics which were marketed abroad 
through a number of strategic alliances. Here are a few more alliances in recent times. 
- Strides Arcolab Ltd. and GSK to supply of drugs for semi-regulated markets 
- Torrent Pharmaceuticals and AstraZeneca Supply of 18 products for various markets 
- Strides Arcolab Ltd. and Pfizer to supply of 67 generic drugs to Pfizer with focus on 
oncology 
• Strategic alliances and launch of generic products in domestic market 
This study indicates that the Indian pharmaceutical companies of varying sizes find that 
strategic alliances between Indian and foreign pharmaceuticals impact the launch of generic 
products in the domestic market. However, research indicates that the impact on the launch of 
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generic products in India is moderately attributed to strategic alliances between Indian and 
foreign pharmaceutical companies. 
• Strategic alliances and enhanced product portfolio 
This research indicates that Indian pharmaceutical companies across various pharmaceutical 
activities like manufacturing R&D, contract manufacturing and distribution, feel the impact 
of strategic alliances with foreign pharmaceutical companies on their portfolios positively. 
• Strategic alliances and access to regulated markets 
Primary research indicates that strategic alliances between Indian and foreign pharmaceutical 
companies have a positive influence in helping Indian pharmaceutical companies gain access 
into regulated markets like US and Europe. Greene (2007) and Gehl Sampath(2005), have 
established a strong influence of strategic alliances on access to new markets both regulated 
and emerging. Osmotica Pharmaceutical Corp. has announced a strategic alliance agreement 
between Panacea Biotec and Osmotica Kft. for the research, development and 
commercialization of brand and generic products in the United States and key strategic markets 
across the globe. 
• Strategic alliances and investment in sales and marketing 
Primary research indicates that strategic alliances between Indian and foreign pharmaceutical 
companies have a considerable impact in enhancing marketing capability, across all sizes, 
types and activities of the Indian pharmaceutical company. Chitoor, Ray and Sarkar 
('2005y)indicated that alliances enhance investment capabilities among organizations. 
Lupin has signed a deal with Eli Lilly for anti-diabetic drugs. Under the deal. Lupin will market 
and distribute the entire range of Huminsulin brand of Eli Lilly in India and Nepal. Lupin will 
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deploy 300 sales representatives from its formulations business to promote the product and will 
also provide education to physicians and patients. 
• Strategic alliances and access to foreign distribution network. 
Primary research indicates that strategic alliances between Indian and foreign pharmaceutical 
companies have considerably influenced Indian companies, of different sizes, activities and 
types, to gain access into distribution channels in foreign market. Strategic alliances between 
Indian and foreign pharmaceutical companies have helped gain access to channels in foreign 
markets like-Africa, Latin America, Asia Pacific and other regions. 
• Strategic alliances and access to new technology 
Primary research indicates that strategic alliances between Indian and foreign pharmaceutical 
companies have no impact on the acquisition of new technology by Indian pharmaceutical 
companies. Alliances that have occurred before 1999, are predominantly driven by 
manufacturing needs which in turn are technology related. In the current scenario, Indian 
pharmaceutical companies are not undertaking alliances with foreign pharmaceutical 
companies with only technology based reasons. Across all the pharmaceutical companies in 
the study, both with respect to turnover and type of activity undertaken, the companies indicate 
that there is no great impact of alliances on the technology related aspects. 
The recent alliance between DxTech and Piramal indicates just that aspect. The alliance 
includes a license and development agreement relating to DxTech's proprietary technology to 
establish a joint venture between the companies for the marketing and sales of the commercial 
product. 
• Strategic alliances and achieving R&D capability 
Primary research indicates that strategic alliances between Indian and foreign pharmaceutical 
companies have helped Indian companies achieve R&D capability.Indian pharmaceutical 
companies are moving from traditional manufacturing related activities towards R&D and 
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research and strategic alliances are proving to be one of the routes that companies are resorting 
to. 
- Glenmark has entered into an alliance with Forest Laboratories for R&D in Asthma 
and lung infection areas 
- Piramal Resarch is collaborating with Merck for cancer research 
In this study across various types of Indian companies the alliances have helped in the 
development of R&D capability. This is also the case for companies with varying types of 
activity. Indian companies involved in contract manufacturing and distribution are not really 
impacted with R&D capability enhancement through alliances. Strong manufacturing based 
and R&D companies are undertaking alliances which will help them develop their R&D. Most 
companies who seek out alliances for R&D purposes are in the high turnover category. 
Literature references that have corroborated this aK, Linton and Corrado(2007), Kiran and 
Mishra (2009), Bower and Sulej (2007), Gehl Sampath (2005). 
• Strategic alliances and GMP compliant production capacities 
Primary research indicates that strategic alliances between Indian and foreign pharmaceutical 
companies have an impact on Indian companies gain GMP compliant capacities. Indian 
pharmaceutical companies have modern manufacturing facilities which have been used to 
produce generic drugs through reverse engineering processes. There are more than 175 
USFDA and nearly 90 UK-MHRA approved manufacturing facilities in India. Indian 
pharmaceutical companies have been undertaking exports to both regulated and emerging 
markets. Parvatiyar and Gupla(1994) and Gehl Sampath (2005) have acknowledged the 
impact of strategic alliances on modem , GMP compliant manufacturing facilities. In this 
study Indian pharmaceutical companies have confirmed that strategic alliances have helped 
them develop regulatory compliant facilities in India. This is true for different types of 
Indian companies, with differing activities and turnover. However companies not involved in 
production related activities like those involved in R&D , distribution are not really concerned 
with acquiring regulatory approvals for their facilities. 
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• Strategic alliances and access to information 
Primary research indicates that strategic alliances between Indian and foreign pharmaceutical 
companies have helped Indian companies gain access to information. 
One key benefit that alliancing companies enjoy is the access to information. Indian 
pharmaceutical companies have not been innovators. The technologies and various 
developments are documented and upgraded in developed nations like Europe and US. 
When these nations outsource activities to Indian pharmaceutical companies, there is a need 
for harmonization of processes and protocols between the two entities. This calls for sharing 
of data and information, upgradation of processes and methodologies which gives way for 
shared information, beneficial to both the companies. Although there is scope for information 
sharing, the extent would depend on the kind of enterprise. The information is more relevant 
in companies undertaking outsourced R&D activities, in comparison to companies involved in 
distribution activities. 
The study indicates high data and information exchange in clinical research, R&D and 
manufacturing companies. Companies involved in R&D and clinical research have to 
exchange a lot of information between the alliancing firms. In addition the parent company 
involved in the alliance would transfer both tacit and practical knowledge to the other 
company. 
• Strategic alliances and cost optimization 
Primary research indicates that strategic alliances between Indian and foreign pharmaceutical 
companies have no impact on the cost optimisation in the manufacturing activities of Indian 
pharmaceutical companies. 
Aurobindo Pharma has entered into alliance with Astra Zeneca and Pfizer for the supply of 
generic drugs for developed and emerging markets. Novartis has entered into an alliances 
with Torrent Pharmaceuticals for contract manufacturing of formulations. It is a well 
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known fact that drug manufacture is economical In India In comparison to manufacturing 
costs in the developed countries. High costs of drugs and the constant pressure to reduce 
drug costs have encouraged foreign pharmaceutical companies to look, out for options to 
bring down costs. Indian pharmaceutical companies, with reverse engineering and technical 
knowledge have developed drug manufacturing facilities of international standards. 
From Indian company's point of view, there is no Impact of the strategic alliance on the 
optimization of costs. This result is the same across Indian pharmaceutical companies of 
different type, different activities and different turnover. 
• Strategic alliances and achieving operational synergy 
Primary research indicates that Indian pharmaceutical companies have no Implication on 
operational synergy sue to strategic alliances between Indian and foreign pharmaceutical 
companies . 
Literature indicates that strategic alliance helps in economy of scale due to downsizing and 
reduction In duplicity of work. Synergy can be achieved by understanding the many 
processes which are specific to a particular organization and processes which are being 
duplicated in both the organization. Common inputs, production process and facility, support 
function and distribution channels are some of the factors that can be common to the 
alliancing firms. Similarly patented process, customer contacts, sales process , product lines 
are some of the factors that are specific to a particular organization , which may remain 
unique. Understanding the duplicating functions and sorting them can help organizations 
release resources which can be utilized in other areas, thereby enhancing both productivity 
and profitability. 
The study indicates that although there is a considerable scope to achieve operational 
synergy, Indian pharmaceutical companies do not view achieving operational synergy 
between the alliancing company as a strong outcome of strategic alliance between Indian and 
foreign pharmaceutical company. Across all types of Indian pharmaceutical companies and 
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Indian companies performing different pharmaceutical related activities, operational synergy 
is not seen as an outcome of strategic alliance. 
• Strategic alliances and quality management 
Primary research indicates that strategic alliances between Indian and foreign pharmaceutical 
companies have no impact on cost optimisation in their manufacturing activities for Indian 
companies. 
One of the impact that alliances with foreign pharmaceutical have had on Indian 
pharmaceutical companies is the change in their quality management systems. Complying with 
GMP and regulatory needs is a compulsory norm for Indian pharmaceutical companies 
involved in exports to regulated countries. The Central Drugs Standard Control Organization, 
Ministry of Health and Family Welfare controls information on the regulatory requirement in 
India. Chaudhuri(2005), mentions that small pharmaceutical companies find it difficult to 
adhere to GMP standards as the investments for upgrading the production facilities and 
maintaining them is substantially high. Upto 1970, Schedule M of India's Drug and Cosmetic 
was in place. In 1991 after TRIPS and GATT, emphasis and awareness for the need of GMP 
in pharmaceutical manufacturing was highlighted. Small and medium size enterprises are still 
in the process of adopting GMPs. 
Many Indian companies have adopted quality management process as they were involved in 
exporting the drugs to foreign countries which were following GMP practices. 
The study indicates that pharmaceutical companies involved in API and formulations have 
been benefitted by strategic alliance to gather the technology to upgrade their manufacturing 
facilities to become quality compliant. However there is no direct correlation between strategic 
alliances and the enhanced quality procedures of Indian pharmaceufical companies. There are 
many factors like US FDA regulations, changes in the Schedule M which are more relevant 
and compelling reasons for companies to upgrade themselves and open up new markets for 
their products. 
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• Strategic alliances and increased market share 
Many pharmaceutical companies have increased their 
market shares over the years due to enhanced economic 
activities, which has increased their turnover and in turn increased their market share. 
Companies actively involved in enhancing their portfolio through strategic alliances have 
steadily increased their presence in the Indian pharmaceutical market. 
• Strategic alliances and increased overall profitability 
Primary research indicates that strategic alliances between Indian and foreign pharmaceutical 
companies have helped Indian companies achieve overall profitability. 
The profitability of the Indian pharmaceutical company is dependent on the overall turnover of 
the companies. In the last decade, Indian pharmaceutical companies have increased their profits 
many folds. This has been achieved by many activities like increased market penetration, 
enhanced products, diversified activities etc. Many of these activities are direct consequences 
of strategic alliances with many foreign pharmaceutical companies. 
In 2005, Cadila Healthcare earned profits of 192 cr, which grew to 657.5cr in 2012, Lupin 
grew from 180cr to 804.37cr, DRL increased their profits from 21.1 crto912.4cr , Cipla grew 
from 445.6 to 1123.96 and Sun Pharma from 668 to 1927.98 cr. {collated from quarterly 
economic times reports. 
In the study Indian pharmaceutical companies indicate a strong impact on the company's 
profitability which is attributed to the alliances between foreign pharmaceutical companies. 
Across all Indian pharmaceutical companies of various types , activities and turnover, the 
Indian pharmaceutical companies feel a positive relation between strategic alliances and 
profitability. This is also evident from the fact that the toplO Indian pharmaceutical companies 
have high turnover and profitability and also have undertaken maximum number of alliances 
in the last decade. 
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• Strategic alliances and brand building 
Primary research indicates that strategic alliances between Indian and foreign pharmaceutical 
companies have helped Indian companies enhance their brand value. 
Brand name and goodwill are two elements that is crucial for a pharmaceutical firm. Many 
Indian pharmaceutical companies have built strong brands and image for themselves in the 
international market. Indian companies were well known for their manufacturing capabilities 
thanks to reverse engineering methods adopted by them. This competency and adherence to 
Indian regulations built a strong domestic market. International markets required stringent 
adherence to international regulations and norms. Indian pharmaceutical companies started to 
concentrate on getting FDA approved manufacturing sites and ventured into international 
alliances which helped them build credibility and gain recognition. 
In the current study, companies with high turnover have indicated that strategic alliances 
with foreign pharmaceutical companies have helped them establish new brands and generate 
a brand name, Brands are an advantage for any organization , as they differentiate the 
organizations. In pharmaceutical industry, since new products are introduced frequently, a 
brand ensures recall which in turn ensures high revenues. Hence it is the endeavor of every 
pharmaceutical organization to create brands and ensure a constant stream of revenue for the 
organization. Cost efficiency, diversified portfolio, economic drivers and domestic presence 
makes Indian pharmaceutical companies a brand in itself This is further intensified by the 
alliances which have helped them become international in their activities and approach. 
• Strategic alliances and acquiring superior managerial skills 
Primary research indicates that strategic alliances between Indian and foreign pharmaceutical 
companies have helped Indian companies acquire superior managerial skills. 
Technical industrial like pharmaceutical is dependent on people and process for its long term 
success. Gaining knowledge on a specific activity in the pharmaceutical company involves 
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extensive training and on the job experience. Thus highly trained and qualified employees are 
an asset to the organization which adds to the competitive advantage quotient of the 
organization. Although Indian pharmaceutical companies have been recruiting qualified 
scientists inthe pharmaceutical sector, knowledge on regulations, audits, internationalization, 
processes are critical to every organization. One of the positive outcomes of strategic alliance 
between Indian and foreign pharmaceutical companies is the focus on training andhnical 
competency of the staff In addition to management of technical aspects, there is critical roles 
with reference to handling foreign delegation, auditors, inspectors and managing staff 
performance in a different cultural environment. 
The current study indicates that alliances between Indian and foreign pharmaceutical 
companies have indeed helped the develop management skills among the Indian companies. 
Across all companies of differing turnover, strategic alliances have influenced the acquisition 
of superior management skills among the managers which has added to the competitive 
advantage of the Indian organization. 
Strategic alliances between Indian and foreign pharmaceutical companies impact the following 
aspects of business namely: Product Marketing Technology Manufacturing and Competitive 
advantage 
Strategic alliances between Indian and foreign pharmaceutical companies impact many aspects 
of the business for Indian pharmaceutical companies. The impact is high in activities relating to 
new products, marketing and enhanced technology. Moderate impact is seen in case of 
manufacturing related activities and the aspects relating to competitive advantage of 
Indian pharmaceutical firms. 
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6.1.3 Conclusions Relating to Hindrances for Strategic Alliance 
The fallout of the alliance between Biocon and Pfizer indicates that it is just not sufficient to 
look out for alliancing partners and have an alliance. Many things can go wrong in the 
alliance. The alliance is an expensive process involving time and resource and it is necessary 
that the objective of the alliance be met. There are many factors which hinder the formation and 
successful progress of an alliance with a foreign pharmaceutical company. For a successful 
progress these aspects need to be identified and monitored. 
In this study the respondents consider lack of policies, guidelines and governmental support as 
a key deterrent for the formation of strategic alliances between Indian and foreign 
pharmaceutical companies. 
• External: Lack of information 
It is not easy to get information of various companies and their work and competencies which 
will encourage prospective alliance partners to approach each other. This is a real hindrance. 
Even if the information is known, there is no scope for due diligence from the 
government or any centralized body which can be a reference. In certain European countries, 
specific details of the organization, with details of their product lines, pipelines and current 
areas of work along with the areas where they seek for alliance is maintained and updated. This 
approach is worth emulating as the background of the companies can also be verified , thus 
helping build trust and increasing the rates of success for the alliance. 
In this study the respondent consider the lack of information as a strong factor which impedes 
the formation of strategic alliance between Indian and foreign pharmaceutical companies. 
• External: Governmental policies 
Companies indicate that there is no involvement of the government in alliances between 
Indian and foreign pharmaceutical countries. In case of failure of the alliance, neither of the 
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companies can fall back to anybody for arbitration. Alliances are built on trust, many a times 
the trust is breached and the companies will be at loggerheads with reference to shared 
resources. Since the risks involved are high in alliance with a both Indian and a foreign 
company, a lack of centralized body which regulates and monitors the alliance is expected. 
Lack of such a body can prove to be a deterrent for alliance formation. 
In this study the respondents consider lack of policies, guidelines and governmental support 
as a key deterrent for the formation of strategic alliances between Indian and foreign 
pharmaceutical companies. 
• Internal: Unclear objectives 
Many companies have undertaken alliances riding the "me too" wave, or just to outplay their 
competition without much thought given to the ultimate objectives and deliverables of a 
particular partnership. If the objective of alliances is not clear then the alliance cannot be 
monitored vv'hich can lead to misunderstanding and confusion in both the organizations. 
Alliance agreements are normally written down documents with a specific time frame. For 
instance: 
Sun Pharma - Merck, for developing, manufacturing and marketing branded generics 
across emerging markets. 
- Cadila Healthcare - Abbott, wherein Cadila will license 24 branded generics to 
Abbott for 15 emerging markets 
- Biocon - Bristol Myers Squibb, for partnership in the research space with focus on 
discovery and development of NCEs 
In the study the respondents indicate that clear objective goes a long way in determining the 
success of a partnership. 
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• Internal .Lack of communication 
Many alliances fallout before their reach their objectives. One of the reason for this is the lack 
of communication with the parties involved. Alliances involves the coming together of two 
firms whose background, culture, countries of origin are different. Open communication can 
help a lot to quell many of the negative aspects as resolution process can be fast and effective. 
In the current study, the respondents indicate that lack of communication does cause fractures 
in the alliance which can ultimately lead to failure to achieve the objectives 
• Internal: Non monitoring of alliances 
Pharmaceutical companies who have successful alliance outcomes have a team of staff who 
monitor the progress of the alliance. Generally alliances between pharmaceutical companies are 
a strategic decision, which has clear outcome expectation. Dedicated personnel monitoring the 
progress of the strategy and its outcomes can provide inputs of the progress of the alliance so 
that corrective actions can be taken. 
In this study the respondents indicate that it is critical to monitor the alliance progress and the 
success of the alliance is dependent how close the top management is involved in the alliance 
and its progress. 
• Internal: Lack of trust 
Trust is an important factor which determines the success of an alliance. If the ailiancing 
companies, have clearly stated alliance objectives, then to achieve the objectives both the 
parties have to trust each other. If there even an inkling of doubt that one firm is misusing 
the resources of another firm then the alliance will lead to bad vibes which can ultimately 
result in alliance fallout. The objectives that govern the alliance are more often than not very 
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sensitive and the proprietary asset of the firm. For instance, marketing a new product or 
conducting R&D for a NCE are activities which are based on trust factor. 
The respondents in the study have indicated strongly that lack of trust is a serious threat to the 
success of any alliance. Trust can be built by communication, interactions, transparency and 
clarity on the objectives of both the alliancing companies 
6.2 Recommendations for Indian Pharmaceutical Companies Undertaking 
Strategic Alliances 
Based on the study and analyses of strategic alliance between Indian and foreign 
pharmaceutical companies, the following strategic orientation can be adopted for Indian 
pharmaceutical companies. The recommendations are categorized into three types: based on 
turnover, based on activities undertaken by the pharmaceutical companies and based on the 
types of pharmaceutical companies . 
6.2.1 Based on Turnover: 
Small pharmaceutical companies 
• Concentrate on meeting stringent regulatory norm specified by USFDA, GMP etc. This 
will help generate new avenue for growth by entering into contract manufacturing for 
MNCs. 
• Develop and upgrade the manufacturing facilities both for capacity enhancement and 
quality related aspects, this will open up opportunities 
Middle tier pharmaceutical companies 
• Generic sales particularly to foreign market is a large business segment with scope to 
grow, Indian pharmaceutical companies should make use of this growth phase. Getting 
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into alliances with MNCs whose drugs are expected to go off patent, can be an approach. 
This will help in enhancing the capacity of middle tier companies and help them to 
reach new market and increase their turnover. 
Concentrate on enhancing their production capacities to be able to take advantage of the 
growing demand for cheaper drugs. This can be achieved by undertaking collaborations 
with firms both in India and abroad. 
Gain expertise in regulatory requirement across the world, to develop the necessary 
competency to cater to all the market across the world. This can be achieved by 
alliance with a partner with adequate market specific experience and knowledge in 
regulatory requirement and is in compliance. 
Large pharmaceutical companies 
• Current Indian skill set is in synthetic chemistry. There is scope for growth in area like 
new lead molecule new target in new area like medicinal biology and protein chemistry. 
High level of research and new drug development can be achieved with collaboration 
with MNC. 
• Concentrate effort in BioPharma for both regulated and non regulated markets. 
Indian pharmaceutical companies can enter into collaboration with BioPharma 
companies to develop new products. This will take top pharmaceutical companies 
towards innovation. 
6.2.2 Based on Type of Activities Undertaken 
Manufacturing : 
• Develop international grade of manufacturing facilities which can meet stringent 
regulatory requirements. 
• Undertake alliances with Indian and foreign pharmaceutical firms to utilize the 
capacity to the fullest and undertake contract manufacturing 
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R&D: 
• Develop strategic alliances with research oriented pharmaceutical companies to access 
latest advancements in science and technology. 
• Provide contract research facilities to other pharmaceutical firms 
Contract manufacturing : 
• Develop manufacturing capacities to high standards to enable international companies 
get into alliances 
• Focus on meeting stringent regulatory norms both domestic and international 
• Enhance production capacities to meet the requirement of the off patent drugs 
6.2.3 Based on Type of Company : 
Active Pharmaceutical Ingredient Manufacturing : 
• Develop capabilities to move upwards the value chain towards the manufacturing of 
formulations and specialty drugs. Can be achieved by alliances and self 
development. 
• Concentrate on alliances with different pharmaceutical companies to supply and 
develop new API molecules with the growing demand in the market 
Formulations : 
• Adopt competencies to move towards specialty drugs and R&D . This can be 
achieved through alliances with suitable partner 
• Invest in R&D 
• Invest in development of facilities to meet stringent regulations thereby enhancing 
prospects in domestic and international market 
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Clinical Research : 
• Develop competencies to meet regulatory requirements across the world to enable 
more scope of clinical research in India . 
Strategies for long term success of alliance 
• Alliance should be well thought out and directly should be linked to growth 
objective . 
• Alliances should have a clear monitoring at every stage with roles and 
responsibilities defined 
• Comimunication should be focused on both e internally and with the alliancing 
partner 
• Trust is developed slowly, and can be enhanced with successful alliances for various 
aspects 
Suggestions 
• Government needs to initiate a database of each company about the current alliances 
and the core competency of each company to help prospective alliances select right 
allaincing partners. 
6.3.Future Research Directions 
This research work delving on aspects of strategic alliances between Indian and foreign 
pharmaceutical companies, throws fresh insights into many areas like : reasons for the 
alliance formation, impact of the strategic alliance and hindrances for alliance success. This 
is not an exhaustive work, but adds to the already existing literature by reiterating some 
aspects. However the research has some limitations which can be a future course for in 
depth research. They are as follows: 
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The study has indicated that product related factors of strengthening product 
portfolio, launching new brands in foreign market and launching new products 
influence strategic alliance formation. However these are not very strong factors. There 
may be some specific product related factors which are influential. Future research can 
throw some more light in this direction. 
The marketing related factors of accessing new global emerging markets and 
regulated markets and distribution channel abroad may not be the only factors, that 
encourage alliance formation. There is scope for future research to identify more 
factors that influence strategic alliances between Indian and foreign pharmaceutical 
companies. 
Future research can throw light on other technological reasons for strategic alliance. 
This research study indicates a collaborative R&D to be a significant driver for alliances. 
Although manufacturing related reasons drive strategic alliances between Indian and 
foreign pharmaceutical companies, the research does not indicate their strong 
influence. Future research can identify other manufacturing related factors that can 
influence strategic alliances between Indian and foreign pharmaceutical companies. 
Future research can be directed towards identifying more competitive factors which 
influence alliance formation between Indian and foreign pharmaceutical companies. 
The current research identifies only 5 areas where the impact of strategic alliances 
are observed namely :products, marketing, technology, manufacturing and gaining 
competitive advantage. Strategic alliances has impact on many more aspects of the 
organization like employees, customers, other alliances etc which are not covered in 
their research. This can be a future scope of study as this will give the entire picture 
of the strategic alliance and its impact. 
The factor undertaken in the 5 aspects which are investigated here are not necessarily 
the only factors that are impacted by strategic alliances. There are other factors 
which can be influenced by alliances and this is a scope for future research. 
Future research can analyse the other hindrances for the alliance like employee related 
aspects, training and learning related aspects and market related aspects. 
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ANNEXURE1 
QUESTIONNAIRE 
alliances between Indian and foreign pharmaceutical companies, please rate the factors that have 
encouraged Indian pharmaceutical companies to form strategic alliances with foreign pharmaceutical 
companies. Rate the factors in a scale 1 to 5, with I being the least possible Factor and 5 being the 
most possible Factor that has motivated the alliance.. 
lA : Product Related aspects 
j 
a Need to strengthen product portfolio i 
b Establish brands and products abroad 
c Launch new products in domestic and foreign markets 
IB: Marketing Related aspects 
a Access to global emerging markets 
b Access to highly regulated markets 
c Access to distribution channel in foreign markets 
IC: Technology Related aspects 
a Access to new technology 
b Collaborative R&D 
c Gain knowhow of USFDA approval processes for 
production plants 
1 
ID: Manufacturing Related aspects 
Overall cost minimization 
1 2 3 4 
' 
5 
203 
b F.xploit common assets 
c Access quality management systems 
IE: Gain Competitive Advantage 
Improve market positions 
Develop financial strength through high turnover 
Build strong company image and goodwill 
3 4 5 
J,,.. 
2. What has been the impact of strategic alliance between your company and a foreign 
pharmaceutical company. P/ea^e rate the below mentioned aspects on a scale from 1 to 5. With 1 
being the area of least impact and 5 being the area of maximum impact. 
1 
2A : Products Related aspects 
a Launched new patented molecules 
b Launched new generic products in foreign 
c Launched new generic molecules in domes 
markets 
tic markets 
1 2 3 4 5 
Gained wider baskets of products in the portfolio 
2B: Marketing Related aspects 
Access to highly regulated market 
b Gained capability to invest in marketing and sales 
promotional activity 
c Access to foreign distribution channels 
2C: Technology Related aspects 
1 2 3 4 5 
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: a Gained access to new technology 
b 
c 
Achieved R&D capability 
Gained GMP compliant manufacturing capabilities 
d Gained access to the latest information on 
technological and product related upgrades 
2D: Manufacturing Related aspects 
Achieved increased market share 
Achieved increased profitability 
Established a strong brand name in global market 
Gained knowledge on superior managerial skills and 
techniques 
a Achieved cost optimization 
b Able to exploit common assets and achiev 
operational synergy 
\ 2 
e 
c Gained knowledge on superior quality management 
skills and techniques 
2E: Gain Competitive Advantage 
3 4 5 
L . , . 
2 3 4 
3. Rate the factors which you think are hindrances in the formation of strategic alliances between Indian 
and foreign pharmaceutical companies. 
External 
a Lackof information and data on organization 
interested in alliance 
b Lack of government policies and guidance 
Internal 
5 
1 2 3 4 5 
) 
.............. .^  
I i 
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I c i Un clear objectives for alliance formation 
d Lack of communication between alliancing partners 
e N'on monitoring of alliance progress 
f Lack of trust among alliancing partners 
1 
4. About the company: 
1 
4A: NAME OF THE COMPANY 
1 
4B 
Type Of 
Company 
API (generic) Formulations Clinical 
Research 
R&D 
4C 
Type Of 
Activity 
Manufacturing R&D Contract 
manufacturing 
Distribution 
4D 
Turnover <100Cr 100-300Cr 300-500 Cr >500Cr 
4E Name of Respondent: 4F . Designation of the respondent 
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ANNEXURE 2 
Collaborations between Indian and foreign pharmaceutical companies (1976-88) 
:li.,. 
Sarabhai Chemicals 
Sarabhai Chemicals 
Ranbaxy Laboratories 
Alembic chemicals 
Mc Graw Ravindra 
Chemosyn Pvt ltd 
Dabur Ltd 
IDPL 
Unique Pharmaceuticals 
Ranbaxy laboratories 
UnitedChemalode Industries 
Hoechst India 
Lupin Laboratories 
Ranbaxy laboratories 
Ranbaxy laboratories 
Pradhan and Alakshendra 
1976 
1976 
1977 
1977 
1979 
1980 
1981 
1982 
1982 
1983 
1984 
1985 
1987 
1987 
1988 
(2006) 
Indonesia 
Malaysia 
Nigeria 
UAE 
Malaysia 
Tanzania 
Nigeria 
Nigeria 
Nigeria 
Malaysia 
Nigeria 
Nepal 
Thailand 
Thailand 
Nigeria 
JV 
JV 
JV 
JV 
JV 
JV 
wos 
JV 
JV 
JV 
H*"'"""" 
Antibiotics 
Pharma formulation 
Drugs & Pharmaceuticals 
Pharmaceuticals 
IV transfusions solutions 
Pharmaceutical formulation 
Pharmaceuticals 
Pharmaceuticals 
Pharmaceuticals 
Pharmaceuticals 
Pharmaceuticals 
Pharmaceuticals 
Bulk Drugs 
Pharmaceuticals 
Pharmaceuticals 
Area of *; 
collabf'ratiim 
Manufacturing 
Manufacturing 
Manufacturing 
Manufacturing 
Manufacturing 
Manufacturing 
Manufacturing 
Manufacturing 
Manufacturing 
Marketing 
Manufacturing 
Manufacturing 
Manufacturing 
Manufacturing 
Manufacturing 
Collaboration between Indian and foreign Pharmaceutical companies( 1993-1999) 
Indian Company 
Ranbaxy Laboratories 
Lupin Laboratories 
Shasun Chemicals 
Source : Pradhan and 
Year 
1993 
1993 
1999 
Foreign compan\ 
Eli Lilly 
American Cyanamid 
Austin Chemical 
Alakshendra (2006) 
Head 
quarters 
USA 
USA 
USA 
Description 
Intermediate for Cefaclor 
Intermediate for Ethambutol 
Joint process development 
Collaboration between Indian and foreign Pharmaceutical companies(2000-2009) 
iA...l..'i±:H..,^L. '•»'' 'Indlan PharmaceMticff^fepliitilfBWflP?' 
Indian Company 
Ranbaxy Laboratories 
Aurobindo Pharma Ltd 
Ranbaxy Laboratories 
Ranbaxy Laboratories 
Dr Reddy's Laboratories 
Unichem 
Ranbaxy Laboratories 
Year 
2000 
2001 
2002 
2002 
2002 
2002 
2002 
Foreign company 
Bayer AG 
Shanghai Wide Tex Chemical Co ltd 
Veratide , from Procter & Gamble 
Nihon Pharmaceuticals 
BMS Laboratories and Meridian 
Healthcare 
Niche Generics 
Signature Pharmaceuticals 
HQ 
Germany 
China 
Germany 
Japan 
UK 
UK 
USA 
Description 
Generics 
60% stake 
OTC market 
10% equity 
Foray into European 
market 
Liquid manufacturing 
facility 
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Sun Pharmaceuticals 
Aurobindo Pharma Ltd 
Zydus Cadila 
Ranbaxy Laboratories 
Wockhardt Ltd 
Suven Pharmaceuticals 
Jubilant Organosys 
Glenmark 
Pharmaceuticals 
Wockhardt Ltd 
Glenmark 
Pharmaceuticals 
Nicholas Piramal India 
Dr Reddy's Laboratories 
Sun Pharmaceuticals 
Glenmark 
Pharmaceuticals 
Matrix Laboratories 
Strides Arcolab 
Glenmark 
Pharmaceuticals 
Nicholas Piramal India 
Matrix Labortaories Ltd 
Torrent Pharmaceuticals 
Sun Pharmaceuticals 
Strides Arcolab 
Dr Reddy's Laboratories 
Ltd 
Strides Arcolab 
Glenmark 
Pharmaceuticals 
Ranbaxy Laboratories 
Dishman Pharma 
Nicholas Piramal 
Jubilant Organosys 
Sun Pharmaceutical 
Malladi Drugs 
Jubilant Organosys 
2002 
2003 
2003 
2003 
2003 
2003 
2004 
2004 
2004 
2004 
2004 
2004 
2004 
2005 
2005 
2005 
2005 
2005 
2005 
2005 
2005 
2005 
2005 
2005 
2005 
2005 
2005 
2005 
2005 
2005 
2005 
2005 
Caraco Pharmaceutical 
Shanxi Tongling 
Alpharma 
RPG (Aventis) 
CP Pharmaceuticals 
Synthon 
Pharmaceutical Services and PSl 
Supply 
Laboratorios Klinger 
Esparma Gmbh 
Clonmel Healthcare 
Rhodia OrganiqueFine Ltd 
Trigenesis Therapeutics 
Women's First Healthcare 
Servycal SA 
Docpharma N V 
Strides Latina 
Institute biochimico Industria 
Farmaceutica Ltda 
Biosyntech 
Mchem group 
Heumann Pharma Gmbh & Co 
Generica KG 
Valeant Pharma 
Beltapharm 
Roche's API unit 
Sterile Manufacturing facility 
BouwerBarlett 
Efarmes Sa 
Synprotec Ltd 
Avecia Pharmaceuticals 
Trinity Labs 
Able Labs 
Novus Fine chemicals 
Trinity Laboratories 
USA 
China 
France 
France 
UK 
USA 
Belgium 
Brazil 
Germany 
Ireland 
UK 
USA 
US 
Argentina 
Belgium 
Brazil 
Brazil 
Canada 
China 
Germany 
Sun 
Italy 
Mexico 
Poland 
South 
Afi-ica 
Spain 
UK 
UK 
USA 
USA 
USA 
USA 
Additional stake of 4% 
50% stake - JV 
Formulation business 
Two FDA approved 
products 
Inhalation Anesthetics 
Acquired 3 brands 
12.5% stake 
Hormonal brand, Uno -
Ciclo 
IVpercent stake 
60 percent stake 
Manufacturing 
70% stake 
64 percent equity 
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Jubilant Organosys 
Strides Arcoiab 
Marksans Pharma 
Dr Reddy's Laboratories 
Kemwell Pvt 
Dishman Pharmceuticals 
Aurobindo Pharma 
Natco Pharma 
Ranbaxy Laboratories 
Ranbaxy Laboratories 
Matrix 
2005 
2005 
2006 
2006 
2006 
2006 
2006 
2006 
2006 
2006 
2006 
Target Research Associates 
Biopharma 
Nova Pharmaceuticals 
Betapharm Arzneimittel 
Pfizer's manufacturing plant 
I03SLtd 
Milpharm 
NICK'S Drug store 
Seneteck's Autoinjector business 
Allen SpA- division of GSK 
Mylan 
Source : Compiled from Pradhan and Alakshendra (2006). krc 
pharma outlook 
USA 
Venezuela 
Australia 
Germany 
Sweden 
Switzerlan 
d 
UK 
USA 
USA 
Italy 
USA 
51 percent equity 
Patents, trademarks 
Unbranded Generics 
-pharma -2009, India pharma2015. KPMG- Indian 
Nicholas Piramal - Alliances 
Outward 
Nicholas Labs 
Roche Products Lt d 
Boehringer Mannheim 
Hoechst Research centre 
Rhone Poulence India Ltd 
ICl Pharma 
Global Bulk Drugs 
Sarabhai Piramal 
Rhodia UK 
Avecia Pharmaceuticals 
Pfizer Morepeth Site 
Khandelwal Laboratories 
HLPL Bangalore 
Minrad International Inc 
RxElite Inc 
Alliances and Joint venture 
Biogen 
Chiesi 
PFDC 
Gilead Sciences 
Genzyme C 
Allergan 
1988 
1993 
1996 
1998 
2000 
2002 
2003 
2003 
2005 
2005 
2006 
2008 
2008 
2009 
2009 
Italy 
USA 
USA 
^"iiiiaiiiiiiiH 
Generics 
Diagnostics 
Diagnostics 
Generics 
Products 
Generics 
Generics 
Manufacturing 
Manufacturing 
Generics 
Generics 
Manufacturing 
Manufacturing 
Generics 
Generics 
Generics 
Generics 
Manufacturing 
Manufacturing 
Manufacturing 
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IVAX corp 
Glaxo Smithkline - Alliances 
UK 
Company 
Dr Reddys(2009) 
Ranbaxy 
. ^ . « . . - - 1 ^ -
Reason 
Market selected products 
R&D 
' ^IBH^HHIillll^^ 
Portfolio 
emerging markets excluding India 
NCE and co-commercialization 
Zvdus - Alliances 
i.... 
Outward 
Company 
Bayer Schering 
Mallinckrodt 
Abbott 
Inward 
Eli Lilly 
Zambon Group 
Domestic 
Kopran 
Bharath serums 
Pharma 
and vaccines 
Country 
Germany (2010) 
USA(2005) 
USA(2010) 
USA(2009) 
Italy (2005) 
Marketing and 
manufacturing 
Manufacture 
NDDS(2005) 
• ' •iiiiiilifiii^ ^^ ^^ ^^ ^^ ^ 
Products 
Manufacturing 
Generic manufacturing 
Market ZC products in emerging markets 
Research in CV drug development 
formulation, development and marketing of API 
formulation brands (2001) 
anticancer for global market 
Alembic - Alliances 
' S T 'ji.i.j..~™-. .; ,... ™ _ - , . . . , 
Inward 
Company 
Chiron Corporation (2003) 
Domestic 
Dabur Pharma (2007) 
Country 
USA 
Products 
Contract research- cancer and vaccines 
CVS, Diabetic and GI - lifestyle 
segment 
Recent Alkem - Alliances 
Inward 
Company 
Oculus Innovative Sciences 
Country 
California 
(USA)- 2006 
Products 
super oxidized solution with Microcyn 
technology, for wound and abrasions 
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Annexure 3 
LIST OF PUBLICA TIONS 
Publications 
o Branding in Pharmaceutical industry: Integration of condition and product 
branding for effective DTC ( Direct - to- consumer) marketing, Anvesha, Vol. 3 
No. 2 , July- Dec 2010, ISSN:0974-5467 
o Retailing in generic pharmaceutical products in India: A study of B2B customer 
perceptions on opportunities, challenges and strategies for sustainable growth, 
Epoch Strategies for Marketing, Family business and Entrepreneurship, Nirma 
University Ahmedabad , ISBN: 978-93-81361-68-9 
'Strategic Alliances in Indian Pharmaceutical Industry: A Competitive 
Collaborative Advantage' in 'Collaborative Competition & Other Readings' 
published by DMIMS, Nagpur, 2010. ISBN: 978-81-8488-690-0 
Conferences- Paper Presentation 
o IMRA international conference on "Emerging Markets and New Dynamics of 
Management" London, UK. Poster presentation on "strategic alliances between 
Indian and foreign pharmaceutical companies" 
o International conference - Nirma Institute of Management. Presented paper on 
"Retailing in Generic Pharmaceutical Products in India: A study of B2B 
Customer Perceptions on Opportunities, Challenges and Strategies for 
Sustainable Growth" 
o National conference - MS Ramiah Institute of Management. Presented paper 
on "Branding in pharmaceutical industry: Integration of condition and 
product branding for effective DTC ( Direct - to - Consumer) marketing. 
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Annexure 4 
GLOSSARY 
Foreign Pharmaceutical company : Pharmaceutical companies based in a foreign country 
Indian pharmaceutical companies : Piiarmaceuticai companies started and based in India 
New patented molecules: Pharmaceutical molecule developed and patented for the first time 
(jeneric Pharmaceutical products Pharmaceutical molecule which has gone off patent 
Product port/olio for a pharmaceutical company: Refers to the product basket under various 
therapeutic segments. 
R&D Capability: Ability to undertake research independently to produce new therapeutic 
molecules 
GMP compliant manufacturing sites .'Manufacturing facility which complies with GMP -
Good Manufacturing Facility Practices 
Global Markets : Refers to international markets 
Regulated Market: Pharmaceutical market in US, Canada, UK , European Union , Australia 
Profitability : Overall profits including sales turnover 
Managerial knowhow: Managerial skills 
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